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 III 
Abstract 
The ω-3 polyunsaturated fatty acids (ω-3 PUFAs), eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), have been shown to have cardioprotective and anti-
atherosclerotic actions. While it has been proposed that ω-3 PUFAs may structurally stabilise 
atherosclerotic lesions, the underlying mechanisms have yet to be fully elucidated. There is 
evidence that increased dietary intake of ω-3 PUFAs alters the concentration of 
endocannabinoids (ECs) in central and peripheral tissues and, since synthetic cannabinoid 
agonists have been shown to exert anti-atherosclerotic effects, this thesis explored whether a 
link exists between the endocannabinoid system and the beneficial effects of ω-3 PUFAs in the 
setting of experimental atherosclerosis. Therefore, the present studies were performed to (1) 
determine the impact of long-term intervention with ω-3 PUFAs on several physiological 
parameters, including the function of the endocannabinoid system, in an in vivo model of 
hypercholesterolaemia and (2) to examine the role, if any, of the activated endocannabinoid 
system in the activity of an in vitro model of macrophage lipid accumulation. At the cellular 
level, the present study demonstrated the interference of cannabinoid receptor signalling with 
intracellular uptake and accumulation of DHA, an effect which was demonstrated to be 
mediated, at least in part, via CB2 receptor signalling. Moreover, the study provided the novel 
observation that DHA treatment of activated macrophages significantly inhibited 2-
arachidonoylglycerol (2-AG) synthesis. This finding is strongly suggestive of an association 
between the effects of ω-3 PUFAs and regulation of the endocannabinoid system and its 
function. In the ApoE
-/-
 mouse model of experimental atherosclerosis, maintenance on an 
atherogenic diet induced significant hyperlipidaemia, an effect which was associated with 
endothelial dysfunction, cardiac remodelling, and significantly elevated anandamide (AEA) and 
2-AG levels in brain, heart and aortic tissues. Supplementation of the atherogenic diet with the 
EPA, while having a negligible impact on endothelial dysfunction or cardiac remodelling, 
improved the hypercholesterolaemic profile and normalised the overproduction of ECs in both 
central (brain) and peripheral (heart and vascular) tissues. Fenofibrate, a lipid lowering control 
administered as a supplement to the atherogenic diet, was observed to significantly attenuate 
hypercholesterolaemia, endothelial dysfunction and elevated EC levels although no effect on 
cardiac remodelling was observed. In light of the observation that hypercholesterolaemia was 
associated with elevated tissue EC levels, together with the demonstration that EPA improved 
hypercholeseterolaemia and attenuated EC levels suggests (1) a detrimental role of the 
endocannabinoid system in hypercholesterolaemia in the ApoE
-/-
 model and (2) regulation of 
this interaction by ω-3 PUFAs. Given the mounting evidence implicating the endocannabinoid 
system in various disease pathologies, the capacity of ω-3 PUFAs to influence the activation 
and function of this system may prove key to their beneficial effects. 
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1.1 Vascular physiology 
1.1.1 Blood vessel structure 
The circulatory system is responsible for mediating the supply, exchange and removal of nutrients, 
vital gases and waste products at a cellular level. It is comprised of two independent structures: - the 
cardiovascular system which distributes blood and the lymphatic system which distributes lymph. 
Arteries underpin the main function of the cardiovascular system to supply nutrient rich, oxygenated 
blood to parenchymal organs and are functionally diverse from capillaries, which represent a gas 
exchange interface, and veins, which return deoxygenated blood to the heart and lungs. Three 
morphologically distinct layers comprise the normal arterial wall: the tunica intima, tunica media and 
tunica adventitia. 
1.1.1.1 Tunica intima 
The innermost layer of the arterial vascular wall, the tunica intima, constitutes a monolayer of 
endothelial cells exposed to the vessel lumen. The endothelium is supported by an underlying layer of 
connective tissue, containing collagen bundles and laminin interspersed with smooth muscle cells, 
which is bound to a fenestrated elastic lamellae boundary, the internal elastic lamina (IEL).  The 
endothelium acts as an interface between circulating blood and vessel wall components, provides 
physical structure to the vessel and conducts a number of synthetic and metabolic functions. These 
functions include: (1) maintaining a non-thrombogenic luminal surface through regulation of 
thrombosis and platelet adherence; (2) modulating vascular tone; (3) preservation of the supporting 
basement collagen membrane; (4) production of growth factors and (5) regulation of inflammatory 
responses by controlling the interaction of white blood cells on the vessel wall (as reviewed by 
Sumpio, Riley and Dardik, 2002). 
1.1.1.2 Tunica media 
The middle layer of the vascular wall, the tunica media, is composed of concentric layers of smooth 
muscle cells embedded within an extracellular matrix (ECM) of fibril-forming collagens (type I, III 
and V), elastic fibres and dermatan and chondroitin sulphate proteoglycans. Viscoelasticity imparted 
by the presence of coiled elastic fibres in the ECM of the tunica media allows the vessel to expand or 
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rebound, buffering pressure variations that occur during the cardiac cycle to maintain a constant flow 
of blood (as reviewed by Arribas, Hinek and Gonzalez, 2006).  
Under normal physiological conditions, the principal function of arterial smooth muscle cells is to 
contract. The cylindrical shape and circumferential orientation of smooth muscle cells in the tunica 
media enables modulation of arteriolar diameter. Vasoactive (constrictor and dilatory) substances 
derived from the endothelium (e.g. nitric oxide and endothelin) and the circulation (e.g. angiotensin 
II) contribute to arterial tone. However, smooth muscle cells may convert to a „synthetic‟ state in 
response to alterations in local conditions (often mechanical or inflammatory changes) in which they 
can conduct a number of non-contractile functions including migration, proliferation, 
synthesis/degradation of ECM components, and release of inflammatory mediators such as 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-  (Loppnow and Libby, 1990; Li et al., 1999). 
1.1.1.3 Tunica adventitia 
The exterior layer of the vascular wall, which is separated from the tunica media by the external 
elastic lamina (EEL), is known as the tunica adventitia. It is composed of vascular fibroblasts 
embedded within a collagen rich ECM. Vaso vasorum are present in larger arteries: networks of small 
blood vessels that penetrate the tunica media ensuring a continual supply of nutrients and oxygen to 
the endothelium. Perivascular innervation of this layer suggests the tunica adventitia may regulate 
vascular tone. Indeed, Laflamme et al (2006) demonstrated the ability of the adventitia (independent 
of the media and intima) to contract and relax in response to vasoactive substances.  
1.1.2 Collagen in the vasculature 
Collagen represents a principal component of the ECM of blood vessels. The majority of vascular 
collagen is derived from vascular smooth muscle cells; however endothelial cells, adventitial 
fibroblasts and macrophages have also been reported to produce collagen (Sage et al., 1983; Shi et al., 
1997; Weitkamp et al., 1999). In excess of 25 types of collagen have been identified to date, which 
are categorised into either: - (1) fibrillar and network forming collagens; (2) FACITs (fibril-associated 
collagens with interrupted triple helices); (3) MACITs (membrane-associated collagens with 
interrupted triple helices) or (4) MULTIPLEXINs (multiple triple-helix domains and interruptions) 
based on their supramolecular organisation (as reviewed by Shoulders and Raines, 2009). While 
several collagen types have been identified in the vasculature, the fibrillar collagens Types I and III, 
which confer tensile strength and elastic resilience respectively, represent the predominant collagen 
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fibrils present in blood vessels (Shekhonin et al., 1985). Taken together, Type I and III collagen fibres 
provide structural stability and elasticity to the blood vessel enabling the structure to remain 
compliant but resist multi-directional stress. 
1.1.3 Collagen in the myocardium 
Cardiac fibroblasts, which constitute 60-70% of the cellular content of the human heart, represent the 
primary source of ECM component production in the myocardium. The ECM of the myocardium is 
composed mainly of the fibrillar collagens Type I (approximately 85%) and Type III and contains 
smaller amounts of fibronectin, laminin and elastin (Heeneman et al., 2003). The foremost function of 
the cardiac ECM is to act as a scaffold for the transmission of mechanical, electrical and chemical 
signals between the various components of the myocardium enabling organised contraction and 
preventing myocardial movement (reviewed by Porter and Turner, 2009). Under physiological 
conditions, the synthesis and deposition of collagen is essential for normal cardiac function as it 
serves as the major stress-bearing element of the ECM, conferring tensile strength and structure to the 
myocardium. However, excessive collagen accumulation in the heart, known as cardiac fibrosis, can 
lead to tissue stiffening and cardiac dysfunction and has been implicated in the early stages of heart 
failure (Norton et al., 1997; Kuwahara et al., 2002; Gurtl et al., 2009).  
1.1.3.1 Collagen Synthesis 
Transcriptional regulation of collagen synthesis is primarily dependent upon cell type but the process 
can be modulated by a number of growth factors and cytokines including transforming growth factor-
β1 (TGF- β1), interleukin-1 (IL-1) and platelet derived growth factor (Amento et al., 1991; Durante et 
al., 2001). Collagens are synthesised from proto-collagen, precursor chains which contain additional 
end terminal propeptides (Bellamy and Bornstein, 1971). Newly synthesised protocollagen strands 
undergo a degree of post-translational modification, primarily hydroxylation and glycosylation, and 
associate into procollagen trimers. Disulphide bonds at the COOH terminus stabilise the three 
protocollagen chains and subsequent folding of the triple helix progresses to the NH2 terminus. 
Following assembly, procollagen is secreted to the extracellular matrix where removal of terminal 
propeptides is facilitated by the action of the matrix metalloproteinases (MMPs) NH2 proteinase and 
COOH proteinase (Kohn et al., 1974; Hojima et al., 1985). Processed procollagen strands are referred 
to as tropocollagen monomers.  
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1.1.3.2 Maturation 
The process of collagen fibrillogenesis alters the molecular structure and stability of collagen triple 
helices and increases the tensile strength of collagen fibrils. Upon assembly, tropocollagen monomers 
spontaneously aggregate into intermediate collagen fibrils, named microfibrils. As demonstrated via 
electron density mapping by Orgel et al. (2001), microfibrils are comprised of five tropocollagen 
monomers organised in a quasi-hexagonal three-dimensional stack to form a right-handed, super 
twisted structure. Mature collagen fibrils are composed of interdigitated microfibrils. 
The macromolecular structure of mature collagen is further strengthened by the formation of covalent 
bonds, known as collagen cross-links, between the protein sub-units. Immature (difunctional) cross-
links stabilise collagen microfibrils by forming intermolecular bonds between the tropocollagen 
monomers of the microfibril unit (Kang, 1972; Nicholls and Bailey, 1980; see Figure 1.1). The 
mechanism of immature cross-link formation in fibrillar collagen is facilitated by the reactions of 
aldehydes derived from the telopeptide precursor‟s lysine or hydroxylysine, a process which is 
facilitated by the action of the copper dependent enzyme, lysyl oxidase (Williamson and Kagan, 
1986). Lysine derived aldehydes follow the allysine cross-linking pathway in which the aldehydes 
condense with adjacent lysine residues on adjacent molecules to form the reducible aldimine base 
cross-links. Dehydro-hydroxylysinonorleucine (deH-HLNL) and dehydro-lysinonorleucine (deH-
LNL) represent the most common lysine-aldehyde derived cross-links (as reviewed by Eyre and Wu, 
2005). Hydroxylysine derived aldehydes follow the hydroxyallysine cross-linking pathway to 
generate the reducible keto-imine bases dihydroxy-lysinonorleucine (DHLNL) and to a lesser extent 
lysinohydroxynorleucine (LHNL) (as reviewed by Eyre and Wu, 2005).  
The subsequent conversion of immature cross-links into mature (trifunctional) cross-links is 
spontaneous and governed by the structural organisation of the collagen fibril. Mature cross-links 
constitute covalent intermolecular bonds between individual microfibrils (see Figure 1.1) which are 
significantly more stable than the immature cross-links (Light and Bailey, 1985). The aldimine bases 
are converted to non-reducible histidin adducts (deH-LNL reacts with histidine to form histidino- 
hydroxylysinonorleucine [HHL]) (Yamauchi et al., 1987). The keto-imine bases react with either 
hydroxylsine residues or another keto-imine base on adjacent collagen microfibirls to generate the 
pyridinium cross-links (Fujimoto et al., 1978; Ogawa et al., 1982) hydroxylysyl-pyridinoline (PYD) 
and deoxy-pyridinoline (DPD). 
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Figure 1.1 Collagen cross-link formation: Diagram illustrating 
the placement of immature and mature cross-links within, and 
between collagen microfibrils.  
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1.2 Coronary heart disease 
1.2.1 Aetiology 
Coronary heart disease (CHD) presents a major cause of death in the westernised world. 
Atherosclerosis, a manifestation of CHD, is a chronic inflammatory condition characterised by the 
accumulation of fatty material within the wall of arterial blood vessels. The progression of 
atherosclerosis is asymptomatic. However at the advanced stage, plaque complications can instigate 
potentially fatal clinical repercussions including myocardial infarction and stroke. Anitschkow and 
Chalatow (1913) reported the first evidence of a direct link between cholesterol and atherosclerosis 
development when it was observed that rabbits fed a cholesterol rich diet developed human-like 
atherosclerotic lesions (Anitschkow and Chalatow, 1913 as cited in Williams and Tabas, 1995). From 
these initial findings emerged the lipid infiltration hypothesis that high intake, and hence circulating 
levels, of cholesterol lead to the development of atherosclerosis. Other theories of disease origin have 
been proposed, including the monoclonal theory and infectious theory of atherosclerosis (Benditt and 
Benditt, 1973; Fabricant et al., 1978). The response-to-injury hypothesis, initially proposed by Ross 
and Glomset (1973), suggests that endothelial injury induced by abnormal physiological conditions 
(e.g. hypercholesterolaemia, hypertension and hypoxia) precedes lesion development which is fuelled 
by an overactive immune response (Davis et al, 2003). However, the alternate (although not entirely 
dissimilar) response-to-retention theory advocates that the key to atherosclerosis lesion development 
is the retention of atherogenic lipoproteins in the subendothelial space in association with ECM 
proteoglycans, which triggers subsequent inflammation (Williams and Tabas, 1995). While the 
causative „event‟ initiating lesion formation may differ between the injury and retention theories, both 
support a role of inflammation in disease development. 
1.2.2 Development of early atherosclerotic lesions 
In humans, fibrocellular thickening of the tunica intima, referred to as diffuse intimal thickening 
(DIT), occurs in the aorta and coronary arteries in an age dependent manner, irrespective of race. DIT 
comprises primarily stable, non-proliferative smooth muscle cells, elastin, proteoglycans and a small 
macrophage population with no lipid pool present (Stary et al., 1992). DIT has been reported in 
foetuses and infants, with thickening of the proximal left anterior descending artery evident three 
months after birth (Ikari et al., 1999). Moreover, the intima:media ratio increases to >1.0 in young 
adults (Nakashima et al., 2002). In human autopsy subjects (aged between 36 weeks gestation and 30 
years old), the systemic distribution of DIT was consistently localised to the atherosclerosis-prone 
8 
 
(abdominal and descending aorta, coronary, carotid and iliac) arteries (Nakashima et al., 2002), hence 
DIT is thought to be related to early atherosclerosis development. 
Type I lesions, as defined by the American Heart Association (AHA) histological classification (Stary 
et al., 1994), constitute focal accumulations of extracellular lipid in pre-existing DIT, preferentially in 
those located at vessel bifurcations and branches where blood flow is turbulent. While it is generally 
agreed that the large lipid core characteristic of advanced atherosclerotic lesions is derived from the 
apoptosis of foam cell (lipid laden) macrophages (see section 1.2.5), numerous studies indicate that 
accumulation of extracellular lipid precedes macrophage infiltration in the early Type I lesion. Indeed 
in humans, electron microscopy revealed evidence of an early lipid core in non-diseased aortic intima 
from young adults (Guyton and Klemp, 1993). Furthermore, the accumulation of apolipoprotein B 
(apoB)-containing lipids in the aortic intima of human foetuses, which was increased significantly by 
maternal hypercholesterolaemia, was reported in the absence of macrophage infiltration (Napoli et al., 
1997). While the formation of intimal extracellular lipid pools characterises Type I lesions, 
progression to more advanced stages involves macrophage infiltration. Indeed in human coronary 
arteries, the presence of CD68-positive macrophages in the deep intima was demonstrated to increase 
proportionately to increasing lipid accumulation (Nakashima et al., 2007). 
1.2.2.1 Lipoprotein accumulation  
Lipoprotein particles are removed from the circulation and transported across the endothelium to the 
subendothelial space via transcytosis. In vivo and in situ experimental models of 
hypercholesterolemia, employing either low-density (LDL) or very-low-density lipoproteins (VLDL), 
have demonstrated a correlation between elevated plasma lipoproteins and increased transcytosis of 
lipoproteins across the endothelium (Schwenke and Carew, 1989; Nordestgaard, Tybjaerg-Hansen 
and Lewis, 1992; Fry et al., 1993; Truskey et al., 1993). Transcytosis is facilitated by caveolae, 
membrane invaginations present on the surface of endothelial cells. The importance of caveolae 
mediated lipoprotein transcytosis in atherosclerosis development was highlighted in a study by Frank 
et al (2004) who observed a 70% reduction in aortic lesion formation in caveolin-1 (a major protein 
component of caveolae) deficient apolipoprotein E knockout
 
(ApoE
-/-
) mice compared to control 
ApoE
-/-
 mice, despite maintenance on an atherogenic diet. Although not fully understood, caveolae 
are thought to transport lipoproteins across the endothelium via either: - (1) receptor mediated transfer 
or (2) fluid phase transfer. Candidate receptors suggested for the former pathway include the 
scavenger receptor B1 (SR-B1) and the LDL receptor (as reviewed by Frank, Pavlides and Lisanti, 
2009).  
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The retention of trancytosed lipoproteins in the sub-endothelial space of the blood vessel is thought to 
be facilitated, in part, by their association with various proteoglycan components of the ECM. Indeed, 
in comparison to mice expressing wild-type LDL, atherosclerosis development was markedly reduced 
in mice expressing LDL which could not bind proteoglycans (Skalen et al., 2002). Biglycan, a 
chondroitin sulphate/dermatan sulphate containing proteoglycan, has a reported binding capacity for 
apoB-containing lipoproteins (Olin-Lewis et al., 2002) and has been observed to co-localise with 
lipoproteins in DIT, early and advanced atherosclerotic lesions (O‟Brien et al., 1998; Nakashima et 
al., 2007). 
1.2.2.2 Lipoprotein modification 
During transcytosis and/or following retention in the sub-endothelial space, lipoproteins are subject to 
chemical modification, a process that endows particles with a greater pro-inflammatory and pro-
atherogenic profile than native lipoproteins. Proteolysis, lipolysis and most importantly oxidation 
appear key to this process. Endothelial cells, smooth muscle cells, monocytes and macrophages are 
capable of oxidising LDL particles (Morel et al., 1984; Steinbrecher et al., 1984; Parthasarathy et al., 
1986). The exact mechanism(s) of cell-mediated oxidation are not precisely understood. The 
identification of stable oxidation products in LDL particles extracted from atherosclerotic plaques 
however, indicate an involvement of reactive nitrogen species, myeloperoxidase, metal ion and 
lipoxygenase pathways (Folcik et al., 1995; Hazen and Heinecke, 1997; Leeuwenburgh et al., 1997a; 
Leeuwenburgh et al., 1997b).  
The oxidative damage incurred by lipoprotein particles retained in the vascular intima, particularly 
LDL, induces alterations to their biochemical properties. LDL in its oxidised form (oxLDL), but not 
its native form, propagates a number of pro-inflammatory actions that can activate and damage 
endothelial cells. Cellular internalisation of oxLDL induces apoptosis and necrosis via upregulation of 
reactive oxygen species (ROS) formation (superoxide anion and hydrogen peroxide) and activation of 
the nuclear factor-κB (NF-кB) pathway, an effect which has been demonstrated in bovine and human 
endothelial cells (Cominacini et al., 2000; Chen et al., 2007). OxLDL is also known to modulate 
monocyte recruitment to the endothelium. OxLDL was demonstrated to mediate a significant increase 
in the adhesion of monocytes to human coronary artery endothelial cells in vitro (Li and Mehta, 
2000), an effect which was associated with a marked increase in the expression of the chemokine, 
monocyte chemoattractant protein-1 (MCP-1). The aforementioned effects of oxLDL were reported to 
be mediated by its binding to, and activation of lectin-like oxLDL (LOX-1) receptors (Cominacini et 
al., 2000; Li and Mehta, 2000; Chen et al., 2007), Class E scavenger receptors which are expressed 
primarily on endothelial cells (as reviewed by Twigg et al., 2012).  
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1.2.2.3 The early inflammatory response  
The damage incurred by endothelial cells following their exposure to, and uptake of, modified 
lipoproteins, induces cell activation and the upregulated expression of a number of pro-inflammatory 
genes. Upregulated expression of adhesion molecules (selectins, integrins and the immunoglobulin 
superfamily of cell adhesion molecules) triggers the well documented adhesion cascade in which 
circulating leukocytes transmigrate the activated endothelium to aggregate at the site of injury 
(Metsas and Ley, 2008). The expression of pro-inflammatory cytokines, particularly IL-1 and TNF-α 
further upregulates adhesion molecule expression, primarily intercellular adhesion molecule-1 
(ICAM-1), ICAM-2 and vascular cell adhesion molecule-1 (VCAM-1) (reviewed by Fogel and Pober, 
2012). 
1.2.3 Fatty streak formation 
Type II lesions (defined by the AHA classification; Stary et al., 1994), often referred to as fatty 
streaks, are characterised by an accumulation of lipid-laden macrophages (stratified in adjacent 
layers) and smooth muscle cells (known as foam cells), T lymphocytes and a small number of mast 
cells. The majority of the lipid present in Type II lesions is sequestered within macrophage derived 
foam cells, while the extracellular space contains only dispersed, isolated lipid droplets.   
Foam cell formation involves the unregulated internalisation of lipoprotein particles to generate a 
lipid engorged cell, a process which is primarily due to an imbalance between lipoprotein uptake and 
cholesterol efflux. Macrophage uptake of modified lipoproteins is enabled by both receptor dependent 
and independent mechanisms. Receptor mediated endocytosis of modified lipoproteins (acetylated 
and oxidised) is facilitated by several receptors, primarily those of the scavenger receptor family 
including the SR-A (I and II), CD36, SR-B1, CD68 and LOX-1 receptors (Smirnova et al., 2004; Sun 
et al., 2007; as reviewed by Greaves and Gordon, 2009). Studies suggest a major role of the CD36 
and SR-A receptors in macrophage mediated oxLDL (modified by the myeloperoxidase/peroxynitrite 
pathways) clearance in vitro. Indeed, the CD36 and SR-A receptors have been reported to mediate 75-
90% of cholesterol ester accumulation in mouse peritoneal macrophages (Podrez et al., 2000; 
Kunjathoor et al., 2002). A more recent study however, reported a significant attenuation of 
atherosclerotic lesion progression but no significant abrogation of foam cell formation in mice 
genetically deficient in SR-A/CD-36 receptors, suggesting the involvement of other receptors in vivo 
(Manning-Tobin et al., 2009). Macrophages have also been reported to internalise lipoproteins via 
micro- and macropinocytosis of extracellular fluid (Zhao et al., 2006; Yao et al., 2009; Anzinger et 
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al., 2010). Unlike receptor mediated endocytosis which only permits uptake of modified lipoproteins, 
receptor independent mechanisms facilitate the internalisation of native lipoproteins and subsequent 
foam cell formation. 
Intimal smooth muscle cells have also been demonstrated to express SR-A and CD36 scavenger 
receptors in vitro and in vivo (Mietus-Snyder et al., 2000; Zingg et al., 2002; Rong et al., 2003). Foam 
cells derived from a smooth muscle cell lineage can be distinguished from macrophage derived foam 
cells due to expression of vimentin and S-100 proteins (Vukovic et al., 2006). Both macrophage and 
smooth muscle foam cells exhibit upregulated gene expression of pro-inflammatory cytokines (MCP-
1, IL-6) and MMPs (Klouche et al., 2000; Shiffman et al., 2000). Smooth muscle foam cells 
demonstrate impaired collagen and fibronectin assembly (Frontini et al., 2009). Foam cell production 
of pro-inflammatory mediators promotes local inflammation which, in combination with persistent 
transcytosis of lipoprotein particles from the circulation, perpetuates monocyte recruitment, foam cell 
formation and ultimately, lesion progression. 
1.2.4 Development of fibrofatty lesions 
Gradually, fatty streaks develop into fibrofatty lesions (Type III lesions as defined by the AHA 
classification; Stary et al., 1994). The fibrofatty lesion represents an intermediate morphological link 
between early lesion development and progression to the advanced atheroma. Early lesions (Type I to 
III) represent clinically silent manifestations of atherosclerosis. Type II lesions are histologically 
characterised by the presence of microscopically visible pools of extracellular lipid droplets dispersed 
throughout the lesion. Lipid pools develop among the layers of smooth muscle cells that constitute the 
location of the DIT and lie below the stratified layers of macrophages and foam cell macrophages. 
Lipid pools displace intercellular matrix proteoglycans and force smooth muscle cells apart. 
Extracellular droplet accumulation is most likely the result of: - (1) lipid entry into the vessel wall 
exceeding the phagocytic ability of macrophages (Libby et al., 2000) and (2) the apoptosis (and 
subsequent expulsion of cell contents) of macrophages due to excessive accumulation of free 
cholesterol which is cytotoxic to these cells (Warner et al., 1995).  
1.2.5 Progression to advanced, complicated lesion 
The prominent histological feature of Type IV lesions (as defined by the AHA classification; Stary et 
al., 1995), also known as atheroma, is the presence of a dense core of extracellular lipid. It is believed 
that the lipid core originates from the amalgamation of smaller lipid pools which are known to be 
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dispersed throughout the preceding Type II lesion (Stary et al., 1994). Furthermore, continued 
apoptosis of saturated macrophage foam cells is thought to contribute to the growing lipid core (Ball 
et al., 1995). In the case of Type IV lesions, the presence of a lipid core results in thickening of the 
arterial wall, but does not compromise vascular lumen diameter due to the capacity of the vessel for 
outward remodelling. However, it is worthwhile to note that should the lipid core develop rapidly in 
size, this lesion may impinge on vessel diameter. A connective tissue layer, corresponding to the 
proteoglycan rich layer of the normal intima, separates the lipid core and the endothelial surface and 
is referred to as the fibrous cap. This region contains primarily proteoglycan-collagen matrix, smooth 
muscle cells and some macrophages and T lymphocytes (Virmani et al., 2000). Concentrated pockets 
of macrophages, T lymphocytes and macrophage foam cells populate the lesion periphery. Type IV 
lesions are susceptible to physical disruption such as fissures and macroscopic ulceration due to flow 
induced stress and strain. Disturbances tend to occur in the shoulder regions of the lesion, where the 
cap is thinnest with little tensile strength. In response to the aforementioned physical disturbances, 
haemorrhage can occur within the vessel lumen or vaso vasorum of the adventitia, with accumulation 
of platelet and fibrin aggregates at lesion sites.  
Type V lesions (as defined by the AHA classification; Stary et al., 1995) are not dissimilar to type IV 
lesions and are characterised by thinning of the fibrous cap region. Morphology of type V lesions 
varies considerably, as does the potential for vascular remodelling and a reduction in lumen diameter. 
Nomenclature is based upon the composition of material underlying the thinned fibrous cap. 
Fibroatheromas (type Va lesions) comprise several lipid core layers segregated by thick layers of 
connective tissue. It has been suggested that such lesions may develop as a result of lesion surface 
disruption where subsequent haematomas and thrombotic deposition act as a structural framework for 
the accumulation of more macrophages and extracellular lipid droplets. Calcified lesions (type Vb 
lesions) are characterised by mineralisation of the lipid core due to calcification of extracellular lipid 
and smooth muscle organelle remnants (Stary et al, 1995). Mineral deposits can often replace the 
entire lipid core. Fibrotic lesions (type Vc) contain a core rich in connective tissue which lacks 
substantial levels of extracellular lipid. In addition, it is found that connective tissue gradually 
replaces the normal intima.  
Complications of Type IV and Type V lesions (surface disruptions, haematoma and/or haemorrhage, 
thrombotic deposition) are generally responsible for the morbidity and mortality associated with 
atherosclerosis. Type VI lesions constitute either a Type IV or Type V lesions exhibiting one or more 
of the aforementioned complications. 
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1.2.5.1 Macrophages: role in atherosclerosis 
Macrophages represent a key cellular component of atherosclerotic lesions. Indeed, the importance of 
these cells in disease manifestation and progression was demonstrated in vivo, where mice deficient in 
macrophage colony-stimulating factor (M-CSF), a growth factor required for monocyte and 
macrophage maturation, exhibited markedly reduced atherosclerotic lesion development compared to 
wild-type controls (Smith et al., 1995). Macrophages present within the atherosclerotic plaque exhibit 
phenotypic heterogeneity. During the process of transmigration, local levels of M-CSF and 
granulocyte colony-stimulating factor (GM-CSF), as well as the levels of pro- and anti-inflammatory 
mediators together determine the phenotypic outcome of monocyte maturation (reviewed by Newby 
et al., 2009). Macrophages derived from an environment dominated by pro-inflammatory signalling 
(IL-1, TNF-α, interferon-γ (IFN-γ)) are termed „classically activated‟ (M1) macrophages. M1 
macrophages exhibit enhanced phagocytic and cytotoxic activity, upregulated scavenger receptor 
expression, and increased secretion of pro-inflammatory cytokines. Conversely, macrophages derived 
from an environment dominated by anti-inflammatory signalling (IL-4, IL-13) are termed 
„alternatively activated‟ (M2) macrophages and promote resolution of inflammation and tissue repair. 
Atherosclerotic lesions are thought to contain primarily M1 macrophage derived foam cells, although 
foam cells carrying markers of both M1 and M2 phenotypes have been identified in mouse 
atherosclerotic lesions (Bouhlel et al., 2007). Recently, in vivo studies in mice have identified another 
macrophage foam cell phenotype, the MOX foam cell, which demonstrates anti-inflammatory and 
anti-oxidant activity (Boyle et al., 2009). The presence of this phenotype in human lesions has yet to 
be confirmed, therefore, the relevance of the MOX phenotype to human atherosclerosis progression 
remains to be determined.  
In the atherosclerotic lesion, macrophages act as a potent source of pro-inflammatory cytokines and 
ROS, which serve to augment the local inflammatory response, maintaining endothelial activation and 
leukocyte recruitment. Furthermore, macrophages secrete a number of proteinases including, most 
notably, the matrix metalloproteinases (MMPs). MMPs constitute endopeptidases involved in the 
direct degradation of ECM components. In studies examining human atherosclerotic lesion 
composition, it has been demonstrated that the expression of MMPs, particularly MMPs-1, -2, -3, and 
-9, are significantly elevated in diseased vessels compared to control vessels (Orbe et al., 2003; 
Higashikata et al., 2006; Dollery and Libby, 2006). The excessive degradation of elastin and 
interstitial collagen (including the fibrillar collagens Type I and III) by activated MMPs is thought to 
play a role in vascular remodelling and plaque destabilisation. The importance of the macrophage 
foam cell in atherosclerosis pathology is emphasised by their capacity to propagate and maintain local 
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inflammation and to induce structural alterations within the developing lesion, effects which can 
influence the clinical outcome of lesion progression. 
1.2.6 Clinical outcome of atherosclerosis progression 
The clinical outcome of atherosclerotic lesion rupture is incredibly difficult to predict as the severity 
of the event is largely dependent upon the underlying composition of the lesion. Lesion rupture can 
manifest in one of two forms: - frank rupture or superficial erosion. Dependent on the form of rupture, 
there may or may not be significant clinical repercussions (as reviewed by Schoenhagen et al., 2002). 
Myocardial infarction (MI), sudden death and stroke are potential complications of atherosclerotic 
lesions should they rupture and, through thrombus formation (and possibly, embolism), lead to vessel 
occlusion. 
1.2.7 Animal models of atherosclerosis 
A number of animal models are currently available to study atherosclerosis in vivo, and while 
advantages to using such systems exist, no model is without its drawbacks. Pigs, rabbits, dogs and to a 
lesser extent, non-human primates, represent large animal models currently in use. Such models 
exhibit similar physiology to humans including cardiovascular anatomy (pig) and thrombogenic 
profiles (non-human primates and dogs) however their use entails ethical, financial and logistical 
difficulties (reviewed by Vilahur et al., 2011; Zaragoza et al., 2011).  
Of the small animal models available (mouse, rat, hamster and guinea pig), murine models are the 
most widely used. Wild-type mouse strains are generally resistant to spontaneous lesion development 
due to their lipid physiology which differs drastically from that of humans. The cholesterol of wild-
type mice is transported largely in HDL particles, conferring a degree of protection against 
atherosclerosis. C57BL/6J represents the wild-type strain most sensitive to the development of mild 
lesions when maintained on a high fat diet (Paigen et al., 1987). Genetic manipulation of C57BL/6J 
mice has enabled the generation of new strains which are susceptible to, and exhibit varying degrees 
of, atherosclerosis. The LDL receptor deficient (LDLr
-/-
) mouse, apolipoprotein-E deficient (ApoE
-/-
) 
mouse and ApoE*3-Leiden (E3L) transgenic mouse constitute three such models. Both LDLr
-/-
 and 
E3L mice, which exhibit only mild hyperlipidemia and limited lesion development when maintained 
on regular chow (Ishibashi et al., 1993; Sehayek et al., 2001; Moore et al., 2003), are considered 
moderate models of atherosclerosis due to their development of moderate hyperlipidemia and lesions 
following high fat feeding (Ishibashi et al., 1993; van Vlijmen et al., 1994).  
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ApoE
-/-
 mice are considered a severe model of atherosclerosis. Apolipoprotein E (apoE), a 
glycoprotein component of plasma lipoproteins, serves as a ligand for cell surface lipoprotein 
receptors (such as the LDL receptor) and facilitates the removal of lipoproteins from the circulation 
(Mahley, 1988). Homozygous deletion of the apoE gene, results in a marked increase of plasma LDL 
and VLDL even when animals are maintained on regular chow (Plump et al., 1992). ApoE
-/-
 mice 
develop extensive lesions that mimic those of humans in terms of anatomical location and 
development. Early lesions, which resemble fatty streaks, can be detected in the aortic root and 
proximal aorta around 10 weeks of age and develop, over time, into fibrous, complicated plaques 
which are detected throughout the macrovasculature (Zhang et al., 1994; Nakashima et al., 1994; 
Reddick et al., 1994). Maintenance on a high fat diet significantly accelerates this process and further 
elevates plasma cholesterol (Nakashima et al., 1994). One shortcoming of the ApoE
-/- 
model is that 
the majority of plasma cholesterol is confined to the VLDL lipoprotein fraction as opposed to the 
LDL fraction in humans. In addition, evidence that ApoE has immunomodulatory actions (Tenger and 
Zhou, 2003) has raised questions regarding the effect of ApoE removal on the inflammatory 
component of atherosclerosis. However despite these limitations, the ApoE
-/-
 mouse is currently the 
most widely utilised murine model for the study of atherosclerosis progression. 
1.2.8 Pharmaceutical intervention 
Dyslipidaemia in the form of elevated plasma lipoproteins represents a major risk factor for the 
development of atherosclerosis. Lipoprotein metabolism has thus been identified as a target for 
pharmaceutical intervention in the prevention and/or treatment of atherosclerosis. Cholesterol 
represents a functional constituent of cell membranes and serves as an essential precursor in the 
biosynthesis of steroid hormones, bile acids and vitamin D. Cholesterol is obtained either 
exogenously, from dietary cholesterol, or endogenously through its synthesis, which occurs primarily 
in the liver. Due to its hydrophobic nature, the transport of cholesterol in the circulation requires its 
sequestration in lipoprotein particles: macromolecular complexes of triglycerides, cholesterol esters, 
non-esterified cholesterol, phospholipids and apolipoproteins. There are five major classes of 
lipoproteins: - (1) chylomicrons; (2) VLDL; (3) intermediate-density lipoproteins (IDL); (4) LDL and 
(5) high-density lipoproteins (HDL). Elevated plasma concentrations of apolipoprotein B (apoB) 
containing lipoproteins (chylomicron, IDL and LDL lipoprotein fractions) have been associated with 
elevated CHD risk, while HDL represents a strong inverse indicator of CHD risk (Walldius et al., 
2001; Luc et al., 2002; Talmud et al., 2002). 
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1.2.8.1 Statins 
The statin class of drugs constitute powerful lipid lowering agents used in the primary and secondary 
prevention of primary hypercholesterolaemia and mixed dyslipidaemias. The key rate limiting step of 
endogenous cholesterol biosynthesis is the reduction of 3-hydroxy-3-methylglutaryl CoA (HMG-
CoA) to mevalonic acid via the enzymatic action of HMG-CoA reductase. Statins represent potent 
inhibitors of HMG-CoA reductase and thus impair cholesterol synthesis. The net result of reduced 
cholesterol synthesis is reduced assembly and secretion of lipoproteins, upregulated hepatic LDL 
receptor expression and increased hepatic uptake of lipoproteins (Igel et al., 2002). Two sub-classes 
of statins exist: - the fermentation derived statins (lovastatin, pravastatin, and simvastatin) and the 
synthetic statins (atorvastatin, cerivastatin, fluvastatin). Randomised trials have reported that lowering 
LDL lipoprotein cholesterol through statin treatment decreases the incidence of major cardiovascular 
events by 25-35% (Ridker et al., 2008). The beneficial actions of statins extend beyond lipid-lowering 
to include anti-inflammatory, anti-oxidant and immunomodulatory effects however monotherapy has 
been associated with adverse side effects including myopathy, rhabdomyolysis, and elevated hepatic 
transaminases in some patients (Paoletti et al., 2002; Heeba et al., 2009). 
1.2.8.2 Fibrates  
The fibrate class of drugs constitute a group of fibric acid derivatives used in the treatment of 
hypoalphalipoproteinaemia (low plasma HDL) and hypertriglyceridaemia. Of the drug preparations 
currently available (including bezafibrate, clofibrate and gemfibrozil), fenofibrate  represents the most 
widely clinically used fibrate. Fibrates are selective agonists of the peroxisome proliferator-activated 
receptor (PPAR) family of nuclear receptor proteins. As lipid sensitive nuclear transcription factors, 
PPARs regulate multiple cellular functions including fatty acid metabolism, cytokine production and 
glucose homeostasis (reviewed by Soskic et al., 2011). Three ligand-specific isoforms of PPAR exist: 
- PPARα, PPARγ and PPARδ. Upon activation, PPARs heterodimerise with the retinoic X receptor 
(RXR) to recognise and bind DNA sequences, termed the peroxisome proliferator response elements 
(PPREs), upstream of the target gene (Muerhoff et al., 1992; Keller et al., 1993). In addition to 
positively regulating gene expression, there is evidence to suggest that PPAR signalling can trans-
repress the expression of non-target genes through physical interaction with other transcription factors 
including NF-κB and Smad-3 (Delerive et al., 1999; Fu et al., 2001). PPARα is highly expressed in 
the liver and is found in the heart, skeletal muscle and kidney, where its main function is to regulate 
fatty acid and lipoprotein metabolism (Braissant et al., 1996; Soskic et al., 2011). PPARγ is involved 
in glucose homeostasis and insulin sensitivity, while the function of PPARδ, which is not well 
understood, is thought to involve metabolism (Soskic et al., 2011). 
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Fibrates bind to PPARα, mimicking the endogenous lipid ligands which bind the receptor. The most 
pronounced effect of fibrate treatment, which underpins their clinical use in the management of 
dyslipidaemia, is a decrease in plasma triglycerides. Fibrate treatment has been reported to lower 
LDL-cholesterol and to elevate HDL-cholesterol (Caslake et al., 1993; Guerin et al., 2002); however 
these effects vary in magnitude depending on patient baseline plasma concentrations and the dose and 
potency of the fibrate used. Fibrates have been shown to alter the concentrations of LDL lipoprotein 
sub-fractions, lowering the plasma content of smaller, denser and more atherogenic LDL particles and 
increasing the plasma content of larger, buoyant, less atherogenic LDL particles (Caslake et al., 1993; 
de Graaf et al., 1993; Tokuno et al., 2007; Soskic et al., 2011). Furthermore, fibrates are reported to 
reduce the expression of apoC-III, an apolipoprotein which inhibits the activity of lipoprotein and 
hepatic lipases and represents a marker of atherogenesis (Chapman et al., 2010). Fenofibrate-
mediated activation of PPARα has also been reported to reduce the cholesterol ester and triglyceride 
exchange between HDL and VLDL-lipoproteins, an activity which is mediated via the cholesteryl 
ester transfer protein (CETP) (Guerin et al., 2002). 
Experimental evidence of the triglyceride lowering action of fibrates has given insight into the major 
underlying mechanisms conferring these effects. Murine studies have reported an increase in hepatic 
free fatty acid uptake and conversion to acyl-coA due to upregulated expression of the fatty acid 
transporter protein (FATP) and acyl-CoA synthetase (ACS) activity following fibrate treatment 
(Schoonjans et al., 1995; Martin et al., 1997). This induction of the β-oxidation pathway may serve to 
sequester the pool of free fatty acids available for assembly and secretion of triglyceride-rich 
lipoproteins, thus lowering hepatic lipoprotein secretion. Another likely mechanism suggests 
increased lipoprotein lipolysis. This notion is supported by experimental evidence from murine and 
human studies where fibrate treatment was demonstrated to suppress hepatic gene expression and 
secretion of ApoC-III (Staels et al., 1995; Staels et al., 1998). The subsequent reduction in the ApoC-
III content of lipoproteins would therefore increase their accessibility for triglyceride hydrolysis via 
the enzymatic action of lipases.  
1.3 Diet and coronary heart disease 
Saturated, monounsaturated and polyunsaturated fats constitute the three forms of naturally occurring 
fats. Until recently, consumption of fat in any of the aforementioned forms was considered 
detrimental to health. The key observation that Greenland Inuit populations exhibit low mortality 
rates from CHD despite consuming a diet rich in fat, led to the notion that reduced CHD mortality rate 
was due to the high percentage of polyunsaturated fats present in the diet (Dyerberg et al., 1975).  
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Fatty acids constitute carboxylic acids with carbon chains which can vary in length between two and 
thirty-six carbons. Polyunsaturated fatty acids (PUFAs) are characterised by the presence of two or 
more double bonds in the carbon chain structure. PUFA nomenclature is derived from the location of 
the first double bond relative to the methyl terminus of the molecule. The PUFAs linoleic acid (LA; 
18:2n-6) and α-linoleic acid (ALA; 18:3n-3) are denoted essential fatty acids (EFAs) as the human 
body lacks the required desaturase enzymes (∆12- and ∆15-desaturase) to synthesise these fatty acids 
de novo (Nelson and Cox, 2005 cited in Tvrzicka et al., 2011). LA and ALA serve as precursors to the 
ω-6 series of fatty acids, e.g. arachidonic acid (AA; 20:4n-6), and the ω-3 series of fatty acids, e.g. 
eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), respectively. The 
production of these sub-families of PUFAs is therefore directly related to the availability of EFAs. 
The Westernised diet is rich in ω-6 PUFAs, largely due to intensive production of cultured meats and 
eggs through modern agricultural practice. Modern Western diets are generally deficient in ω-3 
PUFAs compared to ancestral diets. Current estimates of an ω-6: ω-3 PUFA ratio of ~25:1 in modern 
Western diets as opposed to the likely <2:1 in ancestral diets supports this notion (Sayanova and 
Napier, 2004).  
The ω-6: ω-3 PUFA ratio has significant implications in terms of cell signalling and function. The 
eicosanoids represent a family of bioactive lipid mediators derived from the oxidation (primarily via 
the activity of cyclooxygenase and lipoxygenase enzymes) of PUFAs which regulate the magnitude of 
inflammatory responses. Eicosanoids derived from the ω-6 PUFA AA, including thromboxanes, two-
series prostaglandins (PGs) and four-series leukotrienes, tend to promote a physiological state that is 
pro-inflammatory, pro-thrombotic and induces vasospasm and vasoconstriction (reviewed by Harizi et 
al., 2008). If formed in large quantities, such mediators can contribute to the pathophysiology of 
certain inflammatory conditions and therefore serve as a recognised target of anti-inflammatory 
therapeutics. However, it is worthwhile to note that ω-6 PUFA derived eicosanoids are not solely pro-
inflammatory mediators as anti-inflammatory properties of the AA derived lipoxins have been 
described (Serhan et al., 2003). The ω-3 PUFAs EPA and DHA are also precursors for the 
lipoxygenase and cyclooxygenase oxidative pathways; however the products of their oxidation differ 
from AA to include the three-series prostaglandins, five-series leukotrienes and the anti-inflammatory 
E- and D-series resolvins (Serhan et al., 2000; Hong et al., 2003). The generation of eicosanoids from 
ω-3 PUFAs, which are often, although not exclusively, of a lesser potency than ω-6 PUFA derived 
eicosanoids, is largely associated with an anti-inflammatory, anti-thrombotic and vasodilatory 
physiological profile (Russo, 2009). It is these properties of ω-3 PUFAs which have been studied 
extensively in relation to their therapeutic potential in various disease pathologies.  
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1.3.1 Dietary sources of ω-3 PUFAs  
Botanical sources of ALA, the parent fatty acid of the ω-3 PUFAs, include soybeans, linseed, 
blackcurrant seeds and their oils. The ALA metabolites EPA and DHA can be directly sourced from 
cold water oily fish including salmon, sardines, mackerel and herring (Tvrzicka et al., 2011). Fish oil 
supplements, which contain 30%-50% ω-3 PUFAs by weight, are an important source also. The 
majority of EPA and DHA present in humans is exogenously sourced from fish or fish oil 
supplements as human metabolism of ALA is relatively inefficient (Brenna et al., 2009). 
1.3.2 Endogenous biosynthesis of long chain ω-3 PUFAs 
The long chain ω-3 PUFAs, EPA and DHA, are synthesised from the elongation and desaturation of 
ALA. The initial desaturation of ALA by the enzymatic action of ∆6-desaturase (D6D) constitutes the 
first and rate limiting step of long chain ω-3 PUFA synthesis. PPAR agonists and EFA deficiency 
have been demonstrated to influence D6D activity (Kawashima et al., 1990; Cho et al., 1999). 
Desaturation of ALA generates the transient production of octadecatetraenoic acid (OTA; 18:4n-3) 
which is further desaturated by ∆5-desaturase (D5D) to form EPA (see Figure 1.3 for structure). The 
subsequent biosynthesis of DHA is thought to occur via one of two main pathways. The first pathway, 
involves two consecutive elongations of EPA to yield tetracosapentaenoic acid, which is desaturated 
by D6D and undergoes a final C2 shortening cycle via β-oxidation in the peroxisome to yield DHA. 
This pathway is largely considered the predominant route of DHA biosynthesis in mammals 
(reviewed by Sayanova and Napier, 2004). The alternate linear pathway involves the elongation of 
EPA to docosapentaenoic acid (DPA; 22:5n-3) which is then desaturated by ∆4-desaturase (D4D) to 
generate DHA (reviewed by Sayanova and Napier, 2004), the structure of which is illustrated in 
Figure 1.3. The presence of the linear pathway remained speculative until the isolation and 
purification of D4D from the marine protist Thraustochytrium spp. (Qiu et al., 2001), confirmation of 
the pathways existence. The biosynthetic pathways of EPA and DHA are illustrated in Figure 1.4. 
 
 
 
 
 
20 
 
(A)  
HOOC CH3
 
 
 
 
(B) 
 
HOOC
CH3
 
 
 
 
Figure 1.2 Structures of EPA and DHA: The diagram illustrates the structure of (A) EPA and (B) 
DHA. 
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Figure 1.3 Biosynthesis of the ω-3 series of PUFAs: Diagram illustrating the endogenous 
biosynthesis of the ω-3 PUFAs EPA and DHA from the dietary precursor ALA. 
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1.3.3 ω-3 PUFAs and cardiovascular function 
Experimental evidence suggests that ω-3 PUFAs have the capacity to influence cardiac function. 
Indeed a recent study reported an inverse correlation between the DHA content of serum 
phospholipids and resting and 24 hour ambulatory diastolic blood pressure (Liu et al., 2011). A meta-
analysis of 36 randomised trials reported an association between fish oil intake (median dose 3.7g/day 
EPA + DHA) and reduced systolic and diastolic blood pressure; effects which were most noticeable in 
elderly and hypertensive populations (Geleijnse et al., 2002). Another meta-analysis of randomised 
trials, reported a reduced heart rate in individuals receiving fish oil (~3.5g/day EPA + DHA) 
compared to placebo (Mozzaffarian et al., 2005). The study also revealed that a greater reduction in 
heart rate was reported in longer interventions (>12 weeks) and in patients with higher baseline heart 
rates (>69 beats per minute). While the aforementioned findings reflect the effects of higher ω-3 
PUFA doses, studies employing low to moderate doses demonstrate equivocal results. It was recently 
reported that low dose DHA (700mg/day for 12 weeks) significantly lowered resting diastolic, but not 
systolic, blood pressure compared to placebo while in contrast, low dose EPA (480mg/day for 12 
weeks) had no effect on BP (Dokholyan et al., 2004; Theobald et al., 2007).  
The ω-3 PUFAs have also been implicated in the modulation of endothelial function, although there is 
a degree of ambiguity between experimental findings. Ex vivo studies conducted in bovine and ovine 
isolated vessel preparations (pulmonary and coronary arteries) have demonstrated the capacity of 
EPA to dose-dependently relax blood vessels; an effect which is associated with nitric oxide 
production (Omura et al., 2001; Singh et al., 2010). However, further investigation of the association 
between ω-3 PUFAs and endothelial function in humans has yielded findings inconsistent to those of 
animal experiments. Indeed, the majority of human studies have reported no effect of ω-3 PUFA 
supplementation (0.45-3.4g/day EPA + DHA) on flow mediated dilatation and/or arterial stiffness, 
markers of endothelial function (Anderson et al., 2010; Sanders et al., 2011; Skulas-ray et al., 2011; 
Mackay et al., 2012).  
1.3.4 ω-3 PUFAs and lipid metabolism 
The hypotriglyceridaemic effects of ω-3 PUFAs are well established. A meta-analysis of thirty-six 
cross-over and twenty-nine parallel-design studies collated the observed effects of ω-3 PUFA 
supplementation on serum lipids. The study reported a 25-30% reduction in serum triglycerides with 
intakes of approximately 4g/day of ω-3 PUFAs; effects which were dose-dependent and proportionate 
to baseline levels (Harris, 1997). Despite the well accepted capacity of ω-3 PUFAs to lower fasting 
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and postprandial serum triglycerides, the molecular mechanisms through which these effects are 
achieved are yet to be fully elucidated.  
The bulk of experimental evidence derived from pre-clinical studies suggests two major routes of 
triglyceride reduction: - (1) a reduction in hepatic triglyceride synthesis (and assembly and secretion 
of triglyceride-rich VLDL) and (2) enhanced clearance of triglycerides from the circulation (reviewed 
by Harris et al., 2008). The reduction in hepatic triglyceride reduction is thought to be the result of 
decreased hepatic lipogenesis. Indeed, fish oil feeding of mice was reported to decrease serum 
triglycerides and, concomitantly, to decrease hepatic mRNA expression of the sterol regulatory 
element-binding protein (SREBP) SREBP-1c, a transcription factor involved in the regulation of de 
novo lipogenesis (Kim et al., 1999). This finding was supported by the observation that EPA 
mediated inhibition of SREBP-1c protein expression was associated with decreased triglyceride 
synthesis in human hepatoma cells (Zaima et al., 2006). EPA and DHA represent ligands of PPAR 
receptors. In light of this, it has been postulated that EPA and DHA may modulate hepatic 
peroxisomal and/or mitochondrial fatty acid β-oxidation via interaction with PPARα receptors (Harris 
et al., 2008). Supplementation with both EPA and DHA (administered individually, 4g/day for 4 
weeks) has been reported to significantly reduce chylomicron half-lives, to reduce chylomicron 
particle size and to significantly enhance pre-heparin lipoprotein lipase activity during the fed state 
(Park and Harris, 2003). As chylomicrons represent triglyceride rich lipoproteins, these data provide 
evidence to suggest enhanced triglyceride clearance from the circulation following regular intake of 
ω-3 PUFAs. 
1.3.5 ω-3 PUFAs: Role in atherosclerosis 
In a review of twenty-five studies that examined the association between ω-3 PUFA supplementation 
and CHD risk, Harris et al. (2007) highlighted the collective demonstration of an inverse correlation 
between tissue levels of EPA and DHA and the occurrence of major cardiovascular events. In support 
of this finding, several large-scale randomised trials (DART Trial, GISSI-Prevenzione Study, JELIS 
Study) have documented the effectiveness ω-3 PUFA supplementation in the primary and secondary 
prevention of CHD. Indeed consumption of ω-3 PUFAs, either in the form of oily fish or fish oil 
capsules, has been reported to significantly reduce all cause mortality (≥1 year follow up), major 
cardiac events (non-fatal myocardial infarction and stroke) and sudden cardiac death (Burr et al., 
1989; GISSI-Prevenzione Investigators, 1999; Yokoyama et al., 2007).  
Considering the acute, often fatal, clinical repercussions of atherosclerotic plaque rupture, the effects 
of ω-3 PUFAs may arise from modulation of processes key to atherosclerosis progression. Indeed, 
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several epidemiological studies have provided evidence to support this notion. In patients exhibiting 
angiographically evident coronary artery disease, supplementation with fish oil concentrate (EPA + 
DHA, approximately 1.5g/day for 24 months) was demonstrated to reduce coronary artery lesion 
progression and the occurrence of acute cardiovascular events in comparison to individuals receiving 
the placebo intervention (von Schacky et al, 1999). A population based, cross-sectional study 
examined sub-clinical atherosclerosis in three cohorts: - (1) 360 Caucasian men residing in the U.S.; 
(2) 281 Japanese men residing in the U.S. and (3) 281 Japanese men residing in Japan, using intima-
media thickness (IMT) and coronary artery calcification (CAC) as markers of disease. Although there 
were no difference in CAC burden between cohorts, serum ω-3 PUFA levels were found to inversely 
correlate with IMT in the Japanese men residing in Japan cohort, while no such correlation was 
demonstrated in the other cohorts (Sekikawa et al., 2008). These findings support the proposed anti-
atherosclerotic effects of ω-3 PUFAs; however the underlying mechanism(s) conferring these effects 
remain unclear. 
One of the mechanisms postulated to confer the anti-atherosclerotic and cardioprotective benefits of 
ω-3 PUFAs is the stabilisation of atherosclerotic plaques – an effect which would slow disease 
progression to the advanced, complicated stages and therefore reduce the likelihood of an acute 
cardiovascular event. A number of direct and indirect mechanisms have been propounded to account 
for the potential plaque stabilising effects of ω-3 PUFAs. The aforementioned effects of ω-3 PUFAs 
on lipid metabolism may represent one such indirect mechanism. Indeed, hypertriglyceridaemia is a 
recognised risk factor for cardiovascular disease, therefore its attenuation by ω-3 PUFA 
supplementation most likely contributes to their overall effects. Furthermore, dietary supplementation 
with ω-3 PUFAs (1.24g/day for 12 weeks) has been reported to modify the phenotype of lipoproteins 
in patients exhibiting metabolic syndrome. Ω-3 PUFA enrichment of LDL lipoproteins was 
demonstrated to shift the phenotype of particles from the small, dense atherogenic LDL sub-class 
pattern B, to the larger, more buoyant, less atherogenic LDL sub-class pattern A (Hartwich et al., 
2009). The phenotype of the LDL particles infiltrating the developing lesion may influence lesion 
progression, as small dense LDL particles are known to promote inflammation and oxidative stress – 
key factors in disease development. The recruitment of leukocytes to the atherosclerotic vessel wall 
may also be influenced by the effects of ω-3 PUFAs. Indeed, dietary fish oil intake has been 
documented to lower chemoattractant production in mononuclear cell fractions, including platelet 
derived growth factor (PDGF) and MCP-1 (Baumann et al., 1999). Moreover, in vitro studies have 
reported the capacity of ω-3 PUFAs to decrease surface expression of the adhesion molecules ICAM-
1 and VCAM-1 by cultured human aortic endothelial cells (Wang et al., 2011). Reduced leukocyte 
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infiltration into developing plaques could serve to contain, even mitigate, the inflammatory response 
which fuels plaque progression. 
Other lines of evidence support a direct plaque stabilising property of ω-3 PUFAs. Thies et al. (2003) 
reported the key observation that dietary fish oil supplementation (1.4g/day EPA + DHA) directly 
altered plaque morphology inducing structural changes consistent with increased stability. Indeed, 
plaques obtained from fish oil supplemented individuals tended to be of the more stable Type IV 
phenotype (lipid core, thick fibrous cap) in contrast to plaques collected from placebo treated 
individuals, which tended to be of the less stable Type V phenotype (lipid core, thin fibrous cap). 
Furthermore, macrophage infiltration of plaques was found to be reduced in ω-3 PUFA supplemented 
individuals. Together, these findings were attributed to the effects of EPA, which was found to 
populate lesions in greater quantities than DHA. A more recent study in patients awaiting carotid 
endarterectomy revealed that in individuals randomly assigned to receive ω-3 PUFA ethyl ester 
capsules (providing 0.81g EPA and 0.675g DHA/day), the EPA content of plaque phospholipids 
inversely correlated with plaque instability and inflammation (Cawood et al., 2010). Interestingly, the 
study reported a significant reduction in foam cell infiltration and mRNA expression of MMP-7, 9- 
and 12 in plaques from ω-3 PUFA supplemented individuals. Downregulation of MMP activity could 
serve to stabilise plaques through preservation of the collagen component of the plaque. Indeed this 
notion is supported by the findings of Matsumoto et al (2008), who reported a significant increase in 
the collagen content of aortic root plaques in high fat fed ApoE
-/- 
mice supplemented with 5% EPA 
(w/w) respective to high fat fed controls. It is worthwhile to note that the overall potential of ω-3 
PUFAs to stabilise plaques may involve a combination of the aforementioned mechanisms, and 
perhaps, alternative effects which have yet to be determined.  
1.4 The endocannabinoid system 
The endocannabinoid system constitutes an endogenous signalling system which plays a pivotal role 
in a variety of centrally and peripherally regulated physiological processes. Pain sensation, appetite, 
memory and mood are influenced by the activity of the endocannabinoid system. Intense investigation 
of tetrahydrocannabinol (
9
-THC), the pyschoactive component of Cannabis sativa, preceded the 
discovery and subsequent identification of the various components of the endocannabinoid system 
which comprises: (i) G-protein-coupled receptors (GPCRs); (ii) endogenous cannabinoid ligands, of 
which N-arachidonoyl-ethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) 
represent the most intensively studied,  and (iii) the associated enzymatic apparatus which controls 
their synthesis and degradation (as reviewed by Montecucco and Di Marzo, In Press).  
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1.4.1 Cannabinoid receptors 
Molecular cloning has permitted the identification of two cannabinoid (CB) receptors, the CB1 
receptor and the CB2 receptor (Matsudo et al., 1990; Munro et al., 1993). The CB1 receptor, which has 
been cloned in human and murine tissue, is a seven transmembrane, GPCR containing 472 (human) or 
473 (rat) amino acids (as reviewed by Suguira and Waku, 2002). CB1 receptors are predominantly 
expressed in the central nervous system (e.g. the cortex, hippocampus, basal ganglia and 
hypothalamus), but are also located in numerous peripheral tissues including the heart, vasculature, 
adipose, liver and pancreas (reviewed by Vemuri et al., 2008; Rajesh et al., 2008). The CB2 receptor 
is also a GPCR which, in humans, shares ~44% amino acid sequence homology with the CB1 
receptor. CB2 receptors are expressed primarily in the periphery, particularly by immune cells, 
although there are reports of receptor expression by microglial cells and neurones (Van Sickle et al., 
2005). “Classical” CB receptor transmission is coupled through inhibitory G-proteins (Gi/o) linked 
either negatively, to adenylate cyclase, or positively, to mitogen-activated protein kinase, to 
downstream signals. However, CB1 receptors, via Gi/o, are also coupled to certain ion channels 
(reviewed by Vemuri et al., 2008). There is also experimental evidence that CB1 receptor activation 
may stimulate adenylate cyclase via a Gs protein coupled mechanism (Glass and Felder, 1997). 
Furthermore, evidence from functional studies has suggested the existence of non-CB receptor targets 
of the endocannabinoids. For example ∆9-THC, which is known to exert profound hypotension via 
CB1 receptor activation in vivo (Lake et al., 1997), did not induce vasodilation in the same rat 
mesenteric vascular bed preparations in which AEA induced sustained vasodilation (Wagner et al., 
1999). Indeed, several non-CB receptor targets of the endocannabinoids have since been identified 
including transient receptor potential vanilloid type-1 (TRPV1) channels (activated by AEA), PPARs 
and the speculated orphan receptor GPR55 and the vascular „anandamide‟ receptor (Zygmunt et al., 
1999; reviewed by Montecucco and Di Marzo, In Press). 
1.4.2 Endogenous cannabinoids 
Endogenous cannabinoids (endocannabinoids) represent long-chain fatty acid derivatives that were 
discovered shortly after characterisation of the CB receptors to be natural ligands of the 
endocannabinoid system. The first endocannabinoid described, anandamide (AEA), was extracted 
from porcine brain in 1992, while a second endocannabinoid, 2-AG, was later isolated from canine 
gut (Devane et al., 1992; Mechoulam et al., 1995). AEA is a partial agonist of CB receptors, with a 
marginally higher affinity and markedly higher efficacy for the CB1 receptor compared to the CB2 
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receptor, while 2-AG, which has a similar affinity for both CB receptors as AEA, has a higher 
efficacy at the CB2 receptor compared to AEA (reviewed by Pertwee and Ross, 2002). The 
endocannabinoids docosatetraenyl-ethanolamide, N-arachidonoyl dopamine, virodhamine and noladin 
ether have also been identified but not studied with the same intensity as AEA and 2-AG (Hanus et 
al., 2001; Porter et al., 2002; reviewed by Hiley, 2009). The endocannabinoids AEA and 2-AG, of 
which the structures are illustrated in Figure 1.4, are of relevance to the present study and will be 
discussed further below. 
1.4.2.1 Anandamide: biosynthesis and metabolism 
Anandamide is synthesised from the phospholipid precursor N-arachidonyl-phosphatidyl 
ethanolamine (NAPE), an N-acylated derivative of phosphatidyl-ethanolamine (PE). The primary 
pathway of synthesis involves the hydrolysis of NAPE by a calcium (Ca
2+
) sensitive, NAPE-selective 
phospholipase D (NAPE-PLD) to yield AEA (Di Marzo et al., 1994). Indeed, it was reported that 
stable overexpression of NAPE-PLD in mammalian cells led to a 50-90% reduction in NAPE levels, 
and a significant increase in AEA levels (Okamoto et al., 2005). However, the finding that brain AEA 
levels were unaltered in NAPE-PLD knockout mice compared to wild-type mice and moreover, that 
AEA could be synthesised from NAPE in a Ca
2+
 independent manner (Leung et al., 2006), suggested 
the presence of alternate routes of AEA biosynthesis. One such pathway has been identified, in which 
NAPE is converted to 2-lyso-NAPE via the enzymatic action of phospholipase A2, and then to AEA 
through a Ca
2+
 independent mechanism (Sun et al., 2004). The production of AEA via this pathway is 
thought to involve the enzyme α/β-hydrolase 4 (Abhd4), which was shown to generate 
glycerophospho-arachidonoyl ethanolamide (GpAEA) from lyso-NAPE, which in turn can be cleaved 
by a phosphodiesterase to yield AEA (Simon and Cravatt, 2006). A third pathway was also 
characterised in murine macrophages, whereby hydrolysis of NAPE by phospholipase C (PLC) yields 
the intermediate phospho-anandamide (pAEA), which is further hydrolysed by the activity of several 
phosphatases (notably PTPN22 and SHIP1) to produce AEA (Li et al., 2006; Li et al., 2008). The 
three main pathways of AEA synthesis are illustrated in Figure 1.5.  
Inactivation of AEA mediated signalling is achieved by its degradation. AEA is hydrolysed to its 
components, AA and ethanolamide, primarily via the activity of fatty amide hydrolase (FAAH), a 
membrane bound enzyme expressed by several tissues including the brain, heart and bladder (Riley et 
al., 2009; Strittmatter et al., 2012). Confirmation of FAAH mediated degradation of AEA was 
provided by in vivo studies in FAAH knockout mice where brain AEA levels were elevated >10 fold 
compared to wild-type counter-parts (Cravatt et al., 2001). In addition to the hydrolysis of AEA by 
FAAH, oxygenation pathways have been reported in the characterisation of AEA metabolism, 
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namely: (1) the lipoxygenase pathway, which metabolises AEA to hydroperoxyeicosatetraenoic acid 
ethanolamides (HETE-EAs); (2) the cyclooxygenase pathway, which metabolises AEA to prostamide 
products (PGE2 and PGD2) and (3) cytochromes P450, which metabolise AEA to epoxyeicosatrienoic 
acids (reviewed by Rouzer and Marnett, 2011).  
1.4.2.2 2-arachidonoylglycerol: biosynthesis and metabolism 
To date, two major pathways have been described for the synthesis of 2-AG, which is generated from 
arachidonic acid containing phospholipids. The first pathway involves the production of 
diacylglycerol from phosphatidylinositol via the activity of PLCβ (Kondo et al., 1998). 
Diacylglycerol is subsequently hydrolysed by an sn-1 specific diacylglycerol lipase (sn1-DAGL), 
evidence implicates sn1-DAGLα and sn1-DAGLβ, to yield 2-AG (Bisogno et al., 2003). The second 
pathway is typified by the generation of the intermediate lyso-phosphatidylinositol (lyso-PI) from 
phosphatidylinositol via the action of phospholipase A1. Lyso-PI is hydrolysed by a lyso-PI selective 
PLC to yield 2-AG (Ueda et al., 1993; reviewed in Muccioli, 2010). The biosynthetic pathways of 2-
AG production are illustrated in Figure 1.5. 
The metabolism of 2-AG to its constituent components, AA and glycerol, has been characterised to a 
lesser degree than that of AEA. The majority of experimental evidence implicates the activity of 
monoacylglycerol (MAGL), a serine hydrolase originally purified and cloned from adipose tissue 
(Tornqvist and Belfrage, 1976), although it is believed FAAH may also play a role in 2-AG 
metabolism. Indeed, convincing evidence of MAGL mediated 2-AG hydrolysis was provided by Dinh 
and colleagues, who demonstrated that overexpression of MAGL in rat neurones significantly 
depleted 2-AG concentrations, while in MAGL expressing HeLa cells, silencing of MAGL 
significantly elevated 2-AG concentrations (Dinh et al., 2002; Dinh et al., 2004). A more recent study 
confirmed that ~85% of 2-AG hydrolysis in the brain is mediated by MAGL activity. Furthermore, 
the same study reported the activity of two previously uncharacterised enzymes, ABHD12 and 
ABHD6, which were demonstrated to account for a further ~9% and ~4% of 2-AG hydrolysis 
respectively (Blankman et al., 2007).  
1.4.3 Cardiovascular effects of the endocannabinoid system 
Under normal physiological conditions, the endocannabinoid system can regulate cardiovascular 
homeostasis. In humans, the acute effects of smoking marijuana have been documented to include 
peripheral vasodilation, increased heart rate, altered cardiac function and moderate changes in blood  
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Figure 1.4 Endocannabinoid structures: Diagram illustrating the structure of (A) anandamide and (B) 2-AG. 
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Figure 1.5 Biosynthetic pathways of the endocannabinoids AEA and 2-AG: Diagrams illustrating the 
various pathways in which (A) AEA and (B) 2-AG are synthesised.  
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pressure (reviewed by Montecucco and Di Marzo, In Press). In anaesthetised animals, administration 
of the phytocannabinoid ∆9-THC induces bradycardia and a prolonged hypotensive effect (Lake et al., 
1997). Similarly, the endocannabinoid AEA has been reported to exert vasodilatory and cardio-
depressive actions compounded in a triphasic response involving: - (1) an initial vagally modulated 
period of bradycardia and hypotension; (2) a transient pressor stage and (3) a prolonged hypotensive 
effect (Varga et al., 1995; Lake et al., 1997; Pacher et al., 2004). The third phase of the response to 
AEA, and the prolonged hypotension associated with ∆9-THC, was found to be sensitive to the effects 
of the cannabinoid SR-14176A, a CB1 selective antagonist, strongly suggesting a role of the CB1 
receptor in this effect (Varga et al., 1995; Pacher et al., 2004). Similar to AEA, the endocannabinoid 
2-AG has been reported to induce sustained hypotension in anaesthetised animals, however, in 
contrast to the actions of AEA, this effect was associated with tachycardia (Varga et al., 1998; Járai et 
al., 2000). 
The endocannabinoid system and its components have also been implicated in cardiovascular 
pathophysiology. Ischaemia/reperfusion (I/R) injury represents the principle cause of tissue damage 
during incidences of stroke, myocardial infarction and circulatory shock. Multiple studies have 
reported elevated levels of tissue and circulating endocannabinoids following cerebral, hepatic and 
myocardial I/R injury (Wagner et al., 2001; Berger et al., 2004; Batkai et al., 2007). The cellular 
source and exact role of the endocannabinoids remains a point of contention however receptor studies 
have provided some evidence of their potential function in this setting. In murine models of 
myocardial I/R injury, pre-conditioning was found to significantly reduce infarct size and the 
occurrence and duration of arrhythmias; an effect which was abrogated by antagonism of the CB2 
(AM630), but not the CB1 (AM251), receptor (Hajrasouliha et al., 2009; Montecucco et al., 2009). 
Moreover selective agonism of the CB2 receptor prior to reperfusion, using the synthetic cannabinoid 
JWH133, was associated with attenuation of oxidative stress and inflammation (Montecucco et al., 
2009). Taken together, these studies propose a cardioprotective effect of endocannabinoids in the 
setting of I/R injury, mediated via CB2 receptor signalling.  
In relation to other cardiac pathologies, evidence from experimental models of heart failure implicate 
a detrimental role of CB1 receptor signalling in ventricular dysfunction, myocardial injury and 
oxidative/nitrative stress (Mukhopadhyay et al., 2007; Rajesh et al., 2012). Furthermore, plasma 
endocannabinoid levels were significantly elevated in patients with severe heart failure and in the 
myocardium of mice exhibiting type-1 diabetic cardiomyopathy (Weis et al., 2010; Rajesh et al., 
2012). 
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1.4.4 The endocannabinoid system and atherosclerosis 
In the vasculature, the endocannabinoid system has been demonstrated to influence atherosclerosis 
pathophysiology. Indeed Sugamura et al (2009) demonstrated activation of the endocannabinoid 
system in patients exhibiting advanced coronary artery disease, where patients displayed elevated 
levels of circulating endocannabinoids and increased CB1 receptor expression in coronary plaques. In 
2005, Steffens and colleagues reported the key observation that exogenous administration of the 
phytocannabinoid ∆9-THC dose dependently reduced the progression of atherosclerotic lesions in the 
aortic sinus of high fat fed ApoE
-/-
 mice. The reduction in lesion progression was associated with 
reduced leukocyte adhesion to the vascular wall; effects which were abolished by co-administration of 
∆9-THC with SR144528, a CB2 selective antagonist. More recently, Dol-Gleizes et al (2009) 
demonstrated a pro-atherogenic role of the CB1 receptor in a murine model of atherosclerosis, where 
administration of a CB1 selective antagonist (rimonabant) attenuated lesion development, suggesting a 
possible pro-atherogenic effect of endocannabinoid signalling at this receptor. Endocannabinoids may 
influence lesion progression through their effects on inflammatory cells. Indeed, AEA has been 
demonstrated to dose dependently attenuate TNF-α induced expression of ICAM-1 and VCAM-1 in 
human coronary artery endothelial cells (HCAECs) and moreover, to attenuate TNF-α stimulated 
THP-1 monocyte adhesion; both effects of which were sensitive to CB1 and CB2 receptor blockade 
(Batkai et al., 2007). Furthermore, there is evidence to suggest a possible pro-thrombotic role of the 
endocannabinoids (AEA and 2-AG), which have been reported to activate platelets (Braud et al., 
2000; Maccarrone et al., 2001). Taken together, it is evident from the literature that there is a 
functional involvement of components of the endocannabinoid system, in atherosclerosis 
development. 
There is some preliminary evidence to suggest a potential interaction between the long chain ω-3 
PUFAs and activation of the endocannabinoid system. Indeed, in vivo feeding studies have 
demonstrated the capacity of dietary intervention with ω-3 PUFAs to modulate the levels of 
endocannabinoids present in the brain (Berger et al., 2001; Wood et al., 2010), although it is currently 
unknown whether or not a similar effect would occur in the cardiovascular system. In animal models 
of experimental hyperlipidaemia, feeding of an atherogenic diet has been reported to influence 
endocannabinoid levels present in peripheral tissues (Matias et al., 2008; Montecucco et al., 2009). 
Given the association between hyperlipidaemia and CHD risk and, considering the previously 
discussed role(s) of ω-3 PUFAs and endocannabinoids in atherosclerosis pathology, it is plausible that 
their interaction may influence the development and clinical outcome of the disease, although such an 
effect is yet to be fully characterised. 
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1.5 Hypothesis 
While the cardioprotective and anti-atherosclerotic effects of long chain ω-3 PUFAs are well 
documented, the underlying cellular mechanisms conferring such benefits remain elusive. Given that 
there is an emerging body of evidence implicating the involvement of the endocannabinoid system in 
a variety of disease pathologies including atherosclerosis (Di Marzo, 2008), that preliminary evidence 
exists that dietary supplementation with long chain ω-3 PUFAs alters endocannabinoid levels in 
experimental animals (Berger et al., 2001; Wood et al., 2010) and that the metabolic pathways for 
both ω-3 PUFAs and endocannabinoids share some common steps, it is possible that some of the 
mechanisms underlying the anti-atherosclerotic and plaque stabilising properties of ω-3 PUFAs may 
involve components of the endocannabinoid system. This study therefore set out to test this 
hypothesis, with the following specific aims and objectives. 
1.5.1 Objectives 
The aim of the present study was to examine the potential mechanisms underlying the anti-
atherosclerotic effects of the long chain ω-3 PUFAs EPA and DHA and to assess whether such effects 
are related to activation of the endocannabinoid system and/or cardiovascular remodelling. The key 
objectives of the project were as follows: - 
(i) To undertake studies using an in vivo model (high fat/high cholesterol fed ApoE
-/-
 mouse) to 
determine the effects of dietary supplementation with fish oil (containing EPA) on: 
 a. Hepatic lipid physiology and plasma lipoprotein profiles 
 b. Cardiac and vascular remodelling 
 c. Tissue endocannabinoid levels 
 d. Endothelial function 
(ii) To develop an in vitro model of lipid loading in a human monocytic cell line to allow 
investigation of: 
 a. The impact of cannabinoid receptor signalling on lipid accumulation and inflammatory 
marker production (MCP-1) 
 b. Endocannabinoid synthesis 
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Chapter 2: General Methods 
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2.1 In Vitro techniques 
2.1.1 THP-1 cell resuscitation 
Frozen human acute monocytic leukaemia (THP-1) cells were removed from liquid nitrogen storage 
and warmed to 37ºC as quickly as possible. The contents of the warmed ampoule were transferred to 
9ml of RPMI-1640 GlutaMAX medium supplemented with 10% heat-inactivated FBS and 1% 
penicillin streptomycin solution and centrifuged at 1200rpm for 5 minutes. Cell pellets were then 
resuspended in 2ml of medium and aliquots of 0.5ml were transferred to four 25cm
2
 culture flasks. 
Cells were subsequently incubated in a humid atmosphere at 37ºC with the addition of 5% carbon 
dioxide. Medium preparation as well as subsequent resuscitation and subculture was conducted within 
a Class II Microbiological Safety Unit (Aura 2000 M.A.C, Bioair Instruments, Italy). 
2.1.2 THP-1 cell freezing 
THP-1 cells were systematically frozen down at different passages in order to establish plentiful 
frozen supplies. Cells to be frozen were centrifuged at 1400rpm for 5 minutes and the pellet 
resuspended in 1ml fresh medium. Following assessment of cell numbers (method reported in section 
2.1.4.1), cells were distributed to cryovials in aliquots of 1x10
6 
cells. In addition, freezing medium 
(10% dimethyl sulfoxide (DMSO) in fresh medium) was added to the cryovials to give a final volume 
of 1ml. Cells were incubated at -20ºC for several hours in a Nalgene® cryogenic freezing container 
(Thermo Scientific, UK) and then stored at -80ºC overnight. Following this incubation period, cells 
were transferred to liquid nitrogen storage. 
2.1.3 THP-1 cell culture 
THP-1 cells were purchased (ECACC, UK), resuscitated (see section 2.1.1) and sub-cultured as 
follows. Culture was conducted in T75cm
2
 Nunc™ flasks (Nunc, Thermo Scientific, UK) and cells 
were maintained in the exponential phase of growth with numbers never exceeding 8x10
5
 cells/ml. 
Cells were sustained on RPMI-1640 GlutaMAX medium as described in section 2.1.1. To refresh 
medium, cells were collected and centrifuged at 1400rpm for 5 minutes. The pellet was resuspended 
in 1ml fresh medium and transferred to a new T75cm flask containing 15ml of fresh medium.  Whole 
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medium changes were performed weekly and a 5ml top-up of fresh medium was added to each flask 
bi-weekly. Cell population size was regularly assessed using the method described in section 2.1.4.1. 
2.1.4 Cell counting assays 
2.1.4.1 Trypan blue staining 
The size of individual cell populations was regularly assessed during routine culture using trypan blue 
– a stain derived from toluidine. Based on the dye exclusion method, viable cells were visualised and 
distinguished from non-viable cells which, due to the lack of a functional membrane, retained dye. 
In order to count viable cells, a 1:4 dilution of cell suspension was prepared. During replenishment of 
medium, a 10µl aliquot was removed from the resuspended cells and transferred to an eppendorf 
containing 10µl fresh medium and 20µl 0.4% trypan blue stain. The solution was incubated for 5 
minutes at room temperature then placed in a haemocytometer. In the central quadrant, unstained 
(viable) cells were enumerated while stained (dead) cells were not enumerated. This was repeated 3 
times and the mean number of viable cells was thus calculated (Equation 2.1). 
 
 
Equation 2.1 
2.1.4.2 Coomassie brilliant blue staining 
Coomassie Brilliant Blue R-250 represents a popular dye for visualising proteins. The following 
method was employed to visualise and enumerate cell adherence in culture plates, as detailed in 
Chapter 3 section 3.2.1. 
Five hundred millilitres of staining solution (see Table 2.1) and one litre of destain solution (see Table 
2.1) were prepared. The staining solution was filtered through two filter paper sections (grade 1, 
Whatman) prior to use. Cells were fixed as described in section 2.1.5. One millilitre of staining 
solution was applied to each well for 20 minutes. The staining solution was aspirated off and each 
well rinsed with destain solution until the wells appeared clear. Stained cells were viewed under the 
microscope (x40 magnification) and within a designated 1cm
2
 cube, 3 fields of vision were chosen at 
random. The number of adhered cells was enumerated. 
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Staining Solution (500ml) 35ml acetic acid, 175ml methanol and 2.5ml Coomassie Blue R-
250 diluted in 287.5ml distilled H2O 
Destain Solution (500ml) 35ml acetic acid and 175ml methanol diluted in 290ml distilled 
H2O 
4% Paraformaldehyde 4g paraformaldehyde dissolved in 100ml PBS 
Table 2.1 Coomassie Blue Stain: Preparation of staining solutions and fixative. 
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2.1.5 Cell fixation 
Following completion of experimental protocols, cells were washed with 1ml room temperature 
phosphate buffered saline (PBS; see Table 2.2 for preparation) and were fixed in 1ml of 4% 
paraformaldehyde (at 4ºC, see Table 2.1 for preparation) for 20 minutes at room temperature. 
Following fixation, cells were rinsed with 1ml distilled H2O to remove any residual paraformaldehyde 
and the plates were allowed to dry for 30 minutes prior to beginning staining. 
2.1.6 Bradford dye-binding assay 
The Bradford dye-binding procedure constitutes an elegant colorimetric assay used to determine total 
protein concentrations. First described by Bradford (Bradford, 1976), the assay quantifies protein 
concentration through measuring the binding of Coomassie Brilliant Blue G-250 dye to basic and 
aromatic amino acid bases and comparing such binding to samples of known protein concentration. 
Binding can be visualised as a characteristic colour change from brown to blue. 
In a 96 well microtiter plate, 50µl of the blank (deionised H2O) and gamma globulin standards 
(prepared as in Table 2.3) were added to wells in quadruplicate. Samples were added to the plate in 
quadruplicate to a final volume of 50µl. Two hundred microlitres of Bradford reagent was added to 
each well and the plate was tapped gently to mix the solutions. The reaction was incubated for 5 
minutes at room temperature and the absorbance was measured at 595nm using a 96-well plate reader 
(µQuant model, BioTek, UK). 
2.1.7 Oil red O staining 
Oil red O (ORO), a lysochrome diazo dye, was employed to selectively stain lipids thus enabling the 
study of lipid uptake in fixed cell populations as detailed in Chapter 3, section 3.2.2. The method is 
outlined as follows. 
ORO stock solution was prepared (see Table 2.4) and stirred overnight at room temperature. The 
stock was then filtered through two filter paper sections (grade 1, Whatman) and stored at 4
o
C. 
Working ORO solution was prepared from the stock (as illustrated in Table 2.4) and filtered before 
use. Cells were washed and fixed in 4% paraformaldehyde as described in section 2.1.5. One millilitre 
room temperature ORO working solution was applied to each well for 10 minutes. Wells were  
39 
 
Phosphate Buffered Saline 
(PBS) 
1 PBS Tablet was dissolved in 100ml distilled H2O to give NaCl 
8g/L, KCl 0.2g/L  
Table 2.2 Preparation of phosphate buffered saline. 
 
Standard Concentration 
(µg/ml) 
Volume of gamma globulin 
0.1mg/ml 
(µl) 
Volume of diluent: distilled 
H2O 
(µl) 
1 10 40 
2 20 30 
3 30 20 
4 40 10 
5 50 0 
 Table 2.3 Bradford Assay: Preparation of standards. 
 
 
Oil Red O Stock Solution 0.35 grams ORO dissolved in 100ml 100% isopropanol 
Oil Red O Working Solution 6 parts ORO stock solution and 4 parts distilled H2O 
Table 2.4 Oil red O: Preparation of ORO solutions. 
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immediately rinsed with distilled H2O immediately following stain removal and the wells were 
allowed to air dry. The ORO stain was eluted using 1ml 100% isopropanol which was applied to each 
well for around 30 seconds. To quantify the lipid particle content of the sample, the optical density of 
eluted stain was measured at 510nm using a spectrophotometer (Helios Epsilon UV-visible, Thermo 
Scientific, UK). The blank was established using 100% isopropanol. 
2.1.8 ELISA assay 
Enzyme-linked immunosorbent assays (ELISAs) were employed to measure the presence and 
concentration of various proteins in cell culture supernates. DuoSet ELISA kits, buffer, wash 
solutions and stop solutions were purchased from R & D Systems (UK) and the standard method 
detailed in the kit protocol was conducted. Antibody (working) concentrations were kit specific and 
are not detailed below. 
On a 96-well plate, wells were coated with 100µl of capture antibody and sealed with an adhesive 
plate cover for overnight incubation at room temperature with gentle agitation. Each well was 
aspirated and washed three times in 400µl of wash buffer (see Table 2.5), removing any residual wash 
buffer by inverting and blotting the plate against paper towels. Plates were blocked for a period of 1 
hour by the addition of 300µl of reagent diluent (see Table 2.5) to each well. The aspiration and wash 
step was repeated. One hundred millilitres of standards and samples (diluted in reagent diluent if 
necessary) were added to the appropriate wells and the plate was sealed and incubated for 2 hours at 
room temperature. The aspiration and wash step was repeated. Wells were coated with 100µl of 
detection antibody and the plate was sealed and incubated for a further 2 hours at room temperature. 
A further aspiration and wash step was undertaken. Wells were coated with 100µl of streptavidin 
conjugated to horseradish-peroxidase and the plate was wrapped in foil (to avoid light interference) 
and incubated for a further 20 minutes at room temperature. A final aspiration and wash step was 
undertaken. Wells were coated with 100µl of substrate solution (see Table 2.5) and the plate 
incubated for a final 20 minutes at room temperature. Fifty microlitres of stop solution (see Table 2.5) 
was then added to each well and the well contents were gently mixed through tapping. The optical 
density of the samples was immediately measured at 450nm using a 96-well plate reader. 
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Table 2.5 ELISA Assay: Solutions purchased from R&D systems (catalogue numbers in brackets). 
  
Wash Buffer 0.05% Tween® 20 in PBS (#WA126) 
Reagent Diluent 
Substrate Solution 
Stop Solution 
1% BSA in PBS, pH7.2 – 7.4 (#DY995) 
1:1 mixture of H2O2 and tetramethylbenzidine (#DY999) 
2 N H2SO4 (# DY994) 
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2.1.9 MTS assay 
In order to assess cell viability and establish any cytotoxic effects of various compounds, CellTiter 96 
AQueous One Solution reagent was used. The solution contains the key compound [3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; 
MTS
(a)
] which is bioreduced by viable cells to a coloured formazan product. The quantity of formazan 
product produced, which is determined by measuring absorbance at 490nm, is proportionately related 
to the number of viable cells in the sample. Cells were seeded onto a 96-well plate at a density of 
20,000 cells per well, in a total volume of 100µl. A range of concentrations of the compound being 
assessed were applied to the cells in replicates of six. Twenty microlitres of the MTS solution was 
then applied to each sample and the cells were incubated for 2 hours at 37
o
C, in a humidified, 5% CO2 
atmosphere. Following completion of the incubation period, the absorbance was measured at 490nm 
using a 96-well plate reader.  
2.2 In Vivo techniques 
2.2.1 Animal sourcing and housing 
Animals were purchased for subsequent procedures under project licence number 60/4231, granted 
by the Home Office in accordance with the Animals (Scientific Procedures) Act 1986. In addition, 
individual procedures were performed in accordance with the guidelines detailed in the Animals 
(Scientific Procedures) Act 1986 under personal licence, 60/11352. Male ApoE knockout 
(B6.129P2-Apoe
tm1Unc
/Crl*) and wild type control (JAX® C57BL/6J) mice were purchased from 
Charles River Laboratories (UK) and housed at an external facility. Mice were housed in cages of 10 
according to experimental group, in a temperature (21ºC ± 2ºC) and humidity (55% ±10%) regulated 
environment maintained by a TREND BSU Management System (Trend, UK). A 12 hour light/dark 
cycle was regulated by a Philips LightMaster system (Philips, UK). Lights were fully operational 
between the hours of 7am and 7pm. A ramping system, operational between the hours of 6.30am and 
7am and 6.30pm and 7pm, mimicked “dawn” and “dusk” respectively. While housed, mice were 
allowed free access to chow and drinking water. 
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2.2.2 Dietary intervention 
To conduct dietary intervention studies, specialised diets were developed to replace the regular chow. 
Each diet consisted of a purified powdered base (Diet W) containing 0.25% cholesterol w/w, 16% 
crude fat w/w supplemented with a specific additive. The diets were prepared as follows.  
Agar ash was dissolved in distilled H2O, to an end volume of 1 litre per kilogram of diet being 
produced. The agar solution was maintained in a liquid state at 60ºC. Diet W was weighed out and 
systematically homogenised with the appropriate weight of supplement as detailed in Chapter 5, 
section 5.2.2. The agar solution was allowed to cool to 50ºC and mixed with the powdered diet and 
supplement to form homogenous dough. Dough was spread on trays lined with baking paper to a height 
of 1 - 1.5cm and allowed to cool for 60 minutes. Grooves were cut into the chilled dough creating sections 
of 2 x 2cm and stored at -20ºC overnight. Diet was broken into squares and freeze-dried for 2-3 days 
then moved to -80ºC storage. 
2.2.3 Surgical procedure for the measurement of haemodynamics 
The following surgical protocol was used to prepare the mouse. Anaesthesia was induced using a 
combination of ketamine and xylazine, 120mg kg
-1
 and 16mg kg
-1
 respectively (injection volume 
of 0.1ml per 10g weight). Anaesthetic was prepared (as described in Table 2.6) and administered to 
the intra-peritoneal cavity. Induction was followed by a short stabilisation period during which depth 
of anaesthesia was assessed (pinch reflex) prior to beginning surgery. The neck area was sanitised with 
saline (see Table 2.6) and an incision made in the skin by blunt dissection. The carotid artery and 
jugular vein were isolated and cannulated for measurement of arterial blood pressure and drug 
administration respectively using flame-stretched Portex polythene tubing (0.58mm ID x 0.96mm 
OD; Scientific Laboratory Supplies, UK).  
To measure arterial blood pressure, the arterial cannula was connected to a physiological pressure 
transducer which relayed signals through a Bridge Amplifier and Animal Bio Amplifier 
(ADInstruments, UK). Mean arterial blood pressure (MABP) was calculated using the following 
equation: 
 
Equation 2.2 
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Saline Solution 0.9% sodium chloride (0.9g NaCl in 100ml distilled H2O) 
Heparinised Saline 20 units Heparin per 1ml of 0.9% NaCl solution 
Anaesthetic Solution 0.6ml ketamine, 0.4ml xylazine diluted in 4ml distilled H2O 
Table 2.6: Surgical Procedure: Preparation of solutions used in surgery. 
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Heart rate (HR) was calculated from a Lead I electrocardiogram recorded from subcutaneous limb 
leads. Both arterial blood pressure (BP) and HR signals were acquired, visualised and continuously 
recorded using LabChart 5 software (ADInstruments, UK). The trachea was cannulated allowing 
respiration to be maintained artificially using a small animal ventilator (Harvard Apparatus, UK) 
operating at 120 strokes min
-1
 (stroke volume 100µl 10g
-1
). Core temperature was continuously monitored 
through a rectal thermometer and maintained at 37ºC on a heat pad (Pico Services LTD, UK). Depth of 
anaesthesia was regularly assessed (pinch reflex and continuous monitoring of blood pressure) during the 
experimental protocol and, if required, an anaesthetic top-up of 50µl was administered to the intra-
peritoneal cavity. To interpret BP responses accurately, BP was measured at fixed time points over a 420 
second period, commencing just prior to the intra-venous injection of the pharmacological intervention. 
The absolute values (millimetres of mercury: mmHg) recorded were converted to a percentage change 
from the baseline (time point 0). The percentage changes were subjected to area under the curve 
(AUTC) analysis which enabled graphical presentation of reductions in BP. 
2.2.4 Tissue harvest 
Blood was withdrawn via the arterial cannula into 1ml syringes containing heparinised saline, and 
then centrifuged for 5 minutes at 13,000rpm at room temperature. The plasma fraction was collected 
from each sample and snap frozen in liquid nitrogen. The chest cavity was opened and the lungs 
removed and discarded. The thoracic aorta, liver and brain were removed and snap frozen. Hearts 
were removed and were fixed in either formalin or cryomatrix (Thermo Scientific, UK) for histology, 
or snap frozen for biochemical analysis. Following retrieval of all tissues, samples were moved to -
80ºC storage. 
2.2.5 Blood sample analysis 
A Konelab 30 discrete clinical analyser (Thermo Scientific, UK) constitutes an automated system 
capable of undertaking numerous sensitive assays with multiple applications. The clinical analyser 
was employed for the detection of cholesterol, lipoprotein sub-fractions (LDL and HDL) and 
triglycerides in the plasma fraction of blood samples. The samples, which were prepared as outlined 
in section 2.2.4, were placed in the analyser and the pre-programmed assays were allowed to run. 
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2.2.6 Tissue lipid extraction  
Cellular lipids exist in close association with other non lipid cellular components e.g. sugars, 
polysaccharides and proteins. In order to be studied, lipids must be isolated from the aforementioned 
constituents. Extraction of lipids from hepatic tissue was achieved using an adapted version of the 
established Folch method (Folch et al., 1957). Glass bottles containing 10µl internal standard (C:17:0, 
heptadecanoic acid) were placed on ice. A 200mg sample of the tissue being extracted was added to 
each bottle as well as 4ml chloroform: methanol (2:1). Each sample was homogenised for 2 minutes 
(ultra-turrax mixer). Following the addition of 2ml 0.9% sodium chloride, samples were homogenised 
for a further 30 seconds. Samples were centrifuged at 2500rpm for 10 minutes at 20ºC. The aqueous 
layer was discarded and the underlying chloroform layer collected for solvent removal under nitrogen. 
The remaining extracted lipid was weighed and quantified as a percentage of the original tissue 
weight and stored at -20ºC for further analysis.  
2.2.7 FAME analysis 
Determination of the fatty acid methyl ester (FAME) composition of crude lipid extracts, obtained as 
outlined in section 2.2.6, was undertaken using FAME analysis. A 20mg sample of lipid was 
dissolved in 0.5ml hexane with 2ml methanolic HCL (2ml of acetyl chloride added dropwise to 20ml 
of cooled methanol) and 10µl internal standard (C:19:0, nonadecanoic acid 2mg/ml in methanol). 
Samples were boiled for 2 hours followed by a cooling period. To each sample, 2.5ml of distilled, 
deionised H2O and 2.5ml of hexane was added. Samples were then shaken vigorously for 15-20 
seconds and centrifuged briefly at 3000rpm to separate layers. The top hexane layer was collected and 
the original sample re-extracted twice more using 2.5ml of diethyl-ether. The combined hexane/ether 
extract was washed with 4ml H2O and vigorously shaken for 15-20 seconds. The aqueous layer was 
then removed via aspiration and the wash step repeated twice. The top solvent layer was dried with 
anhydrous sodium sulphate and evaporated under nitrogen at 40ºC. The residue was then dissolved in 
0.1ml of 0.02% 2, 6-di-tert-butyl-4-methyl phenol (BHT) in hexane and stored under nitrogen at 4
o
C.  
Identification and quantification of the fatty acid methyl esters was achieved by separation using a 
6890 gas chromtograph (GC; Agilent, UK). A 50m CP Sil-88 capillary column (Varian Chrompack, 
Kinesis, UK) with an inner diameter of 0.25mm and a film thickness of 0.20µm was fitted to the GC. 
Helium was passed through the system at an approximate rate of 0.6ml/min, at a constant pressure 
(14psi). The initial oven temperature of 80ºC was increased to 160ºC at a rate of 25ºC/min, with a 
further increase to 190ºC at a rate of 1ºC/min followed by a final increase to 230ºC at a rate of 
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10ºC/min. Both the injector and flame-ionization detector were set at a temperature of 250ºC, with a 
split mode ratio of 20:1. Samples were injected into the GC and peaks measured on the chromatogram 
were identified through comparison to peaks established from a standard FAME mixture. In addition, 
peaks were corrected for the BHT and/or any solvent peaks that may have been integrated. Peaks 
were then quantified as a percentage of the total sample using the following equation (Equation 2.3). 
 
 
Equation 2.3 
2.2.8 Endocannabinoid measurement 
Solid phase extraction (SPE) and liquid chromatography-mass spectrometry (LC-MS) was employed 
to determine concentrations of both anandamide (AEA) and 2-arachidonoylglycerol (2-AG) in whole 
tissue samples and cellular extracts. Whole tissue samples were harvested, snap frozen and stored at -
80ºC prior to analysis. Cell extracts were obtained through washing treated cells three times in 1ml 
ice cold PBS and collecting and centrifuging the cells at 1400rpm for 5 minutes. The supernatant was 
discarded and the pellets stored at -80ºC in preparation for analysis. The protocol was adapted from a 
method outlined by Giuffrida (Giuffrida et al., 2000) and the assays were undertaken by Mr Gary 
Cameron of the Mass Spectrometry unit at Aberdeen University. In advance of the analysis being 
conducted, all samples were transferred to Aberdeen University on dry ice. 
2.2.8.1 Extraction 
Anandamide and 2-AG standards were prepared in acetonitrile. Samples were weighed and 
homogenised in 1.2ml of acetonitrile/H2O (3:1 solution ratio) containing 6pmol of internal standard 
deuterated AEA (AEA-d4). Samples were diluted in 0.6ml H2O and immediately transferred to -80ºC 
for storage until analysis was undertaken. For analysis, samples and standards were thawed and 
centrifuged at 3000 x g for 10 minutes at 4ºC.  
The resulting supernatant was applied to equilibrated 60mg/3ml Strata-X 33µm polymeric reversed-
phase cartridges (Phenomenex, UK) on a Cerex SPE (positive-pressure) manifold (Crawford 
Scientific, UK) at a flow rate of 1ml/minute. Cartridges were systematically washed with 1ml of 30% 
methanol (in H2O) and 2ml of 70% methanol (in H2O) and dried under nitrogen. The samples were 
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eluted in 1ml methanol which was evaporated off under nitrogen. The remaining sample residue was 
resuspended in 50µl mobile phase of which 10µl was injected onto the chromatograph. 
2.2.8.2 LC-MS/MS conditions 
LC Column:    150mm x 2.1mm ACE 5µm C8 (Hichrom, Reading, UK) 
Column Temperature:  30
o
C 
Tray Temperature:  4
o
C 
Nominal Flow Rate:  200µl/minute 
Mobile Phase:   15% H2O/85% methanol (both in 0.5% formic acid) 
Mass Spectrometer (MS):  TSQ Quantum, triple quadrupole MS (Thermo Scientific, UK) 
Interface:    Electrospray ionisation (positive ion mode) 
Spray Voltage:   3500V 
Sheath Gas:   Nitrogen (40, arbitrary units) 
Auxiliary Gas:   Nitrogen (10, arbitrary units) 
Capillary Temperature:  375ºC 
Collision Energy:  16V 
Collission Gas Pressure: 1.3 milliTor (Argon) 
Ion Transitions:   AEA: m/z 348.2 – 62.2 
    2-AG: m/z 379 – 287 
    AEA-d4: m/z 352.2 – 66.2     
2.2.8.3 Analysis 
Xcalibur 2.0.6 software (Thermo Scientific, UK) was used to conduct quantitative analysis of the LC-
MS/MS output. Linear regression curves were produced from calculating the ratio of sample/internal 
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standard to the concentration of sample in the standard. The concentration of the sample extract was 
then determined from the curve. 
2.2.9 Collagen and collagen cross-link measurement 
Collagen and cross-link measurement, achieved using LC-MS, was undertaken by Dr Simon Robins 
of the Matrix Biochemistry research group within the Rowett Institute of Health and Nutrition (part of 
Aberdeen University). Whole tissue content of collagen (measured as total hydroxyproline), mature 
cross-links (pyridinoline [PYD], histidinohydroxylysinonorleucine [HHL] deoxypyridinoline [DPD]), 
elastin cross-links (desmosine [DES], isodesmosine [IDE]) and reduced intermediates 
(hydroxylysinonorleucine [HLNL], dihydroxylysinonorleucine [DHLNL]) were assessed. To prepare 
the tissue for analysis, samples were removed, „processed‟ (fat and debris was removed from thoracic 
aorta samples and the upper atria section of heart samples was discarded), snap frozen and stored at -
80ºC as described in section 2.2.4. All samples for analysis were subsequently delivered to the Rowett 
Institute on ice.  
2.2.9.1 Preparation of standards and samples 
Deuterated internal standard, dideutero-dihydrodesmosine, was prepared from hydrolysates of bovine 
ligamentum nuchae previously reduced with sodium borodeuteride. PYD and DPD standards were 
isolated from bovine diaphyseal bone and were purified using their fluorescence by reverse-phase 
chromatography, the detailed method of which has been previously reported (Robins, 1996). DES and 
IDE were isolated from bovine ligamentum nuchae using similar procedures. HHL was isolated from 
ovine dermis and an HHL standard stock solution was prepared from the trihydrochloride salt (Robins 
et al., 2003). Using previously described methods, DHLNL and HLNL were isolated from bovine 
bone reduced with potassium borohydride for the preparation of standards (Robins, 1982). 
Samples were prepared for analysis as follows. The samples were rinsed repeatedly prior to 
equilibration in 20mM sodium phosphate (containing 140mM NaCl, pH 7.5) for a minimum of 2 
hours. Potassium borohydride (in 20mM NaOH) to give a final concentration of 1.7mM was added to 
the sample suspension to reduce the immature-cross-links. Following 1 hour of stirring, excess 
borohydride was removed by lowering the pH to 4 using 3M acetic acid after which the tissue was 
rinsed with H2O and lyophilized. Portions of the reduced tissue samples were weighed and hydrolysed 
in 5.7M HCl at 107ºC for 21 hours after which time residual acid was removed by evaporation in 
vacuo.  
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Standards and sample hydrolysates (redissolved in H2O) were fractionated using an adapted version 
of a method previously outlined by Pratt and colleagues (Pratt et al., 1992). Prior to fractionation, 
stock solutions of standards were diluted to produce a range of concentrations from 0 to 100pmol. 
Partition chromatography using an SPE system (Gilson ASPEC II, Anachem Ltd, UK) incorporating 
cellulose CC31 columns with a mobile phase of butan-1-ol, acetic acid, H2O (4:1:1 ratio by volume) 
was undertaken where processed standards/samples were eluted in 0.75ml of 50mM HCl. A 5301 
concentrator (Eppendorf, UK) was used to reduce the eluates to a known volume (100µl - 200µl) 
determined by weight. From the concentration range of standards fractionated, a 6-point standard 
curve was constructed.  
2.2.9.2 LC-MS/MS procedure 
Fractionated eluates of standards and samples were mixed (9:1 v/v) with 10% pentafluoropropionic 
acid (PFPA) containing 30pmol/µl of internal standard, of which 20µl was injected onto the 
chromatograph (25cm x 0.2cm Aquasil C18 column, Thermo Scientific, UK). Mobile phases were 
0.2% PFPA and acetonitrile: H2O (75:25 v/v) containing 0.2% PFPA with a nominal flow rate 
maintained between 200µl-300µl/min. The column was coupled with a triple-quadrupole tandem 
mass spectrometer equipped with an electrospray ionisation interface operating in positive-ion mode 
(API4000 LC/MS/MS System, Applied Biosystems, UK). Data for each standard/sample was 
acquired using multiple reaction monitoring (MRM).     
2.2.9.3 Analysis 
Calibration curves were produced through comparison of the peak area ratio (MRM compound 
area/MRM internal standard area) against the standard concentration (standards run in duplicate). The 
concentrations of cross-links present in the samples were then calculated through interpolating the 
observed peak area ratio on the linear regression line of the corresponding calibration curve. 
2.2.10 Western blotting 
Western Blotting represents a powerful analytical tool for the detection of specific proteins in a 
sample of unknown protein composition. First developed within the biochemistry department of 
Stanford University (Renart et al, 1979), the method involves separation of denatured proteins by gel 
electrophoresis and, following transfer to a membrane, antibody probing of the immobilised proteins 
to identify a specific protein of interest.  
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2.2.10.1 Protein extraction  
Prior to undertaking the Western Blot process, it was necessary to establish the protein concentrations 
of the tissue samples. On ice, 150g of tissue was added to a flat-bottomed vial containing 600mg of 
1mm zirconia beads (Thistle Scientific, UK) and 800µl of 10% protease inhibitor cocktail (complete 
tablet) diluted in 40mM Tris HCl (6.3g Trizma® Base in 1L distilled H2O). Samples were 
homogenised for 30 seconds, a process which was repeated three times. Homogenised material was 
removed and centrifuged at 55,000rpm for 30 minutes at 4
o
C. The protein supernatant was collected 
in a clean microcentrifuge tube and both the pellet and supernatant stored at -80
o
C. Protein 
concentrations were then determined using the previously outlined Bradford assay method (see 
section 2.1.6).  
2.2.10.2 Electrophoresis and immunoblotting 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate the 
sample proteins by molecular weight. A 10% separating gel was prepared as described in Table 2.7. 
The gel was transferred into a glass casting stand and allowed to set at room temperature. Once set, a 
5% stacker gel was added to the separating gel, prepared as illustrated in Table 2.7. A comb was 
inserted into the gel and the gel was allowed to set.  
To load 150µg of sample per well, the samples were diluted (total protein concentration determined 
by Bradford Assay) in Laemmli buffer and boiled for 5 minutes on a heat block set at 100ºC. Once the 
gel was set, the comb was gently removed and the glass casts moved to a gel tank. The gel tank was 
filled with SDS-PAGE running buffer (see Table 2.8) fully submerging the gel. Ten microlitres of 
protein standard (Precision Plus Dual Colour) was loaded into the first well. The remaining wells 
were loaded with 15µl of the denatured samples. The gel tank lid, which is attached to positive and 
negative electrodes, was placed on the gel tank and the leads were attached to a BioRad PowerPac 
3000. 200mv of power was applied to the gel tank for 1 hour. Upon completion of electrophoresis, the 
gels were removed from the gel tank and the stacking gel and wells were cut off and discarded. The 
gels were placed in transfer buffer (see Table 2.8). 
Sections of immobilon-P membrane (Millipore, UK) of roughly 5.5cm x 8.5cm were cut to size and 
submerged briefly in methanol until a colour change from opaque to a translucent grey was observed. 
Membranes were rinsed in distilled H2O and placed in transfer buffer. In addition for each gel, two 
sponges and two sections of filter paper (cut to size) were also placed in transfer buffer. 
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Table 2.7 Western Blot: Preparations of polyacrylamide gels. 
 
Table 2.8 Western Blot: Preparation of solutions required for Western Blotting. 
  
 
Gel Constituent 
Volume for 10% Separating 
Gel 
(mls) 
Volume for 5% Stacking 
Gel 
(mls) 
H2O 
1.5M Trizma® Base pH 8.8 
0.5M Trizma® Base pH 6.6 
sodium dodecyl sulphate 
10% ammonium persulphate 
TEMED 
30% N,N-methylenebis/acrylamide 
8.1 
5.0 
- 
0.2 
0.1 
0.02 
6.6 
6.1 
- 
2.5 
0.1 
0.05 
0.02 
1.3 
SDS-PAGE Running Buffer 
5% milk powder 
Transfer Buffer 
100ml of x 10 Tris-glycine buffer in 900ml distilled H2O 
5g milk powder dissolved in 100mls 0.5% tween® in PBS 
3.05g Trizma® Base and 14.41g glycine dissolved in 
200mls methanol and diluted in 800ml distilled H2O 
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The cassette was laid down flat, with the black side to the back. One sponge was placed on the 
cassette and a section of filter paper was placed on top of the sponge layer. A glass vial was gently 
rolled across the cassette to remove any air bubbles between the sponge and filter paper layers. The 
gel was carefully transferred onto the filter paper and the immobilon-P membrane placed on top of the 
gel. The rolling step was repeated to remove air bubbles. The second sponge was placed on the gel 
sandwich and a final rolling step was undertaken to remove any residual air bubbles. The cassette was 
placed in the transfer-electrode assembly, which was fitted in the gel tank along with an ice box. The 
tank was then filled with transfer buffer. The gel tank was closed and attached to a BioRad PowerPac 
3000. One hundred mV of power was applied to the gel tank for 1 hour. Following transfer, the gel 
tank was opened and the cassette removed from the electrode assembly. The membrane was removed, 
briefly submerged in methanol and allowed to dry at room temperature for blotting at a later stage. 
To undertake the immunoblot, the transferred membranes were briefly submerged in methanol and 
immediately placed in universals containing 20ml 5% milk powder solution (see Table 2.8) to block 
for 1 hour at room temperature with gentle agitation. Membranes were then transferred to bags 
containing the primary antibody diluted in 5% milk solution which were sealed. The antibody 
concentration, incubation length and temperature were dependant on the specific application of the 
protocol. Membranes were transferred to universals and washed with 10ml 0.5% tween® in PBS for 5 
minutes. The wash step was repeated a further two times. The secondary antibody, diluted in 5% milk 
solution, was then added to the universal. The antibody concentration, incubation length and 
temperature were dependant on the specific application of the protocol. The PBS wash step was 
repeated three times. Membranes were placed on cling film, and coated in an equimolar solution of 
chemiluminescent substrate for band identification. Membranes were allowed to develop in 
chemiluminescent substrate for 3-5 minutes. Bands were visualised using a Fujifilm LAS-1000 Dark 
Box. Measurement of band width and intensity was undertaken using Aida Image Analyser software 
(version 3.5.2).  
2.3 Materials 
2.3.1 Antibodies and reagents 
Abcam: Chicken polyclonal to ADFP, goat polyclonal secondary antibody to chicken IgY – H&L 
(HRP) 
Bayer, UK: Xylazine hydrochloride 2% w/v (Rompun®) 
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BioRad, UK: Bradford reagent, protein standard (Precision Plus Dual Colour)  
Cell Signalling Technology, UK: Cell lysis buffer (10X) [#9803] 
Fisher Scientific, UK: Acetyl chloride, anhydrous sodium sulphate, heat-inactivated foetal bovine 
serum, hexane, methanol, penicillin streptomycin solution (1%), sodium chloride  
Hayman's Ltd, UK: Absolute ethanol  
Hope Farms, Netherlands: Diet W 
Invitrogen, UK: Fungizone®, Hams F-12 nutrient mixture medium, RPMI-1640 GlutaMAX medium, 
Waymouths MB752/1 Medium 
Marvel, UK: Milk powder 
Millipore, UK: Accutase, ECL substrate (Immobilon Western) 
Merial, UK: Pentobarbital sodium (Euthatal) 
Oxoid, UK: Phosphate Buffered Saline 
Promega, UK: CellTiter 96 AQueous One Solution reagent  
Pfizer, UK: Ketamine hydrochloride (Vetalar™V) 
Roche, UK: Protease inhibitor cocktail complete tablet   
Severn Biotech: Ammonium persulphate, sodium dodecyl sulphate (10%), 30% N,N-
methylenebis/acrylamide, 0.5% tween® in PBS 
Sigma-Aldrich, UK: Agar ash 2-4%, coomassie brilliant blue R-250, chloroform, diethyl-ether, 
glycine, heparin,  isopropanol, paraformaldehyde, sodium nitroprusside dihydrate ≥99.0%, trizma® 
base, trypan blue stain, oil red o, laemmli buffer , 2, 6-di-tert-butyl-4-methyl phenol (BHT), N,N,N‟, 
N′-Tetramethylethylenediamine (TEMED) 
Tocris: Bradykinin 
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Chapter 3: Modelling lipid accumulation in the activated 
THP-1 macrophage 
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3.1 Introduction  
3.1.1 Foam cell origin and development 
As previously discussed in Chapter 1, the presence of lipid engorged macrophages or ‘foam cells’ in 
the subendothelial space constitutes the earliest visible manifestation of atherosclerosis, known as the 
fatty streak.  
Macrophage foam cells are derived from blood monocytes. Prolonged influx, accumulation and 
retention of lipoproteins in the subendothelial space are synonymous with endothelial cell activation, 
to which circulatory monocytes are recruited. Monocytes represent a highly plastic cell population 
demonstrating phenotypic heterogeneity in both humans and mice. The monocytic sub-set from which 
foam cells originate remains under investigation. In apolipoprotein E-deficient (ApoE
-/-
) mice fed a 
high fat diet, studies have reported rapid expansion of Ly6C
high
 monocytes, an effect which was not 
observed in the counter-part Ly6C
low
 population. Moreover, preferential recruitment and 
accumulation of Ly6C
high
 monocytes in atherosclerotic lesions was also demonstrated, suggesting a 
pro-atherogenic role of the Ly6C
high
 population (Swirski et al., 2007; Tacke et al., 2007).  
Foam cell development thus stems from macrophage infiltration and phagocytic activity at sites of 
lipoprotein accumulation. Chemical modification, mainly oxidation, of low density lipoprotein (LDL) 
present in the vessel wall is pivotal to its uptake and contributes to its pro-inflammatory and pro-
atherogenic profile (as reviewed in Levitan et al., 2010). Uptake of modified LDL via scavenger 
receptors (discussed in Chapter 1, section 1.2.3) is genetically unregulated due to the lack of a sterol 
regulatory element in the scavenger receptor gene. In effect, and in contrast to the LDL receptor 
pathway, scavenger receptor expression is insensitive to intracellular cholesterol concentration and is 
not down-regulated by cholesterol loading (Han et al., 1997). Persistent uptake and hydrolysis of 
modified LDL thus produces macrophages saturated in cholesteryl ester (CE) and free cholesterol 
(FC). Such macrophages are termed ‘foam cells’, in light of the ‘foam’ like appearance of CE rich 
lysosomes present in the cytoplasm. 
Resulting foam cells serve as a potent source of pro-inflammatory cytokines and reactive oxygen 
species which promote local inflammation, further lipoprotein modification and trigger the activation 
of matrix metalloproteinases (MMPs): endopeptidases which facilitate the degradation of extracellular 
matrix (ECM) components (Dollery and Libby, 2006). MMP activity, in a highly regulated fashion, 
modulates the remodelling of tissue in essential processes such as organ development and wound 
healing. In the atherosclerotic plaque however, proteolytic degradation of the matrix reduces the 
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tensile strength conferred by collagenous material and ultimately reduces plaque integrity (Rekhter et 
al., 2000). The degree of instability largely dictates the likelihood of plaque rupture and so in turn, the 
likelihood of a potentially fatal thrombogenic event. 
3.1.2 Atherosclerosis and ω-3 PUFAs 
In the setting of cardiovascular disease, the potentially beneficial properties of ω-3 PUFAs have been 
well investigated, including their ability to modify blood pressure and/or heart rate, cardiac function, 
triglyceride concentrations, platelet aggregation, inflammation and plaque stabilisation (as detailed in 
Chapter 1). Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) represent two key ω-3 
PUFAs. As mentioned previously, fibrillar collagen provides tensile strength to the plaque 
microenvironment and therefore plaques with reduced collagen content will be less stable and more 
prone to rupture. In 2002, Kawano and colleagues demonstrated that EPA supplementation in high fat 
fed rabbits altered plaque composition. EPA treated animals displayed lesions mainly of type I and II 
classification (small foam cells, high collagen content) in contrast to lesions of control animals, which 
were mainly of type III and IV classification (large foam cells, poor collagen content). Subsequent 
human and murine studies have confirmed a direct association between EPA/DHA incorporation into 
lesions and reduced macrophage deposition, reduced macrophage cholesterol content, reduced 
markers of inflammation and an increased incidence of lesions with thick fibrous caps (Thies et al., 
2003; Wang et al., 2009). Such findings support the notion that ω-3 PUFA incorporation into lesional 
macrophages triggers cellular events, perhaps related to cholesterol homeostasis, that confer plaque 
stabilising effects. The exact nature of these cellular mechanisms however has yet to be elucidated. 
3.1.3 In vitro models of foam cell activity 
To gain insight into the cellular events underpinning foam cell formation and activity in vivo: several 
in vitro models have evolved. A number of human myeloid cell lines are available, including KG-1, HL-
60, U937 and THP-1, which are halted at different stages of differentiation (monoblast, pro-monocyte 
and monocyte). The use of cell lines offers several advantages over the use of human macrophage 
isolates, which can be difficult to expand ex vivo, carry risk of contamination and can exhibit phenotypic 
variation (donor variations). Immortalised cells are easily obtained, of plentiful supply and exhibit 
population homogeneity, a desirable characteristic for biochemical study (Daigneault et al., 2010). With 
comparison to the aforementioned cell models, human monocytic leukaemia (THP-1) cells 
demonstrate physical and behavioural traits (morphology and secretory profiles) more similar to 
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native monocytes (Tsuchiya et al., 1980 as reviewed by Auwerx, 1991). In response to treatment 
with differentiation agents, THP-1 cells express recognised markers of differentiation that are 
associated with macrophage development including scavenger receptor type A (SR-A), 
apolipoprotein E (ApoE) and lipoprotein lipase (LPL) (Tajima et al., 1985; Hara et al., 1987; 
Steinberg, 1987). Hence THP-1 cells are widely employed for the study of macrophage and/or foam 
cell behaviour. 
Exposure of THP-1 macrophages to preparations of oxidised LDL (oxLDL) presents a well 
established method of inducing foam cell formation where the expression of scavenger receptors 
(notably CD36 and LOX-1), cytokines and growth factors associated with foam cells are increased 
with oxLDL loading (Han et al., 1997; Nagy et al., 1998; Malden et al., 1991). The mechanisms 
underlying such effects are in part due to oxLDL activation of transcription factor peroxisome 
proliferator-activated receptor  (PPARγ) and possibly PPAR  (Nagy et al., 1998; Vosper et al., 
2001). Experimental production of oxLDL is a relatively inexpensive, but complex, procedure where 
the stage and extent of oxidation in individual preparations can vary substantially. In contrast, 
commercial production of oxLDL generates particles with heightened homogeneity and stability 
however the process is considerably more expensive. The present study sought to develop a model of 
lipid accumulation in activated macrophages. Lipid accumulation, quantified through measurement of 
the cellular content of fatty acid esters (primarily triglycerides), was achieved through exposure of 
cells to free fatty acids. Linoleic acid, an ω-6 PUFA, was employed as a lipid loading agent. Linoleic 
acid and its oxidised metabolites, 9- hydroxyoctadecadienoic acid (9-HODE) and 13- 
hydroxyoctadecadienoic acid (13-HODE), represent known components of oxLDL particles and have 
been shown to upregulate CD36 expression (Nagy et al., 1998; Jostarndt et al., 2002). While uptake 
and accumulation of free fatty acids does not constitute foam cell formation, modelling the 
accumulation of lipid in activated macrophages permitted further investigation of factors which 
influence this process including the potential involvement, if any, of the endocannabinoid system 
(discussed in Chapter 4). 
3.2 Aims 
The intent of this study was to develop a robust and reproducible in vitro model of lipid loading in 
differentiated THP-1 cells. In order to achieve the development of a sound model, the following aims 
were addressed 1) to determine the optimal conditions for lipid loading in activated THP-1 cells, 
using linoleic acid as a lipid loading agent; 2) to demonstrate the effect of ω-3 PUFAs on lipid 
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loading and 3) to employ the optimised model to investigate any effect of cannabinoid agents, be it 
beneficial or detrimental, on loading of ω-3 PUFAs into cells.                                                                                                     
3.3 Methods 
3.3.1 Optimisation of differentiation 
Adherence of activated THP-1 cells to the plate surface was employed as a measurement of 
differentiation levels within the cell population. Determination of both optimum phorbol 12-myristate 
13-acetate (PMA) concentration and incubation time was established using the following protocol.  
THP-1 monocytic cells were acquired and sub-cultured as outlined in Chapter 2 (section 2.1.4). Six-
well plates were seeded with 2 x 10
6
 cells per well in a final volume of 4ml media containing 10% 
fetal bovine serum and 1% penicillin/streptomycin solution. Cells were treated with 1ng, 3ng, 5ng and 
10ng of PMA per well (reconstituted in 100% ethanol, diluted in PBS) for a period of 3, 6, 10 or 24 
hours in a humid atmosphere maintained at 37ºC. At each time point, the cells were removed, washed 
and fixed as described in Chapter 2 (section 2.1.6). Enumeration of cells was achieved through 
staining with Coomassie Brilliant Blue. The final protocol for staining and enumeration was 
conducted as described in Chapter 2 (section 2.1.5.2). The full protocol was undertaken in three 
independent experiments (n=3). 
3.3.2 Optimisation of lipid loading and quantification  
3.3.2.1 Linoleic acid loading 
Six-well plates were seeded with 2 x 10
6
 cells per well in a final volume of 4ml media. Cells were 
treated with a range of concentrations of linoleic acid (LA): 0.5 M, 1 M, 10µM, 25 M and 50 M 
after which cells were incubated with 5ng PMA for a period of 24 hours, the optimal conditions 
determined by the findings from section 3.3.1. Following the 24 hour incubation conducted at 37ºC, 
cells were washed and fixed as described previously (Chapter 2, section 2.1.6) and the plates were 
allowed to dry for 30 minutes. To analyse lipid accumulation, Oil red O (ORO) staining was then 
performed using the protocol described in Chapter 2 (section 2.1.8). The full protocol was undertaken 
in eight independent experiments (n=8). 
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3.3.2.2 Oleic acid loading: comparison to linoleic acid 
Twenty-four-well plates were seeded with 1 x 10
6
 cells per well in a final volume of 2ml media. Cells 
were treated with a range of concentrations of oleic acid (OA): 1 M, 5 M, 10 M, 25 M, 50 M and 
100 M. Following OA treatment, cells were stimulated with 5ng PMA for a period of 24 hours in a 
humid environment at 37ºC. Following the 24 hour incubation, cells were washed and fixed as 
described in Chapter 2 (section 2.1.6) and the plates were allowed to dry for 30 minutes. To stain and 
analyse lipid accumulation, Oil red O (ORO) staining was performed as per the optimised protocol 
described in Chapter 2 (section 2.1.8). The protocol was conducted once in triplicate (n=1). 
3.3.2.3 ω-3 PUFA loading 
Twenty-four-well plates were seeded with 1 x 10
6
 cells per well in a final volume of 2ml fresh media. 
Cells were treated with 50 M of OA, EPA, DHA or the vehicle (ethanol, 0.1%). Following fatty acid 
treatment, cells were stimulated with 5ng PMA for a period of 24 hours at 37ºC. Following the 24 
hour incubation, cells were fixed as described in Chapter 2 (section 2.1.6) and stained with Oil red O 
(ORO) (see Chapter 2, section 2.1.8). Experiments were conducted three times and measured in 
triplicate (n=3). 
3.4 Results 
3.4.1 THP-1 monocyte differentiation 
As shown in Figure 3.1, exposure to PMA elicited a concentration-dependent effect, where an increase 
in PMA concentration positively influenced cell adherence by increasing the number of adhered cells. 
This effect was evident at all assayed concentrations. A time dependent effect of PMA treatment was 
also observed. Increased exposure time to PMA (3, 6 and 10 hours) induced a directly proportionate 
increase in the number of adherent cells. Twenty-four hour exposure to PMA induced a plateau of 
maximum cell adhesion (133±21 cells) that was illustrated to occur even at the lowest concentration 
assayed, 0.4nM PMA (equivalent to 1ng per well). Exposure to 1, 3 and 5ng of PMA per well for 24 
hours was strongly significant (p<0.001, p<0.01, p<0.05 respectively) in comparison to exposure of 
matching treatments for 3 hours. On the basis of these findings, treatment of cells with 5ng PMA for a 
period of 24 hours was defined as the optimum conditions for later experiments. 
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Figure 3.1 Optimisation of THP-1 monocyte differentiation: THP-1 monocytes, seeded at a density of 
2x10
6 
cells/well, were exposed to a range of PMA concentrations (1ng–10ng) across a range of timepoints 
(3-24 hours) in order to determine the optimal conditions for differentiation. Monocytes were between 
passages 32 and 34. Adherent cells were stained with Coomassie Brilliant Blue. A 1cm
2 
area was 
designated at random and the cells within visualised and enumerated under x40 magnification. Enumeration 
was conducted in triplicate. The full protocol was conducted three times (n=3). *p<0.05, **p<0.01, 
***p<0.001 vs respective concentration incubated for 3 hours (two-way ANOVA, Bonferroni’s multiple 
comparosin post-hoc test). Values represent mean±SEM. 
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3.4.2 Optimisation of lipid loading: linoleic acid 
Lipid loading in differentiated cells was measured through staining with ORO – a fat soluble dye 
which stains cellular lipids. Figure 3.2 demonstrates the outcome of staining with ORO, where lipid 
droplets present in cells become red in colour. Loading of differentiated THP-1 cells with linoleic 
acid demonstrated a direct correlation between linoleic acid concentration and absorbance (see Figure 
3.3). Across a concentration range of 0.5µM to 50µM LA, absorbance increased dose dependently. 
Exposure to 10µM, 25µM and 50µM LA induced significant increases in absorbance (0.51±0.10AU, 
0.69±0.12AU and 0.73±0.10AU respectively) compared to 0.5µM LA (0.18±0.01AU; P<0.05). All 
data was corrected to baseline measurements (0µM LA). From the present findings, 50µM LA was 
deduced as the optimal fatty acid concentration to induce lipid accumulation. 
3.4.3 Lipid loading: oleic acid  
Figure 3.4 demonstrates the effects of loading differentiated THP-1 cells with OA. As observed with 
LA treatment, a concentration-dependent effect was observed with OA treatment. Across a 
concentration range of 1µM to 100µM OA, absorbance increased with increasing OA concentration. 
Comparative to the lowest assayed concentration of 1µM, marked increases in absorbance were noted 
at 50µM and 100µM OA. All data were corrected to baseline measurements (0µM OA). The results 
obtained confirmed the suitability of OA as a lipid loading agent thus 50µM OA was concluded as the 
optimal concentration to induce significant lipid accumulation.   
3.4.4 Lipid loading: ω-3 PUFAs 
The accumulation of 50µM EPA and DHA by activated THP-1 cells, compared with an equimolar 
concentration of OA, is illustrated in Figure 3.5. Data was corrected to the blank and expressed as a 
fold change in absorbency compared to the vehicle. The fold change in lipid uptake of OA (2.5±0.2), 
EPA (3.3±0.2) and DHA (3.9±0.4) was significantly increased (P<0.05) compared to the vehicle 
(0.1% ethanol). Statistical comparison between fatty acids revealed that DHA was more readily taken 
up by activated THP-1 macrophages than OA. 
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Figure 3.2 ORO staining of lipid accumulation in activated THP-1 cells: 
Image A displays unstained, activated THP-1 cells (see arrows). Image B 
demonstrates the accumulation of lipid in the cytoplasmic lysosomes (stained 
red) of activated THP-1 cells exposed to 10µM OA. Cells were at passage 35. 
Both images were viewed at 400× magnification.  
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Figure 3.3 Optimisation of lipid accumulation in THP-1 cells using linoleic acid: THP-1 cells treated 
with 5ng PMA were incubated with a range of linoleic acid concentrations (0.5-50µM) for a period of 24 
hours. Cells were rinsed in PBS, fixed in 4% paraformaldehyde and stained with ORO. The absorbance of 
eluted ORO stain was measured at 510nm, using isopropanol as blank. Cells used for experimentation 
were between passages 26-32). Data is corrected to the baseline, 0µM LA. The full protocol was 
conducted eight times n=8. *p<0.05, **p<0.01 vs 0.5µM LA (one-way ANOVA, Dunnett’s multiple 
comparison post-hoc test). Values represent mean±SEM.  
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Figure 3.4 Lipid loading with oleic acid: Similar to linoleic acid treatment, THP-1 cells treated 
with 5ng PMA were incubated with a range of oleic acid concentrations (1-100µM) for a period of 
24 hours. Cells were stained with ORO and the absorbance of eluted stain was quantified at 510nm. 
Cells used for experimentation were at passage 30. Data is corrected to the baseline, 0µM OA. The 
full protocol was conducted once with measurements made in triplicate (n=1). Values represent 
mean±SEM.. 
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Figure 3.5 Lipid loading with omega-3 fatty acids: PMA (5ng) treated THP-1 cells were loaded with 
50µM of either OA, EPA or DHA. Vehicle treated cells received 0.1% EtOH. Lipid accumulation was 
quantified with ORO staining. Absorbance was measured at 510nm and the values corrected to the 
baseline. Data was then expressed as a fold change in lipid accumulation compared to the vehicle. The full 
protocol was independently conducted three times with measurements made in triplicate (n=3). 
*p<0.05,**p<0.01 vs OA (one-way ANOVA, Dunnett’s multiple comparison post-hoc test) and #p<0.05 vs 
OA (one-way ANOVA, Bonferroni’s comparison post-hoc test). Values represent mean±SEM. 
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3.5 Discussion 
The present study sought to develop a robust method of demonstrating lipid accumulation in activated 
macrophages. To generate a sensitive and reproducible model, the following parameters were 
investigated: differentiation conditions, optimal lipid loading concentration, optimal staining 
conditions and lipid loading with various fatty acids. 
The cell seeding density chosen for the model was based on seeding densities reported in the 
methodology of similar studies in which THP-1 culture was conducted in 6-well plates (De Kimpe et 
al., 1998; Zhao et al., 2007) as well as methods used previously in the laboratory. Monocytes 
represent naturally non-adherent cells local to the blood and lymphatic system. To induce 
differentiation of the THP-1 monocytic cells experimentally, cells were exposed to PMA - a phorbol 
diester and potent activator of protein kinase C (Osto et al., 2008). PMA has been demonstrated to 
trigger morphological and functional changes in THP-1 monocytes that include shape alteration, 
adherence capability, alteration in cellular structures, increased phagocytic activity and Fcγ receptor 
expression. Ultimately cells develop a phenotype mimicking that of an activated macrophage and, 
importantly, form an adherent monolayer (Tsuchiya et al., 1982). Other archetypal differentiation 
agents are available such as 1,25-dihydroxyvitamin D3 (VD3). Respective to the THP-1 line however, 
VD3-induced differentiation cannot induce adherence or phagoctyic activity, does not alter 
proliferation and mediates only moderate expression of surface antigens CD11b and CD14 associated 
with macrophage differentiation (Schwende et al., 1996). PMA which mediates reduced proliferation, 
increased adherence and enhanced surface antigen expression, presents a better candidate for this 
particular model. Thus, the relative number of cells that adhered to the plate surface was used as an 
indicator of the extent of differentiation. Quantification of cell numbers did however prove 
problematic. Two techniques (haematoxylin and eosin [H&E] staining and Bradford assay) were used 
to enumerate cell adhesion, however both failed to generate quantifiable results (data not shown). 
Increasing seeding density, renewing stain reagents (for H&E staining purposes only), different 
methods of detachment from plate surface and fixation methods were all attempted, none succeeded 
in rectifying the problem. Successful visualisation and enumeration of adhered cells was eventually 
achieved using Coomassie blue stain. From the results obtained, maximum differentiation was shown 
to occur following 24 hours of PMA exposure. Relative to incubation time, the concentration of PMA 
assayed had no significant effect on the extent of differentiation achieved. Treatment of cells with 5ng 
of PMA for a period of 24 hours was therefore deduced as the optimal conditions for induction of 
differentiation. 
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In light of the optimisation of differentiation, the next stage of model development was to load the 
THP-1 macrophages with lipid. Linoleic acid was employed as a lipid loading agent which (1) 
enabled determination of the optimal fatty acid concentration required to provoke significant lipid 
accumulation in the cells and (2) acted as a reference fatty acid, to which later studies with alternative 
fatty acids were contextualised but not statistically compared. Lipid uptake was quantified using the 
ORO staining protocol originally outlined by Ramirez-Zacarias et al (1992) which selectively stains 
triglycerides and some cholestryl esters. Initial attempts of quantification encountered problems such 
as poor lipid recovery (out with lower detection limits of wavelength measurement) and high 
background staining (data not shown). To overcome these issues, the volumes of stain and wash 
agents used were refined to reflect the well surface and volume of the plate. From the results 
generated, maximum lipid retention was shown to occur in response to treatment with 50µM LA. This 
concentration (50µM) was therefore chosen as the optimum fatty acid concentration for loading the 
activated THP-1 cells. 
Having refined a method for inducing fatty acid accumulation in THP-1 cells employing linoleic acid 
as a loading agent, the decision was made to convert to using oleic acid, a monounsaturated ω-9 
PUFA. The decision to modify the experimental plan was made to improve continuity between the 
experimental approaches applied across the study as a whole, since oleic acid was to be used as 
control oil for the subsequent dietary intervention for the in vivo branch of the investigation. As 
linoleic acid could not therefore be used as a direct control, it was thus decided that oleic acid would 
replace linoleic acid as a reference fatty acid. It was not foreseen that loading of the cells with oleic 
acid, as opposed to linoleic acid, would result in any changes in uptake, however to negate any 
unexpected actions of oleic acid, a comparison experiment was conducted. Furthermore, to improve 
the reproducibility of the protocol, cells were seeded in 24-well plates as opposed to 6-well plates, 
thus allowing duplicate and triplicate treatments to be undertaken. To account for the loss of well 
surface area, the seeding density was reduced from 2 x 10
6
 cells to 1 x 10
6
 cells and the final volume 
was also reduced from 4ml to 2ml. As Figure 3.4 demonstrates, exposure to oleic acid elicited a 
trend mimicking that of exposure to linoleic acid. Compared to the lowest assayed concentration 
(1µM), significant increases in lipid uptake were observed at both 50µM and 100µM oleic acid. The 
observation that both linoleic and oleic acid induced similar responses in relation to lipid uptake 
confirmed no adverse actions of oleic acid nor any functional problems introduced to the protocol by 
changing the plate size. Therefore 50µM was chosen as the optimal loading concentration. 
To standardise loading with ω-3 PUFAs, the accumulation of EPA and DHA was compared to oleic 
acid accumulation in the same experiment. The cellular uptake of EPA and DHA was significantly 
increased compared to the uptake of oleic acid. One potential mechanism to explain increased lipid 
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accumulation in EPA and DHA treated THP-1 macrophages may be EPA/DHA mediated 
dysregulation of cholesterol efflux. Reduced expression and accelerated degradation of ATP-binding 
cassette reporter (ABCA1) in EPA treated THP-1 macrophages has been reported in the literature (Hu 
et al., 2009). As a membrane associated protein, ABCA1 facilitates the extrusion and association of 
cellular cholesterol with extracellular apolipoprotein-I (apoA-I), which combine to form high density 
lipoprotein particles (HDL). It is possible that, while normal cholesterol efflux is maintained in oleic 
acid treated macrophages; reduced cholesterol efflux in EPA- and DHA-treated macrophages is 
responsible for their heightened accumulation. Further studies examining ABCA1 mRNA and protein 
expression would be required in order to confirm such an effect.  
On reflection, the outcome of this body of work was the production of a reproducible model of lipid 
loading in activated THP-1 macrophages, however, due to some inconsistency with the literature it is 
evident that the model is not without its limitations. One such limitation would be the use of ORO 
staining for the quantification of lipid accumulation. While ORO selectively stains triglycerides and 
cholesteryl esters, there is no option for differentiation between the two. Measuring the rate of 
formation and quantity of cholesterol esters, may provide a more accurate indicator of the 
involvement of a particular fatty acid in cholesterol homeostasis. As many studies have investigated 
fatty acid incubation periods in excess of 24 hours, discrepancy in findings may be the result of 
insufficient fatty acid exposure time. Therefore, investigation of the effect of increasing incubation 
times may be worthwhile. Moreover, the validity of the model could be further characterised by 
measuring the expression of markers of foam cell formation such as surface antigens (e.g. SRA, 
CD36 and LOX-1). In summary, a standardised protocol for the differentiation and loading of 
activated macrophages with lipid was developed. For intensive purposes, the model proved valuable, 
however further optimisation would generate a more sensitive, insightful method of detection.  
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Chapter 4: Role of the endocannabinoid system in lipid 
accumulation in the activated THP-1 macrophage 
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4.1 Introduction  
4.1.1 The endocannabinoid system: an overview 
Endocannabinoids (EC) represent endogenous lipid mediators with an extensive and diverse range of 
biological activities. Endocannabinoids, their cellular receptors and the proteins essential for their 
synthesis, transport and degradation together constitute the endocannabinoid system (ES). As 
reviewed in Chapter 1, endocannabinoids exert the majority of their effects through the CB1 and CB2 
receptors; Gi/o protein coupled receptors present in central and peripheral tissue. The two most 
widely characterised ECs are arachidonoyl ethanolamide (AEA) and 2-arachidonoyl glycerol (2-AG): 
the synthesis, action and degradation of which is discussed in Chapter 1. 
4.1.2 Endocannabinoids and disease pathology 
Endocannabinoids have been implicated in a wide range of disease states where receptor studies and 
observed alterations in endocannabinoid concentrations have linked the ES to inflammation, pain, 
diabetes, cancer, obesity and, importantly, cardiovascular conditions (Mukhopadhyay et al., 2010; 
Costa et al., 2007; Annuzzi et al., 2010; Guida et al., 2010; Reidel et al., 2009). The exact role of the 
endocannabinoids in disease is somewhat unclear as reported effects have been of both a beneficial 
and detrimental nature, dependent upon injury type, tissue type and/or the stage of disease 
development. In the setting of cardiovascular disease, ECs have been shown to influence hypotension 
induced by hemorrhagic shock (endotoxic and cardiogenic), myocardial ischemia and reperfusion 
injury, cardiac dysfunction and atherosclerosis (as reviewed by Pacher and Steffens, 2009 and Hiley, 
2009).  
4.1.3 Endocannabinoids and atherosclerosis 
Both CB1 and CB2 receptors have been implicated in atherosclerosis development and progression. 
The majority of reports from the literature suggest a pro-atherosclerotic role of CB1 receptor 
activation and an anti-atherosclerotic role of CB2 receptor activation.  
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4.1.3.1 CB1 receptor mediated effects 
STRADIVARIUS, a randomized, double-blinded trial, examined the role of the CB1 receptor in the 
progression of coronary artery disease in patients exhibiting abdominal obesity and metabolic 
syndrome. Pharmacological blockade of the CB1 receptor using the antagonist rimonabant 
(20mg/day), significantly reduced normalised total atheroma volume in patients with high basal 
triglyceride levels (>140mg/dL) and in those not receiving statin treatment (Nissen et al., 2008). 
Rimonabant treatment has been shown to dose dependently reduce atherosclerotic lesion progression 
in the aorta and aortic sinus of LDL receptor knockout mice (LDLr
-/-
) fed a Western diet (Dol-Gleizes 
et al., 2009). In vitro, it has been demonstrated that treatment of LPS-stimulated mouse peritoneal 
macrophages with rimonabant repressed the expression of pro-inflammatory cytokines IL-6, MCP-1 
and TNF-α (Sugamura et al., 2009). In vascular smooth muscle cells, a key cell type involved in 
atherosclerotic lesion progression and vessel restenosis, a recent study illustrated that CB1 receptor 
antagonism (using rimonanbant) inhibited platelet derived growth factor (PDGF) induced 
proliferation, migration and signalling in human coronary artery smooth muscle cells (Rajesh et al., 
2008a). Therefore it could be postulated that CB1 receptor activation contributes to the progression of 
atherosclerosis, at least in part, through inflammatory mechanisms. 
4.1.3.2 CB2 receptor mediated effects 
The first in vivo evidence of a direct effect of CB2 receptor activation in atherosclerosis was provided 
by Steffens and colleagues (2005). It was noted that in apolipoprotein-E (ApoE
-/-
) knockout mice 
treated with a daily oral dose (1 mg kg
-1
) of 
9
- tetrahydrocannabinol (THC), a derivative of Cannabis 
sativa, lesion progression in the aortic root was significantly reduced compared to untreated controls. 
Through co-administration of THC with a CB2 selective antagonist, SR144528, the lesion reducing 
effects of THC were completely abolished. Moreover, quantitative immunostaining of lesions 
revealed that THC treatment significantly lowered infiltration of macrophages, which highly express 
CB2 receptors (Steffens et al., 2005). Taken together, these findings strongly suggest a protective role 
of CB2 receptor activation in preventing lesion progression. Similarly, a recent study reported that 
genetic ablation of the CB2 receptor in high fat fed LDLr
-/-
 mice significantly aggravated progression 
of early lesions (Delsing et al., 2011). Interestingly, absence of CB2 receptor expression had no effect 
on late stage lesions (>12 weeks), a finding supported by observations in a similar LDLr
-/-
 study 
whereby supplementation of a high cholesterol diet with the CB2 agonist, JWH133, for a period of 16 
weeks had no effect on intimal lesion size or inflammatory profile (Willecke et al., 2011).  
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In contrast, in vitro studies have implicated the involvement of activated CB2 receptors in the 
inflammatory response within the atherosclerotic lesion. Treatment with selective CB2 agonists was 
reported to attenuate TNF-α-induced migration and proliferation of coronary artery smooth muscle 
cells (Rajesh et al., 2008b), reduce TNF-α-induced activation of coronary artery endothelial cells 
(reduced ICAM-1, VCAM-1 and MCP-1 expression) and reduce migration and adhesion of THP-1 
monocytes (Rajesh et al., 2007). While some conflict remains, the majority of the data suggests an 
anti-atherogenic role of CB2 receptor activation.   
4.1.3.3 Endocannabinoids and foam cell formation 
In the setting of foam cell development, evidence of ES activation was provided by Jiang and 
colleagues (2009). In vitro studies demonstrated the ability of ox-LDL treatment to significantly 
increase AEA and 2-AG synthesis, to increase CB1 and CB2 receptor expression and importantly, 
promote cellular cholesterol accumulation (Jiang et al., 2009). It was also observed that selective 
blockade of the CB1 receptor (using AM251) reduced ox-LDL accumulation, suggesting that the 
process of cholesterol overload associated with foam cell development could be regulated by CB1 
receptor activation. While it appears that the endocannabinoid system plays a role in cholesterol 
loading of macrophages, it has yet to be documented if such an interaction is associated with the 
action of PUFAs. 
4.2 Aims     
In light of the optimisation of an in vitro model of lipid accumulation in the THP-1 macrophage 
described in Chapter 3, the central aim of this study was to further characterise the role of the ES in 
lipid accumulation and homeostasis in the THP-1 macrophage. The anti-atherosclerotic effects of the 
ω-3 PUFAs, EPA and DHA, which are discussed in detail in Chapters 1 and 3, are well documented.  
While the lesion-stabilising effects of these fatty acids have been reported, the underlying 
mechanisms conferring such effects remain unclear. Since there is evidence that ECs can influence 
the uptake of cholesterol into macrophages, and that EC levels are increased in response to LDL, it 
would be important to know whether ECs similarly affect ω-3 PUFA uptake, since this could limit 
their lesion-stabilising effects.  Thus the present study sought to determine whether a) selective CB1 
and CB2 receptor activation alters ω-3 PUFA accumulation and the production of inflammatory 
markers in macrophages and b) ω-3 PUFAs influence the production of endocannabinoids by 
macrophages. 
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4.3 Methods 
4.3.1 Optimisation of drug pre-incubation period 
To explore the effect of endocannabinoid and cannabinoid compounds on THP-1 macrophage activity 
and behaviour, it was first necessary to establish the optimal incubation period for drug exposure. A 
range of incubation times were established from the literature and were investigated as follows: 
Twenty-four-well plates were seeded with 1 x 10
6
 cells per well in a final volume of 2ml medium. 
Cells were pre-treated with ACEA or the vehicle (ethanol, 0.1%) for a period of 1, 3, 6 or 24 hours at 
37ºC. Following drug treatment, cells were treated with 50µM OA and stimulated with 5ng PMA for 
24 hours. Following completion of the incubation period, cells were fixed as described in Chapter 2 
(section 2.1.6) and stained with Oil red O (ORO) (see Chapter 2, section 2.1.8). The experiment was 
conducted independently three times in duplicate (n=3). 
4.3.2 The effect of cannabinoid and endocannabinoid compounds on ω-3 PUFA 
accumulation 
Twenty-four-well plates were seeded with 1 x 10
6
 cells per well in a final volume of 2ml medium. 
Cells were pre-treated with either ACEA (synthetic CB1 agonist), 2-AG (endogenous CB1 and CB2 
receptor agonist), AEA (endogenous CB1 and CB2 receptor agonist) and JWH133 (synthetic CB2 
agonist) or vehicle (ethanol, 0.5%) for a period of 6 hours in a humidified atmosphere at 37ºC. 
Following completion of the drug pre-treatment period, cells were exposed to 50µM OA, EPA or 
DHA and stimulated with 5ng PMA for a period of 24 hours at 37ºC. Following completion of the 
incubation period, spent medium was removed and stored at -80ºC for future protein analysis (see 
section 4.3.4). Cells were fixed as described in Chapter 2 (section 2.1.6) and stained with ORO (see 
Chapter 2, section 2.1.8). The experiment was conducted independently four times in duplicate (n=4). 
4.3.3 The effect of cannabinoid and endocannabinoid compounds on cell viability 
Cell viability was assessed by MTS as outlined in Chapter 2, section 2.1.11. Briefly, 96-well plates 
were seeded with 2 x 10
4
 cells per well in a final volume of 100µl fresh medium. Cells were pre-
treated with either AEA or JWH133 or vehicle (ethanol, 1%) for a period of 6 hours in a humidified 
atmosphere at 37
o
C. Following completion of the drug pre-treatment period, cells were exposed to 
50µM DHA and stimulated with 5ng PMA for a period of 24 hours at 37ºC. Following completion of 
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the incubation period, cells were incubated for 2 hours with MTS solution at 37ºC. Following MTS 
exposure, the absorbance was measured at 490nm. The experiment was conducted independently 
three times with six replicates for each condition (n=3). 
4.3.4 The effect of AEA and JWH133 on MCP-1 production 
Spent medium was collected as described in section 4.3.2. The quantity of MCP-1 produced by the 
various cell treatments described in the previous section were assayed by ELISA, the protocol of 
which is outlined in Chapter 2, section 2.1.9. The assay was conducted three times in quadruplicate 
(n=3). 
4.3.5 Endocannabinoid production in lipid loaded THP-1 macrophages 
Twenty-four-well plates were seeded with 1 x 10
6
 cells per well in a final volume of 2ml medium. 
Cells were treated with 50µM OA, EPA, DHA, fibrate or vehicle (ethanol, 0.1%) and stimulated with 
5ng PMA for a period of 24 hours at 37ºC. Following completion of the incubation period, cells were 
washed three times with ice cold PBS and scraped for collection in microcentrifuge tubes. Cells were 
then centrifuged at 14,000 rpm for 10 mins at 4ºC. The resulting supernatant was discarded and the 
pellets were dried and stored at -80ºC. Subsequently, cell pellets were lysed and endocannabinoid 
analysis was undertaken using LC-MS/MS (conducted by Mr Gary Cameron of Aberdeen University) 
as described in Chapter 2, section 2.2.8. The experiment was conducted independently four times in 
duplicate (n=4). 
4.3.5.1 Endocannabinoid analysis: generation of the standard curve 
Standards of varying concentrations and the internal standard were analysed using the previously 
described LC-MS/MS technique. The resultant peaks recorded (examples A-C in Figure 4.1) were 
further analysed by measuring the peak total area. The area ratio of each standard to the internal 
standard was then calculated (see Equation 4.1) and the value plotted against the concentration of the 
known standards. This enabled generation of a standard curve (see Figure 4.2). The area ratio of each 
sample (calculated as demonstrated in Equation 4.1, where the sample peak area replaced the EC peak 
area) was then determined from the total peak area (see Figure 4.3) and the ratio applied to the 
standard curve to establish the sample concentration. 
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Equation 4.1 
4.3.5.2 Normalisation of endocannabinoid results 
To accurately compare samples, it was first necessary to normalise the measured endocannabinoid 
concentrations to the original protein concentration present in the sample. This was achieved using the 
Bradford Assay where samples were normalised to pmol per 1mg total protein (see Equation 4.2).  
 
 
Equation 4.2 
4.4 Results 
4.4.1 Optimisation of drug pre-incubation 
To optimise the conditions for drug pre-treatment, a range of incubation times were investigated using 
arachidonyl-2'-chloroethylamide (ACEA), a synthetic CB1 agonist, in combination with OA as shown 
in Figure 4.4. There were no significant time-dependent differences in OA accumulation in any of the 
cell treatments exposed to ACEA for 1, 3 or 6 hours. This indicated that any differences observed in 
lipid accumulation were specific to the cell treatment, independent of time. Conversely, 24 hour pre-
treatment with ACEA almost completely abolished lipid accumulation. This finding was attributed to 
widespread cell death, perhaps due to drug toxicity. Thus, based on the findings of this experiment, a 
pre-treatment time of 6 hours was deduced as the optimal condition for drug exposure. All data were 
expressed as a fold change in lipid accumulation over the stimulated cell controls. 
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Figure 4.1 Original LC-MS/MS chromatograms of standards and internal standard: 
Example chromatograms demonstrating A) the peak produced by 5pmol of AEA standard; B) 
the peak produced by the internal standard, deuterated anandamide; C) the peak produced by 
50pmol of 2-AG standard.  
 
 
 
 
 
 
 A 
 B 
 C 
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Figure 4.2 Example standard curves for AEA and 2-
AG: Example standard curves produced for both AEA and 
2-AG, generated through plotting the area ratio of known 
standard concentration/internal standard against standard 
concentration. 
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Figure 4.3 Original LC-MS/MS chromatogram outlining sample peak: Example peak 
recorded for a sample.  
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Figure 4.4 The time dependent effects of ACEA pre-treatment on OA uptake in THP-1 
macrophages stimulated with PMA: THP-1 cells (1 x 10
6
 cells/well) were pre-treated with either 
ACEA or vehicle (0.1% EtOH) for 1, 3, 6 or 24 hours. Cells were then stimulated with 5ng PMA 
and treated with oleic acid (50µM) for a further 24 hours. Lipid accumulation was quantified by 
ORO staining. Cells used in experiments were between passages 30 and 33. Data are expressed as a 
fold change in lipid accumulation compared to the control (‘stim cells’: cells stimulated with PMA). 
The full protocol was conducted independently three times in duplicate (n=3). Values represent 
mean±SEM. 
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4.4.2 The effect of endocannabinoid and cannabinoid compounds on OA accumulation in 
PMA-stimulated THP-1 macrophages 
As illustrated in Figure 4.5 and Figure 4.6, OA treatment of cells resulted in significant lipid 
accumulation compared to stimulated cells. Neither ACEA nor 2-AG had any effect on the lipid 
accumulation in response to OA treatment (see Figure 4.5).  Similarly, pre-treatment with either AEA 
or JWH133 failed to affect lipid accumulation in OA-treated THP-1 macrophages (see Figure 4.6).  
None of the cannabinoid ligands demonstrated any significant effect on basal lipid accumulation in 
the absence of OA. 
4.4.3 MCP-1 production in OA and CB agonist treated THP-1 macrophages 
As Figure 4.7 demonstrates, MCP-1 production in OA loaded cells (26±3 pg/ml) was no different 
from that observed in stimulated cells (30±3 pg/ml). Similarly, at a concentration of 10
-5
M, AEA 
alone had negligible effects on MCP-1 production (24±5 pg/ml) compared to stimulated cells. In 
contrast, an equimolar dose of JWH133 induced a significant increase in MCP-1 production (60±14 
pg/ml; P<0.01) compared to stimulated cells. Combined treatment of THP-1 macrophages with OA 
and either AEA or JWH133 had no significant effect on MCP-1 production beyond that of OA alone 
(Figure 4.8). Data is expressed as a fold change in lipid accumulation compared to stimulated cells. 
4.4.4 Endocannabinoid production in OA loaded THP-1 macrophages 
When the production of AEA and 2-AG by OA-loaded THP-1 macrophages was assessed, AEA 
levels were found to be below the lower detection limits of the assay and therefore could not be 
quantified. Figure 4.9 depicts the effect of OA loading of THP-1 macrophages on 2-AG production. 
Data is expressed as a fold change in 2-AG content (nmol/mg total protein) compared to unstimulated 
cells. Compared to unstimulated cells (1.08±0.3 nmol/mg protein), stimulation of cells with PMA 
induced a fold increase in 2-AG production (2.08±0.8 nmol/mg protein). Treatment of PMA 
stimulated cells with both vehicle (0.1% ethanol) and fibrate significantly reduced 2-AG production 
(1.09±0.5 nmol/mg protein and 1.06±0.5nmol/mg protein respectively) compared to stimulated cells 
(P<0.05). OA treatment however, had no effect on PMA-stimulated 2-AG production.  
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Figure 4.5 OA accumulation in ACEA and 2-AG treated THP-1 macrophages stimulated with 
PMA: THP-1 cells (1 x 10
-6
 cells/well) were pre-treated with ACEA, 2-AG or vehicle (0.1% ethanol) 
for 6 hours. Cells were then stimulated with 5ng PMA and treated with 50µM of OA for a further 24 
hours. Lipid accumulation was quantified with ORO staining. Cells used were between passages 30 and 
34. Data are expressed as a fold change in lipid accumulation compared to the control (‘stim cells’). The 
full protocol was conducted independently four times in duplicate (n=4). **p<0.01 vs stim cells (one-
way ANOVA, Dunnett’s multiple comparison post-hoc test). Values represent mean±SEM. 
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Figure 4.6 OA accumulation in AEA and JWH133 treated THP-1 macrophages stimulated with 
PMA: THP-1 cells (1 x 10
-6
 cells/well) were pre-treated with AEA, JWH133 or vehicle (0.1% ethanol) 
for 6 hours. Cells were then stimulated with 5ng PMA and treated with 50µM of OA for a further 24 
hours. Lipid accumulation was quantified with ORO staining and expressed as described previously. 
Cells were used between passages 30 and 34. The full protocol was conducted independently four times 
in duplicate (n=4). *p<0.05, **p<0.01 vs stim cells (one-way ANOVA, Dunnett’s multiple comparison 
post-hoc test). Values represent mean±SEM.  
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Figure 4.7 Baseline MCP-1 production in OA and drug treated THP-1 macrophages: 
MCP-1 production was measured in conditioned media retained from the previously described 
lipid accumulation studies. MCP-1 production, induced by OA, AEA and JWH133 treatment of 
THP-1 macrophages was assayed by ELISA. Data is expressed as a fold change in MCP-1 
production compared to the control treatment (PMA stimulated cells; 30±3 pg/ml). The full 
protocol was conducted independently three times in quadruplicate (n=3). **p<0.01 vs control 
(one-way ANOVA, Dunnett’s multiple comparison post-hoc test). Values represent 
mean±SEM.   
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Figure 4.8 The effect of AEA/JWH133 on MCP-1 production in OA treated THP-1 
macrophages: MCP-1 production was measured in conditioned media retained from the 
previously described lipid accumulation studies. MCP-1 production in OA and drug treated cells 
was assayed by ELISA. Data are expressed as a fold change in MCP-1 production compared to 
OA (26±3 pg/ml). The full protocol was conducted independently three times in quadruplicate 
(n=3). Values represent mean±SEM. 
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Figure 4.9 The effect of OA and fenofibrate on 2-AG production in PMA stimulated THP-1 
macrophages: THP-1 cells (1 x 10
-6
 cells/well) were treated with 50µM fibrate, OA or vehicle 
(ethanol, 0.1%) and stimulated with 5ng PMA for 24 hours. Cells were collected and the 2-AG 
content quantified in the cell supernatant through LC-MS/MS analysis. Data are expressed as a 
fold change in 2-AG production compared to the control (unstimulated cells; 1082±325 pmol/mg 
total protein). The full protocol was conducted independently four times in duplicate (n=4). 
*p<0.002 vs stimulated cells (unpaired t-test). Values represent mean±SEM.  
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4.4.5 The effect of endocannabinoid and cannabinoid compounds on EPA accumulation 
in PMA-stimulated THP-1 macrophages 
As illustrated in Figure 4.10 and Figure 4.11, exposure of THP-1 macrophages to EPA resulted in 
significant lipid accumulation. Pre-treatment of EPA loaded cells with the various endocannabinoid 
and synthetic cannabinoid ligands (ACEA, 2-AG, AEA and JWH133) had no further impact on lipid 
accumulation. 
4.4.6 MCP-1 production in EPA and CB agonist treated THP-1 macrophages 
Figure 4.12 depicts the effect of EPA loading on MCP-1 production. With comparison to PMA 
stimulated cells (30±3 pg/ml), EPA treatment of THP-1 macrophages was shown to increase MCP-1 
production slightly (43±9 pg/ml); however this effect was not significant. The compounding effect of 
exposure to EPA in conjunction with either AEA or JWH133 on MCP-1 production in macrophages 
is illustrated in Figure 4.13, where data have been normalised to EPA alone. Pre-treatment with AEA 
had no additional effect on EPA-induced MCP-1 production at either concentration tested. In contrast, 
JWH133 pre-treatment (10
-5
M) significantly elevated MCP-1 production (74±27 pg/ml) compared to 
EPA alone (43±9 pg/ml; P<0.001). 
4.4.7 2-AG production in EPA treated THP-1 macrophages 
Figure 4.14 depicts the production of 2-AG in EPA loaded THP-1 macrophages. Data is expressed as 
a fold change in 2-AG concentration (pmol/mg total protein) compared to unstimulated cells. As 
described previously, stimulation of cells with PMA induced a fold increase in 2-AG production 
(2.08±0.8 nmol/mg protein) compared to unstimulated controls (1.08±0.3 nmol/mg protein. EPA 
treatment had no effect on 2-AG production beyond the effects of PMA stimulation alone. 
4.4.8 The effect of endocannabinoid and cannabinoid compounds on DHA accumulation 
in PMA-stimulated THP-1 macrophages 
The impact of endocannabinoid and cannabinoid pre-treatment of DHA loaded cells is illustrated in 
Figure 4.15 and Figure 4.16. DHA treatment resulted in significant lipid accumulation compared to 
untreated cells. Neither ACEA, nor 2-AG pre-treatment had any effect on lipid accumulation.  
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Figure 4.10 EPA accumulation in ACEA and 2-AG THP-1 macrophages stimulated with PMA: 
THP-1 cells (1 x 10
-6
 cells/well) were pre-treated with ACEA, 2-AG or vehicle (0.1% ethanol) for 6 
hours. Cells were then stimulated with 5ng PMA and treated with 50µM of EPA for a further 24 
hours. Lipid accumulation was quantified with ORO staining and expressed as described previously. 
Cells were used between passages 30 and 34. The full protocol was conducted independently four 
times and measured in duplicate. **p<0.01 vs stim cells (one-way ANOVA, Dunnett’s multiple 
comparison post-hoc test). Values represent mean±SEM.  
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Figure 4.11 EPA accumulation in AEA and JWH133 treated THP-1 macrophages stimulated 
with PMA: THP-1 cells (1 x 10
-6
 cells/well) were pre-treated with AEA, JWH133 or vehicle (0.1% 
ethanol) for 6 hours. Cells were then stimulated with 5ng PMA and treated with 50µM of EPA for a 
further 24 hours. Lipid accumulation was quantified with ORO staining and expressed as described 
previously. Cells were used between passages 30 and 34. The full protocol was conducted 
independently four times in duplicate (n=4). *p<0.05; **p<0.01 vs stim cells (one-way ANOVA, 
Dunnett’s multiple comparison post-hoc test). Values represent mean±SEM.  
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Figure 4.12 Baseline MCP-1 production in EPA loaded THP-1 macrophages: MCP-1 
production was measured in conditioned media retained from the previously described lipid 
accumulation studies. MCP-1 production in EPA loaded THP-1 macrophages was assayed 
by ELISA. Data are expressed as a fold change in MCP-1 production compared to the 
control treatment (PMA stimulated cells; 30±3 pg/mL). The full protocol was conducted 
independently three times in quadruplicate (n=3). Values represent mean±SEM. 
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Figure 4.13 The effect of AEA/JWH133 pre-treatment on MCP-1 production in EPA 
loaded THP-1 macrophages: MCP-1 production in EPA- and drug-treated cells was assayed 
by ELISA. Data are expressed as a fold change in MCP-1 production compared to EPA (43±9 
pg/mL). The full protocol was conducted independently three times in quadruplicate (n=3). 
**p<0.01 vs EPA alone (two-way ANOVA, Bonferroni post-hoc test).Values represent 
mean±SEM. 
  
92 
 
 
 
Control Stim cells EPA
0
1
2
3
Treatment
2
-A
G
 P
ro
d
u
c
ti
o
n
:
F
o
ld
c
h
a
n
g
e
 v
s
 c
o
n
tr
o
l
 
Figure 4.14 The effect of EPA accumulation on 2-AG production in PMA stimulated 
THP-1 macrophages: THP-1 cells (1 x 10
-6
 cells/well) were treated with 50µM EPA and 
stimulated with 5ng PMA for 24 hours. Cells were collected and the 2-AG content quantified 
as described previously. Data is expressed as a fold change in 2-AG production compared to 
the control (unstimulated cells; 1082±325 pmol/mg total protein). The full protocol was 
conducted independently four times in duplicate (n=4). Values represent mean±SEM. 
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Figure 4.15 DHA accumulation in ACEA and 2-AG treated THP-1 macrophages stimulated 
with PMA: THP-1 cells (1 x 10
-6
 cells/well) were pre-treated with ACEA, 2-AG or vehicle (0.1% 
ethanol) for 6 hours. Cells were then stimulated with 5ng PMA and treated with 50µM of DHA for a 
further 24 hours. Lipid accumulation was quantified and expressed as described previously. Cells 
were used between passages 30 and 34. The full protocol was conducted independently four times in 
duplicate (n=4). *p<0.05; **p<0.01 vs stim cells (one-way ANOVA, Dunnett’s multiple comparison 
post-hoc test). Values represent mean±SEM.  
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Figure 4.16 DHA accumulation in AEA and JWH133 treated THP-1 macrophages stimulated 
with PMA: THP-1 cells were pre-treated with AEA, JWH133 or vehicle as described previously. 
Cells were stimulated with 5ng PMA and treated with 50µM of DHA for a further 24 hours. Lipid 
accumulation was quantified and expressed as described previously. Cells were used between 
passages 30 and 34. The full protocol was conducted independently four times in duplicate. *p<0.05; 
**p<0.01 vs stim cells (one-way ANOVA, Dunnett’s multiple comparison post-hoc test). #p=0.395; 
##
p=0.012; 
###
p=0.0004 vs DHA (unpaired t-test).Values represent mean±SEM. 
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Pre-treatment of cells with AEA (10
-5
M) significantly reduced DHA accumulation compared to DHA 
only treated cells (4.7 vs 7.9 respectively; P=0.0004). JWH133 pre-treatment also significantly 
reduced lipid accumulation compared to DHA only treated cells (3.4 vs 5.5 respectively; P=0.0478). 
All data were expressed as a fold change in lipid accumulation compared to the control treatment – 
PMA stimulated cells.  
Figure 4.17 demonstrates the effect of AEA pre-treatment on cell viability. Exposure of DHA-treated 
cells to AEA, 10
-9
M to 10
-5
M, did not affect cell viability which did not fall below 95%. At 10
-4
M, 
AEA, either alone or in combination with DHA significantly reduced cell viability to 30% (P<0.01). 
Treatment with the vehicle was shown to reduce cell viability to 67% (P<0.05). The effect of 
JWH133 pre-treatment on cell viability is illustrated in Figure 4.18. The viability of DHA treated cells 
exposed to JWH133 (10
-9
M to 10
-5
M) did not fall below 96%. JWH133 alone reduced cell viability to 
79% while the vehicle significantly reduced cell viability to 71% (P<0.05). All data were normalised 
to the DHA treatment, where viability was deemed 100%. 
4.4.9 MCP-1 production in DHA and CB agonist treated THP-1 macrophages 
The production of MCP-1 by THP-1 macrophages loaded with DHA is shown in Figure 4.19. DHA 
was observed to have no impact on MCP-1 production beyond baseline MCP-1 production by 
untreated cells (29±6 pg/ml vs 30±3 pg/ml respectively). As demonstrated in Figure 4.20, pre-
treatment of DHA loaded cells with AEA slightly elevated MCP-1 production with respect to DHA 
only treated cells, although this effect failed to reach statistical significance. Similarly, pre-treatment 
with JWH133 also induced a slight elevation of MCP-1 production however again, this effect lacked 
statistical significance. 
4.4.10 2-AG production in DHA treated THP-1 macrophages 
Figure 4.21 demonstrates the production of 2-AG in DHA loaded THP-1 macrophages. Data is 
expressed as a fold change over unstimulated cells. DHA treatment significantly reduced 2-AG 
production (0.89±0.2 nmol/mg protein) compared to stimulated cells (2.08±0.8 nmol/mg protein; 
P<0.05). 
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Figure 4.17 The effect of AEA treatment on the viability of PMA stimulated THP-1 macrophages: 
THP-1 cells (20,000 cells/well) were pre-treated with AEA or vehicle (1% ethanol) for 6 hours. Cells 
were stimulated with 5ng PMA and treated with 50µM DHA for a further 24 hours. MTS solution was 
applied to the cells for a further 2 hours and the absorbance measured at 490nm. Cells were between 
passages 32-35. Data were normalised to the DHA treatment, where viability was deemed 100%. The full 
protocol was conducted independently three times with six replicates for each treatment (n=3). *p<0.05; 
**p<0.01 vs DHA control (one-way ANOVA, Dunnett’s Multiple Comparison post-hoc test). Values 
represent mean±SEM. 
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Figure 4.18 The effect of JWH133 treatment on the viability of PMA stimulated THP-1 
macrophages: THP-1 cells (20,000 cells/well) were pre-treated with JWH133 or vehicle (1% ethanol) 
for 6 hours. Cells were stimulated with 5ng PMA and treated with 50µM DHA for a further 24 hours. 
MTS solution was applied to the cells for a further 2 hours and the absorbance measured at 490nm. 
Cells were between passages 32-35. Data were normalised to the DHA treatment (viability deemed 
100%). The full protocol was conducted independently three times with each replicates for each 
treatment (n=3). *p<0.05; vs DHA control (one-way ANOVA, Dunnett’s Multiple Comparison post-hoc 
test). Values represent mean±SEM. 
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Figure 4.19 Baseline MCP-1 production in DHA loaded THP-1 macrophages: 
MCP-1 production was measured in conditioned media retained from the previously 
described lipid accumulation studies. MCP-1 production in DHA-loaded THP-1 
macrophages was assayed by ELISA. Data were expressed as a fold change in MCP-1 
production compared to the control treatment (PMA stimulated cells; 30±3 pg/mL). 
The full protocol was conducted independently three times in quadruplicate (n=3). 
Values represent mean±SEM.  
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Figure 4.20 The effect of AEA/JWH133 on MCP-1 production in DHA loaded THP-1 
macrophages: MCP-1 production in DHA and drug treated cells was assayed by ELISA. 
Data were expressed as a fold change in MCP-1 production compared to DHA (29±6 
pg/mL). The full protocol was conducted independently three times and in quadruplicate 
(n=3). Values represent mean±SEM. 
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Figure 4.21 The effect of DHA accumulation on 2-AG production in PMA stimulated 
THP-1 macrophages: THP-1 cells (1 x 10
-6
 cells/well) were treated with the previously 
described controls or 50µM DHA and stimulated with 5ng PMA for 24 hours. Cells were 
collected and the 2-AG content quantified as described previously. Data is expressed as a fold 
change in 2-AG production compared to the control (unstimulated cells; 1082±325 pmol/mg 
total protein). The full protocol was conducted independently four times in duplicate (n=4). 
*p=0.013 vs stimulated cells (unpaired t-test). Values represent mean±SEM. 
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4.5 Discussion 
The intention of the present study was to identify an association, if existing, between the 
endocannabinoid system and ω-3 PUFAs, which are considered to be anti-inflammatory and anti-
atherosclerotic, in the setting of the macrophage. 
To allow investigation of the potential involvement of the endocannabinoid system in macrophage 
activity, it was necessary to optimise drug (cannabinoid and endocannabinoid ligands) treatment 
conditions in the model devised and described in Chapter 3. Based on dose response data obtained 
previously in the laboratory in combination with methodological approaches cited in the literature 
(Gokoh et al., 2007; Correa et al., 2005), drug doses of 10
-5
M and 10
-6
M were chosen for study. 
Although at the upper limit of the previously used dose range, high concentrations were chosen to 
increase the likelihood of observing any potential effects of the drugs. Figure 4.4 demonstrates the 
effect of 10
-5
M ACEA on various cell treatments. The aim of the experiment was to assess any time 
dependent effects of the drug, thus allowing the optimal pre-treatment period to be deduced. It was 
found that there were no time-dependent effects observed with 1, 3 or 6 hour ACEA pre-treatment. 
The end-point of lipid accumulation did not significantly vary, time-dependently, between treatments. 
ACEA pre-treatment for a period of 24 hours did abolish lipid accumulation in certain treatments, an 
effect which was confirmed by light microscopy to be a result of extensive cell death. Therefore the 
pre-incubation period of 6 hours was chosen as the optimal incubation time for the following 
experiments. 
4.5.1 The effect of endocannabinoids and cannabinoids on FA accumulation in THP-1 
macrophages 
Exposure of PMA-stimulated THP-1 macrophages to the various FAs examined significantly 
increased intracellular FA accumulation. While the medium in which the cells were suspended 
contained foetal bovine serum, which is known to contain free FAs, the control treatment (cells 
treated with only PMA) provided an indication of baseline FA uptake. Normalisation of the 
experimental FA data to this baseline negated any effects of the FAs present in the media. None of the 
ligands tested had a direct effect on lipid accumulation in the absence of FAs, this presented 
confirmation that any increases in lipid accumulation beyond that of the control treatment were a 
result of exposure to the experimental FA. 
Activation of the CB1 receptor using the CB1 selective agonist ACEA (Ki=1.4nM) had no impact on 
the cellular uptake of OA, EPA or DHA; an effect that would suggest in this set of experiments, that 
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CB1 receptor activation did not influence FA accumulation. However, this finding may be specific to 
the experimental conditions of the present model. In RAW264.7 macrophages exposed to oxLDL (1-
12µg/ml), Jiang and colleagues (2009) reported a significant increase in total and esterified 
cholesterol accumulation (measured by LC-MS/MS), following treatment with the selective CB1 
receptor agonist WIN,212-2 (1-20µM), an effect which was associated with increased CB1 receptor 
expression. While the contrasting methodology and experimental conditions of the Jiang study do not 
permit its direct comparison to the present study, it is worthwhile to note the model specific 
differences.   
CB2 receptor activation using JWH133, a CB2 selective agonist (Ki=3.4nM), induced a significant 
dose-dependent reduction in DHA uptake yet had no effect on OA or EPA uptake. Based on these 
findings, it could be postulated that the reduced accumulation of DHA was a result of CB2 receptor 
activation. However, this proposed notion is complicated by the observation that the endocannabinoid 
AEA, an endogenous ligand of both CB1 and CB2 receptors, also significantly attenuated DHA 
uptake. In essence, it is not clear from these experiments whether the effect was mediated through the 
CB1 or CB2 receptor. However, the observation that ACEA (a CB1 selective agonist) had no impact on 
lipid accumulation argues against the role of AEA-mediated activation of CB1 receptors in this effect. 
Moreover, reported activity of AEA at the vanilloid receptor type-1 (TRPV1) and the gastrin-
releasing peptide 55 (GPR55) receptors (Smart et al., 2000; Ryberg et al., 2007) suggests that, in this 
instance, AEA may be acting at receptors independent of the CB family entirely. It is intriguing that 
2-AG, which is also an endogenous agonist of CB1 and CB2 receptors with a greater affinity for CB2 
(Mechoulam et al., 1995), did not induce changes similar to that seen with JWH133 or AEA. 
However the lack of effect may be explained by the biological properties of 2-AG, given that 2-AG, 
in comparison to AEA, has a lower potency at the CB receptors (2-AG EC50=519, 618nM at CB1 and 
CB2 respectively vs AEA EC50=31, 27nM at CB1 and CB2 respectively).  
To verify that the effects of JWH133 and AEA on DHA uptake were genuine, and not a result of drug 
induced cytotoxicity, their effect on cell viability was examined. Treatment of DHA-loaded cells with 
neither JWH133 nor AEA had any significant effect on cell viability at the concentrations shown to 
influence DHA uptake, although at a high concentration (10
-4
M), AEA was demonstrated to induce a 
degree of cytotoxicity. Given that AEA has been reported to induce apoptotic body formation and 
DNA defragmentation (characteristic signs of programmed cell death) at micromolar concentrations 
(Maccarrone et al., 2000), this finding was not unexpected. Importantly, the drug concentrations 
employed in the present assay did not reduce cell viability, thereby confirming the authenticity of the 
findings. The mechanism underlying the effect of AEA and JWH133 on DHA uptake remains 
unclear; however there are several potential explanations:  
103 
 
1) Since both cannabinoids and ω-3 PUFAs exert some of their actions through the nuclear PPAR 
pathways it is possible that the action of JWH133 and AEA on DHA uptake is the result of an 
overlapping role in PPAR signalling. DHA may be involved in regulating PPARs and their associated 
signalling pathways, since this has been reported with ω-3 PUFAs previously (Xu et al., 1999). 
Indeed, DHA treatment has been reported to suppress protein expression of the CD36 scavenger 
receptor, a downstream target of PPARα/γ signalling (Malfitano et al., 2007), in human dermal 
microvascular endothelial cells, THP-1 cells and human colon tumour (HT116) cells (Lee and 
Hwang, 2002; Madonna et al., 2011). This effect could be a direct regulation of PPAR protein 
expression or could be due to the action of a DHA metabolite, for example a transcription factor, 
nuclear hormone receptor or lipid second messenger. The capacity of several cannabinoid ligands to 
activate PPARs has also been previously documented (Bouaboula et al., 2005; Sun et al., 2007) and 
an in vitro study reported that treatment of peripheral blood mononuclear cells with anandamide 
(10µM) generated an increase in CD36 scavenger receptor mRNA expression. Consistent with this 
finding, WIN55,212-2 (CB1 receptor agonist) has been shown to increase CD36 mRNA expression 
and to decrease ABCA1 mRNA expression in RAW264.7 macrophages, both of which occurred 
concomitantly with increased PPARγ receptor expression (Jiang et al., 2009). Since CD36 and 
ABCA1 represent the principal receptors involved in the regulation of macrophage cholesterol influx 
and efflux respectively, one might therefore expect cannabinoid treatment to increase FA uptake if 
DHA enters and leaves the cell by the same routes. However, the observation from the present studies 
that AEA and JWH133 reduced, rather than increased, DHA uptake suggest that a change in CD36 
expression by these agents is unlikely to be fully responsible.  
2) DHA mediated regulation of sterol regulatory-element binding protein (SREBP) could interfere 
with fatty acid and cholesterol metabolism. In response to intracellular sterol deprivation, SREBP 
undergoes various stages of cleavage to release n-SBREP, which binds to sterol regulatory elements 
(SREs) in the promoter region of genes regulating lipid metabolism pathways. In vitro studies on a 
range of cell types (African green monkey kidney, Chinese hamster ovary, human hepatoma and 
human non-hepatic cells) have demonstrated the ability of PUFAs, but not SFAs, to significantly 
reduce SREBP activation of SREs at micromolar concentrations (Worgall et al., 1998; Hannah et al., 
2001). EPA, DHA and AA have been shown to have a greater inhibitory capacity than shorter chain 
fatty acids such as OA. In the present study, metabolism of AEA to AA may be acting independently 
or in combination with DHA, to regulate intracellular lipid metabolism. The observed effect of 
JWH133 may also be linked to the SREBP pathway. In colon cancer cell lines, CB2 receptor agonist 
CB13 was recently demonstrated to induce a significant increase in intracellular ceramide production 
(Cianchi et al., 2008); which has been reported to directly inhibit transcription of activated SBREP-1 
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and SBREP-2 though interference with sphingolipid synthesis (Worgall et al., 2002). Thus it is 
possible that JWH133-induced stimulation of ceramide production could interfere indirectly with FA 
uptake.  
While the discussed mechanisms do represent potential explanations for the current findings, it is 
worthwhile to note that these pathways could be extrapolated to the effects of ACEA and 2-AG and it 
is therefore curious that DHA uptake is not altered in these assays. It could be postulated that DHA 
may be influencing PPAR activation and/or SBREP activity under these conditions, however ACEA 
and 2-AG may have no pharmacological influence over the regulation of these pathways. Together 
these finding suggest that while CB receptor activation is capable of modulating intracellular FA 
uptake, the effect is dependent on the type of FA being internalised.  
4.5.2 MCP-1 production in endocannabinoid and cannabinoid FA-loaded THP-1 
macrophages 
To assess the impact of CB receptor activation on inflammatory marker production in FA-loaded 
cells; production of monocyte chemoattractant protein-1 (MCP-1), a pro-inflammatory chemokine, 
was investigated. Over expression of MCP-1 by macrophages present in the atherosclerotic plaque 
has been demonstrated to promote atherosclerosis development in ApoE
-/-
 mice (Aiello et al., 1999) 
while genetic deficiency of MCP-1 in LDLr
-/-
 mice fed a high fat diet, was reported to reduce 
atherosclerotic lesion development (Gu et al., 1998). In stimulated THP-1 macrophages, CB2 receptor 
activation significantly enhanced MCP-1 production compared to control cells. This is in contrast to 
recent studies, where CB2 receptor activation has been associated with anti-inflammatory responses 
(Xu et al., 2007; Montecucco et al., 2008). However, in vitro studies in CB2 receptor transfected 
HL60 (pro-myelocytic line) cells treated with nanomolar doses of CB2 receptor agonist CP-55940 
reported significant upregulation of MCP-1 mRNA and protein expression (Jbilo et al., 1999; Derocq 
et al., 2000). It was proposed that activation of the CB2 receptor in undifferentiated HL60 cells 
induced a degree of differentiation, as exposure to CP-55940 upregulated cytokine production (MCP-
1, IL-8, MIP-1β and TNF-α) and the expression of cell differentiation factors (junB and aldolase C). 
Interestingly, exposure of HL60 cells to the differentiating stimulus Me2SO revealed an inverse 
relationship between differentiation, progression and CB2 receptor expression where maturation 
induced a systematic reduction in CB2 mRNA expression and CP-55940 induced MCP-1 production 
(Derocq et al., 2000). It could be postulated that in the present study, CB2 receptor agonism with 
JWH133 induced further maturation of the THP-1 macrophages and in doing so, stimulated MCP-1 
production. In contrast, there was no direct effect of AEA on MCP-1 production observed in the 
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present study. AEA, at a concentration of 10
-5
M, has been previously demonstrated to reduce MCP-1 
production in human gingival fibroblasts challenged with lipopolysaccharide (LPS; Yumiko et al., 
2006), however the lack of LPS challenge in the present study may have masked this action of AEA. 
As JWH133 selectively binds CB2 receptors with a greater potency than AEA, this finding supports 
the notion that MCP-1 production is CB2 receptor mediated in this particular experimental set-up. 
Intracellular uptake of OA, EPA or DHA did not influence MCP-1 production in this model. This 
finding is in contrast to an earlier study in THP-1 monocytes, where DHA and EPA were 
demonstrated to suppress mRNA expression and protein production of several pro-inflammatory 
cytokines (TNF-α, IL-6 and IL-1β; Weldon et al., 2006). However, the Weldon study did not examine 
the effects of the FAs on MCP-1 production, therefore the differential endpoint of the experiments 
does not allow for direct comparison of the results. Moreover, the fatty acid dose and exposure time 
employed in the Weldon study was 100µM for 48 hours respectively - double that of the current study 
(50µM for 24 hours). Therefore, it cannot be discounted that the differential outcomes of the two 
studies may be dependent on fatty acid exposure time and/or concentration. The most obvious 
methodological difference between the studies was the additional exposure of cells to LPS in the 
Weldon study. LPS exposure drastically elevated basal cytokine production which was significantly 
reduced by EPA/DHA pre-treatment. Perhaps the fundamental design difference in the current study, 
where cells were not challenged with LPS, masked the ability of the fatty acids to down-regulate 
cytokine production by not providing a cytokine stimulating factor. 
Combined treatment of cells with AEA and FAs had no impact on MCP-1 production, an expected 
finding given that neither the drug alone, nor the individual FAs mediated any alteration to basal 
production. In the presence of FAs, JWH133 elevated MCP-1 production, an effect which was 
significant in EPA-loaded cells; however as this effect mirrored the magnitude of response to the 
ligand alone, it was most likely secondary to the drug mediated elevation in MCP-1 production. 
Further modification of the current cell model, perhaps considering fatty acid exposure time and 
concentration as well as including inflammatory stimulation, may provide a clearer insight into the 
inflammatory response occurring in this particular experimental set-up. 
4.5.3 The effect of FA loading on endocannabinoid production 
The production of 2-AG was significantly elevated in PMA-stimulated THP-1 macrophages 
compared to unstimulated cells; an effect which has been previously described in oxLDL stimulated 
RAW264.7 and rat peritoneal macrophages as well as rat microglial cells. This is thought to be a 
result of upregulated platelet-activating factor (PAF) receptor mediated phospholipases activation and 
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reduced degradation (Carrier et al., 2004; Jiang et al., 2009). AEA production in the present study 
was below the assay detection level, despite previous reports of AEA production in activated 
macrophages (Liu et al., 2003; Carrier et al., 2004; Jiang et al., 2009). However in such studies, a 
higher quantity of cells was used for AEA extraction (>2x10
7
 in comparison to 1x10
6
 cells used in the 
present study), and as AEA was found to be produced in lower quantities than 2-AG, it is likely that 
the quantity of cells used in the present protocol was not sufficient to detect alterations to AEA levels.  
Treatment of cells with fenofibrate significantly lowered 2-AG production compared to stimulated 
cells, the first experimental evidence of such an action of fenofibrate. While the underlying 
mechanisms conferring such an effect have not been explored in the present study, it is possible that 
fenofibrate could be influencing the expression and/or activity of phospholipase C and diacylglycerol 
lipase, the enzymes which regulate the principle pathways of 2-AG synthesis, or it could be 
influencing the pool of 2-AG precursor phospholipids. Whether this effect is limited to the present 
model is currently unknown, therefore to fully characterise this novel action of fenofibrate warrants 
further investigation. 
Intriguingly, DHA but not OA or EPA, significantly reduced 2-AG production in stimulated cells. 
Indeed, the elevated synthesis of 2-AG in stimulated cells was completely abolished in the presence 
of DHA where synthesis was equivalent to that of unstimulated cells. However, a similar effect was 
also observed in vehicle treated cells. While this response cannot be disregarded, the negligible 
impact of EPA or OA treatment alone on 2-AG production would suggest that the vehicle effect was 
not fully responsible for the effects of DHA treatment. In complement to the current findings, a recent 
study conducted in 3T3-F442A adipocytes reported that 72-hour treatment with 100µM DHA 
significantly reduced 2-AG synthesis (Matias et al., 2008). It was also found that treatment of cells 
with EPA induced a slight, although not significant, reduction in 2-AG synthesis while OA failed to 
mediate any effects in this particular experimental set-up. The inconsistencies between these findings 
and the findings from the current study could be accounted for by the difference in cell phenotype as 
well as the concentration and incubation time of the fatty acids. As discussed in detail in Chapter 1 
(section 1.4.2.2), 2-AG can be synthesised through several pathways from AA rich membrane 
phospholipids. The main pathway involves phospholipase C mediated hydrolysis of phospholipids to 
sn-1,2-diacyglycerol (DAG) which in turn reduced to 2-AG by the action of sn-1 specific DAG lipase 
(DAGL). An important structural feature of 2-AG is the unusual positioning of the glycerol/AA bond, 
which is esterified at the sn-2 position of the glycerol backbone. Matias and colleagues (2008) also 
observed an inverse correlation between DHA treatment and the occurrence of AA esterified at the 
sn-2 position of precursor DAGs. Hence DHA mediated reductions in 2-AG levels were accompanied 
with a reduction in the occurrence of sn-2 AA rich DAGs. It was thus proposed that DHA may reduce 
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2-AG synthesis by reducing the availability of the essential phospholipid precursors required for its 
production. This could be extrapolated to the current study, thus giving potential explanation for the 
reported reduction however in order to clarify such a proposal, further studies would be required. 
4.5.4 Conclusion 
In summary, the current study set out to investigate a potential association between the activity of the 
ES and the action of ω-3 PUFAs in the activated THP-1 macrophage. Activation of the 
endocannabinoid system was demonstrated to modulate FA homeostasis and pro-inflammatory 
cytokine production. CB receptor agonism reduced intracellular FA uptake; an effect which was 
ligand specific, FA specific and mediated, in part, through activation of the CB2 receptor. 
Furthermore, a direct association between ω-3 PUFAs and the ES was demonstrated with the 
observation that DHA significantly attenuated macrophage endocannabinoid synthesis. Taken 
together, this evidence indicates a clear interaction of the ES with the function of ω-3 PUFAs in the 
activated THP-1 macrophage. As there is evidence to suggest ω-3 PUFAs may promote 
atherosclerotic plaque stability through both structural and anti-inflammatory mechanisms, the present 
findings suggest a potentially detrimental effect of endocannabinoid ligands in terms of plaque 
destabilisation. 
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Chapter 5: The physiological impact of chronic EPA 
intervention in a murine model of atherosclerosis 
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5.1 Introduction  
5.1.1 Ω-3 fatty acids: in vitro to in vivo investigations 
The in vitro observation (Chapter 4) that ω-3 PUFAs modulate lipid homeostasis in activated 
macrophages, an effect shown to involve components of the endocannabinoid system, and, that 
endocannabinoid synthesis is under the direct regulation of ω-3 PUFAs carries potential implications 
in terms of atherosclerosis development and progression. However to examine the actions of ω-3 
PUFAs in a setting resembling the hemodynamic, immunological and haemorrheological conditions 
of the human vascular wall, requires the use of an in vivo model. This chapter describes the effect of 
long-term dietary intervention with EPA on the biochemical, structural and functional changes 
observed in atherosclerosis development in a mouse model, using fenofibrate as a hypolipidemic 
control. As discussed in the previous chapter, the observed interactions between the ω-3 PUFAs and 
endocannabinoid signalling were demonstrated to be DHA specific. DHA is synthesised 
endogenously from its metabolic precursor EPA, albeit via a relatively inefficient, and therefore slow, 
process. However, given the extended length of the dietary intervention (in which time EPA could be 
converted to DHA) and the potential effects of EPA in vivo which could not have been detected in 
vitro, EPA was employed as the intervention PUFA. 
5.1.2 ApoE-/- mice: a tool for atherosclerosis study      
As described in Chapter 1 (section 1.2.7), numerous animal models are currently available for the 
study of experimental atherosclerosis and the action and efficacy of potential therapeutic agents. Mice 
models constitute a popular species of choice due to their low cost, ready availability, ease of 
handling and maintenance and, most importantly, easily manipulated genome. Such genetically 
engineered models include the LDL receptor deficient (LDLr
-/-
) mouse, ApoE*3-Leiden (E3L) 
transgenic mouse, and apolipoprotein-E deficient (ApoE
-/-
) mouse, which has been described in 
Chapter 1 (section 1.2.7).  
ApoE
-/-
 mice are deficient in ApoE, a glycoprotein constituent of lipoproteins that binds to cell 
surface lipoprotein receptors (Mahley, 1988). Homozygous deletion of the ApoE gene prevents the 
hepatocyte mediated clearance of lipoprotein particles from the circulation and thus promotes 
development of a hyperlipidaemic profile. Moreover, atherosclerotic lesions develop spontaneously in 
ApoE
-/-
 mice, even when maintained on low fat chow (Plump et al., 1992). In comparison to LDLr
-/-
 
and E3L mice, the degree of hyperlipidaemia and lesion development in ApoE
-/-
 mice is considered 
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particularly severe. However the sequential events underpinning lesion formation and progression in 
ApoE
-/-
 mice, where initial aortic fatty streaks develop over time into complex lesions situated 
throughout the vasculature, is remarkably similar to that of humans (Zhang et al., 1994; Nakashima et 
al., 1994; Reddick et al., 1994). Furthermore, analysis of the composition of advanced lesions from 
older ApoE
-/-
 mice has demonstrated a striking resemblance to the composition of vulnerable human 
lesions. Advanced lesions from ApoE
-/-
 mice were found to contain a necrotic core surrounded by 
smooth muscles cells, extracellular matrix proteins and evidence of lesion haemorrhage (Rosenfeld et 
al., 2000).  
Despite a number of limitations of the ApoE
-/-
 model (disease severity, differences in lipid particle 
physiology, potential influence on immune system through ApoE absence), ApoE
-/-
 mice constitute 
one of the most widely used animal models for atherosclerosis investigation. The current study 
required a model of progressive atherosclerosis in order to assess the effect of ω-3 PUFAs on the 
development process itself. As a result, the severity of the model was not of particular hindrance to 
this individual study as progression to the advanced lesion stage was desired. Furthermore, in light of 
similarities in disease development between ApoE
-/-
 mice and humans, the ApoE
-/-
 model was deemed 
a suitable model for use in this particular study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
5.1.3 Aims     
As a continuation of the previously reported link between ω-3 PUFAs and the endocannabinoid 
system in vitro (see Chapter 4, section 4.4), the principle aim of this study was to further characterise 
such an interaction in the whole animal. ApoE
-/-
 mice maintained on an atherogenic diet were thus 
employed to determine the effect of long-term EPA supplementation on the following parameters 1) 
endothelial integrity, measured through blood pressure responses to vasodilators bradykinin and 
sodium nitroprusside; 2) blood plasma profiles of total cholesterol, LDL, HDL and triglycerides; 3) 
liver physiology; 4) tissue production of endocannabinoids AEA and 2-AG; 5) cardiac and vascular 
remodelling, measured as changes in collagen and collagen cross-linking, using fenofibrate as a 
control lipid lowering intervention.  
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5.2 Methods 
5.2.1 Study Design 
A total of sixty 5 week old male ApoE
-/-
 (B6.129P2-Apoe
tm1Unc
/Crl*) mice (Charles River 
Laboratories, UK) were purchased and maintained at the Medical Research Facility of the University 
of Aberdeen. Animals were housed for 180 days in conditions outlined in Chapter 2 (Section 2.2.1) 
during which the mice were randomly assigned to one of three study groups and given free access to a 
pre-prepared specialised diet. An allowance of 5 grams (wastage included) was allocated per mouse 
per day. Following completion of the 180-day intervention, animals were used for endpoint studies. 
To obtain control data from wild type mice fed a normal diet, 15 age-matched (6 months) male 
JAX® C57BL/6J (C57) mice fed regular chow (CRM irradiated pellets, Special Diets Service, UK) 
from weaning were purchased (Charles River Laboratories, UK)  and the same endpoint studies 
undertaken. 
5.2.2 Intervention diets 
As outlined in Chapter 2, each diet was composed of a purified powdered base (Diet W) containing 
0.25% cholesterol w/w, 16% crude fat w/w (of which 15% cocoa butter) and agar ash which was 
supplemented with the following additives (see Table 5.1): 
Cohort 1:  Control high fat diet (Diet W base) supplemented with 3% high oleic sunflower (HOSF) 
oil (Lipid Nutrition, Netherlands).  
Cohort 2: Diet W supplemented with 3% eicosapentaenoic oil (EPA; 70% concentrate [additional 
~10% DHA], Croda Chemicals, UK).  
Cohort 3: Diet W supplemented with 3% high HOSF oil and 0.04% fenofibrate (Sigma, UK).  
The percentage of energy provided by both HOSF and EPA oil was 4.2%. The level of anti-oxidants 
(alpha-tocopherol) present in the EPA oil was matched to that of the control HOSF oil. The 
specialised diets were prepared as previously described (Chapter 2, Section 2.2.2). 
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5.2.3 Endpoint Studies 
5.2.3.1 Vascular function studies 
Prior to commencement of the in vivo protocol, mice were fasted for a period of 2 hours. Induction 
and maintenance of anaesthesia and cannulation of the right carotid artery and left jugular vein (for 
blood pressure measurement and drug administration respectively) were performed using the surgical 
procedure detailed in Chapter 2, Section 2.2.3. Following completion of surgery, mice underwent a 
15-minute stabilisation period. 
Following measurement of baseline heart rate and arterial blood pressure, the endothelium dependent 
vasodilator bradykinin (BK) and the directly acting vasodilator sodium nitroprusside (SNP) were used 
to elicit changes in blood pressure (see Figure 5.1 for drug protocol). Bolus injections of 3µg kg
-1
, 
30µg kg
-1
 and 300µg kg
-1
 drug (prepared in heparinised saline, see Chapter 2, Table 10) were 
administered intravenously (i.v.) with an injection volume of 10µl per 10g weight and a flush volume 
of 150µl heparinised saline. Between individual drug doses, mice underwent a 5-minute stabilisation period 
to allow blood pressure to return to baseline. For all experiments, drugs were administered in the order of 
BK followed by SNP due to the sustained hypotensive effect observed following administration of the 
higher SNP doses. Since the bulk of previous data pertaining to endothelial function in ApoE
-/-
 mice 
has been generated from ex-vivo studies, the dose range chosen for the protocol was extrapolated from 
concentrations used previously in murine in vitro studies (10
-12
M – 10-4M; Virdis et al., 2003; Liuba 
et al., 2007; Xu et al., 2007). Upon completion of the protocol, mice were euthanized via anaesthetic 
overdose and tissues were harvested (see Chapter 2, Section 2.2.4). 
5.2.3.2 Lipid profiling 
Blood samples were collected from the arterial cannula prior to termination of the in vivo protocol. 
Plasma levels of total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and 
triglycerides were determined as detailed previously (Chapter 2, Section 2.2.5). 
The crude lipid and triglyceride content of liver tissue was determined using the Folch method of fat 
extraction as described in Chapter 2 (Section 2.2.6). The fatty acid profiles of the liver samples were 
compiled using fatty acid methyl ester (FAME) analysis as previously described (Chapter 2, Section 
2.2.7). The expression of adipose differentiation-related protein (ADFP) in liver tissue was visualised 
and quantified using Western Blotting. As detailed in Chapter 2, liver proteins were extracted 
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(described in Section 2.2.10.1) and electrophoresis and immunoblotting employed to separate and 
identify proteins (Section 2.2.10.2). 
5.2.3.3 Endocannabinoid quantification 
Brain, heart and thoracic aorta tissue was subjected to endocannabinoid quantification. The 
endocannabinoids, 2-arachidonoylglycerol (2-AG) and anandamide (AEA), were extracted from the 
tissues and quantified using LC-MS/MS methods detailed in Chapter 2 (Section 2.2.8).  The assays 
were performed by Mr G Cameron, University of Aberdeen.  
5.2.3.4 Collagen and collagen cross-link quantification 
The remaining cardiac and thoracic aorta tissue was subjected to quantification of collagen and 
collagen cross-link content using HPLC and LC-MS/MS. The full protocol is described in Chapter 2 
(Section 2.2.9). The assays were performed by Dr Simon Robins (The Rowett Institute of Health and 
Nutrition, Aberdeen University) and raw data provided for subsequent analysis and interpretation. 
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Table 5.1 Experimental group details: Details of experimental groups, total numbers and 
intervention diets. 
*
Although 20 mice were originally planned for this group, 2 mice developed 
hydroencephalitis during transit from the supplier to the holding facility and therefore were humanely 
killed.  Thus, the total number of animals successfully starting and completing this intervention was 
18. 
  
 
 
Experimental 
group 
 
 
Total number 
of animals 
 
 
 
Diet Details 
 
 
ApoE
-/-
 mice: high fat 
control 
 
ApoE
-/-
 mice: EPA 
 
 
ApoE
-/-
 mice: fibrate 
 
 
C57 mice: control 
 
18* 
 
 
20 
 
 
20 
 
 
15 
 
Diet W + 3% HOSF oil 
 
 
Diet W + 3% EPA oil 
 
 
Diet W + 3% HOSF oil + 
0.04% fenofibrate 
 
Regular chow 
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Figure 5.1 In vivo drug protocol: Following surgery (T=0), haemodynamic parameters were allowed 
to stabilise. BK and SNP (3-300µg kg
-1
) were administered as bolus, I.V. injections. Between drug 
doses, haemodynamic parameters were allowed to return to pre-injection levels, (roughly 5 minutes 
stabilisation) prior to injection of subsequent doses. 
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5.3 Results 
5.3.1 Baseline measurements 
Body weight, heart weight, brain weight and resting blood pressure of mice from all study groups are 
presented in Table 5.2. With respect to mean body weight, no significant variations were observed 
between C57, control ApoE
-/-
 or EPA supplemented ApoE
-/-
 mice. In contrast, the mean body weight 
of fibrate supplemented ApoE
-/- 
mice (29.0±0.4 g) was slightly, but significantly, reduced compared to 
both C57 (30.8±0.5 g; P<0.01) and control ApoE-/- mice (31.0±0.4 g; P<0.01).  
Mean heart weights ranged between 187-215mg, however there were no significant differences 
between any study groups. Similarly, there was no statistically significant variation in mean brain 
weight or heart/body weight ratios between any study groups.  
5.3.2 Hepatic lipid profiles 
The content of total lipid present in liver samples is illustrated in Figure 5.2, where lipid content is 
expressed as a percentage of the original tissue weight. High fat feeding of ApoE
-/-
 mice (15.0±0.9%; 
P<0.001), significantly elevated the total lipid content of the liver compared to C57 mice (3.5±4.2%). 
Compared to control ApoE
-/-
 mice, both EPA (11.1±0.8%; P<0.001) and fibrate (9.5±1.4 %; P<0.01)  
supplementation significantly (P<0.05) attenuated the increased lipid content induced by high fat 
feeding by a similar magnitude, although these were still elevated compared to C57 mice fed standard 
laboratory chow.  
The triglyceride content of liver samples is shown in Figure 5.3. High fat feeding of ApoE
-/-
 mice did 
not significantly vary the triglyceride content of the liver (6.9±0.6 mg/g tissue) from that of chow fed 
C57 mice (4.5±1.7 mg/g tissue). Similarly EPA supplemented ApoE
-/-
 mice demonstrated no variation 
(4.4±0.5 mg/g tissue). Conversely, fibrate supplemented ApoE
-/-
 mice exhibited significantly elevated 
triglycerides (12.1±1.2 mg/g tissue; P<0.01) compared to both C57 mice and control ApoE
-/-
 mice. 
Figure 5.4 depicts the expression of adipophilin protein in liver samples. Protein expression was 
quantified through conducting area under the curve analysis (presented in arbitrary units). Compared 
to high fat fed ApoE
-/-
 mice (2.4±0.6), fibrate, but not EPA, supplementation significantly elevated 
adipophilin expression (4.8±0.6).   
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Group 
 
 
Body Weight 
(g) 
 
 
Heart Weight 
(mg) 
 
 
Brain Weight 
(g) 
 
 
Heart/Body 
Weight Ratio 
(mg/g) 
 
 
C57 
 
30.8±0.5 
 
215±12 
 
0.39±0.01 
 
7.0±0.4 
 
ApoE
-/-
: High Fat 
 
31.0±0.4 
 
194±3 
 
0.40±0.02 
 
6.4±0.2 
 
ApoE
-/-
: EPA 
 
31.2±0.5 
 
193±8 
 
0.42±0.00
 
 
6.2±0.3 
 
ApoE
-/-
: Fibrate 
 
29.0±0.4*
##
 
 
183±12 
 
0.45±0.05
 
 
6.5±0.4 
Table 5.2 Tissue weights in C57 and ApoE
-/-
 mice: Body weight was recorded at the end of the dietary 
intervention. Heart and brain weights were recorded following their removal. n=10-20. *P<0.05 vs C57 mice; 
##
P<0.01 vs control ApoE
-/-
 mice (one-way ANOVA, Dunnett’s Multiple Comparison post-hoc test). Values 
represent mean±SEM.  
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Figure 5.2 Hepatic lipid profiles - total lipid: The crude lipid content of liver samples collected from 
C57 and ApoE
-/-
 mice post dietary intervention were determined using the Folch method. Data is 
expressed as a percentage of the original sample weight. n=5-10 per group. **P<0.01, ***P<0.001 vs C57 
mice; 
#
P<005, 
##
P<0.01 vs control ApoE
-/- 
mice (one-way ANOVA, Dunnett’s multiple comparison post-
hoc test). Values represent mean±SEM.. 
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Figure 5.3 Hepatic lipid profiles - triglycerides: The triglyceride content of liver samples from C57 
and ApoE
-/-
 mice was measured. Using the Folch method crude lipid was extracted from the liver 
samples, from which triglycerides were measured using a KoneLab 30 analyser. n=5-10 per group. 
**P<0.01 vs C57 mice; 
##
P<0.01 vs control ApoE
-/- 
mice (one-way ANOVA, Dunnett’s multiple 
comparison post-hoc test). Values represent mean±SEM.  
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Figure 5.4 Hepatic lipid profiles - adipophilin expression: The expression of adipophilin protein in 
liver samples from ApoE
-/-
 mice was measured using Western Blotting. Bands corresponding to 
adipophilin expression were positively identified through comparison with bands from control tissue 
(heat shock protein 70; HSP).Band size and intensity was measured using Aida 3.52 software which 
converted the image to a histogram format. Area under the curve analysis enabled quantitative 
measurement of protein expression. n=5-10 per group. *P<0.05 vs control ApoE
-/- 
mice (one-way 
ANOVA, Dunnett’s multiple comparison post-hoc test). Values represent mean±SEM. 
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Figure 5.5 illustrates the fatty acid profiles of liver samples from each study group. Fatty acids have 
been grouped into saturated, monounsaturated and polyunsaturated fatty acids (SFAs, MUFAs and 
PUFAs respectively). The profiles of C57 mice, which were fed a regular chow diet, demonstrated 
equal quantities of SFAs (39%) and PUFAs (44%), while MUFAs comprised only 17% of the profile. 
Of PUFAs, ω-6 (34%) predominate over ω-3 FAs (10%). Both control and fibrate supplemented 
ApoE
-/-
 mice, which were fed a ‘Western’ style base diet, had highly similar profiles composed 
mainly of MUFAs (53-54%), with 31-32% SFAs and only 15% PUFAs. Similar to C57 profiles, 
PUFAs were composed primarily of ω-6 FAs (11% vs 4% ω-3 FAs). In contrast, while EPA 
supplemented ApoE
-/-
 mice also had profiles dominated by SFAs (51%), they contained similar 
quantities of MUFAs (28%) and PUFAs (21%). Moreover, PUFAs were almost equally composed of 
ω-6 and ω-3 FAs (10% and 11% respectively). 
The contribution of EPA and DHA to fatty acid profiles was determined and is illustrated in Figure 
5.6. The DHA content of all ApoE
-/-
 groups was significantly higher than EPA compared to respective 
measurements in C57 mice. High fat feeding alone (1.1±0.1%), and in combination with fibrate 
supplementation (1.4±0.2%) exhibited significantly reduced hepatic DHA content of ApoE
-/-
 mice 
compared to C57 mice (6.2±0.3%; P<0.01). EPA supplemented ApoE
-/-
 mice, however, exhibited a 
significantly increased hepatic DHA content (10.1±0.3 %; P<0.05) compared to both C57 and control 
ApoE
-/-
 mice. Hepatic EPA levels were significantly elevated in EPA supplemented ApoE
-/-
 mice 
compared to C57 mice. EPA levels in high fat fed and fibrate supplemented ApoE
-/-
 mice were below 
the minimum detection limits of the assay.  
5.3.3 Blood plasma lipid profiles 
The total cholesterol content of plasma from C57 and ApoE
-/-
 mice is illustrated in Figure 5.7. 
Compared to chow fed C57 mice, high fat feeding of ApoE
-/-
 mice significantly elevated cholesterol 
levels (0.89±0.1 mmol/L vs 14.00±2.6 mmol/L respectively; P<0.01). Both EPA and fibrate 
significantly attenuated the elevated cholesterol levels induced by high fat feeding to a similar degree 
(8.39±1.7 mmol/L and 8.44±0.99 mmol/L respectively vs 14.00±2.6 mmol/L; P<0.05). A similar 
pattern was observed with low density lipoprotein (LDL) cholesterol levels (see Figure 5.8), where 
high fat feeding of ApoE
-/-
 mice significantly elevated LDL cholesterol levels (10.3±1.8 mmol/L vs 
0.12±0.01 in C57 mice; P<0.001), while supplementation with EPA (4.4±2.9 mmol/L) or fibrate 
(5.9±4.2 mmol/L), significantly attenuated raised LDL cholesterol levels (p<0.05).  
122 
 
 
Figure 5.5 Hepatic lipid profiles - fatty acid profiling: Fatty acid methyl esters (FAME’s) were 
prepared from crude lipid extracts and profiles compiled through conducting GC analysis. The quantity 
of each FAME identified was determined from the area of its corresponding peak. FAME’s were then 
expressed as a percentage of the entire sample profile. Individual FAME’s have been grouped into 
cohorts of saturated (Cx=0), monounsaturated (Cx=1) and polyunsaturated (Cx=2
+
 n6 and Cx=2
+
 n3) 
fatty acids. n=5-10 per group.   
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Figure 5.6 Hepatic lipid profiles – EPA and DHA content of hepatic fatty acid profiles: From the 
hepatic fatty acid profiles compiled previously, the EPA and DHA constituent of each profile was 
assessed. Data is expressed as a percentage of the complete fatty acid profile. n=5-10 per group. 
**P<0.01 vs C57 mice; 
#
P<0.01 vs control ApoE
-/- 
mice (one-way ANOVA, Dunnett’s multiple 
comparison post-hoc test). Values represent mean±SEM.  
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Figure 5.7 Plasma lipid profiles - total cholesterol: The cholesterol content of blood plasma 
collected from C57 and ApoE
-/-
 mice was measured. Blood samples were collected via arterial 
cannula and the plasma fraction isolated and snap frozen for subsequent analysis using a KoneLab 
30 analyser. Samples were analysed in duplicate. n=7-10 per group. **P<0.01, ***P<0.001 vs C57 
mice; 
#
P<0.05 vs control ApoE
-/- 
mice (one-way ANOVA, Dunnett’s multiple comparison post-hoc 
test). Values represent mean±SEM.  
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Figure 5.8 Plasma lipid profiles – LDL cholesterol: The low LDL cholesterol content of blood 
plasma collected from C57 and ApoE
-/-
 mice was measured and analysed as described previously. 
n=7-10 per group. *P<0.05, ***P<0.001 vs C57 mice; 
##
P<0.01 vs control ApoE
-/- 
mice (one-way 
ANOVA, Dunnett’s multiple comparison post-hoc test). Values represent mean±SEM.  
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The high density lipoprotein (HDL) cholesterol content of plasma samples is illustrated in Figure 5.9. 
Compared to C57 mice fed standard laboratory chow, high fat feeding significantly elevated plasma 
HDL cholesterol in ApoE
-/-
 mice (P<0.01), which was unaffected by supplementation with either EPA 
or fibrate. The ratio of total cholesterol to HDL cholesterol was calculated and illustrated in Figure 
5.10. High fat feeding of ApoE
-/-
 mice significantly increased the ratio of total cholesterol to HDL 
cholesterol compared to C57 mice fed standard laboratory chow. Although EPA supplementation 
tended to reduce the cholesterol to HDL cholesterol ratio, this was not statistically significant. In 
contrast, fibrate supplementation significantly lowered the ratio compared to control ApoE
-/-
 mice, to 
a value within the range of wild-type mice. Figure 5.11 depicts the triglyceride content of the plasma 
samples. Although high fat feeding alone had no significant effect on plasma triglycerides, these were 
significantly increased in EPA supplemented ApoE
-/- 
mice compared to both C57 and high fat fed 
ApoE
-/-
 mice (p<0.001).  
5.3.4 Collagen and cross-link measurement 
5.3.4.1  Cardiac Tissue 
The total collagen content of cardiac tissue from all study groups is illustrated in Figure 5.12. 
Collagen content varied between 1.5-1.6% of the original dry tissue weights. There were no 
statistically significant variations between any of the experimental groups. Figures 5.13 and 5.14 
demonstrate the formation of various cross-links in cardiac tissue. High fat feeding of ApoE
-/-
 mice 
significantly increased the formation of the intermediate cross-links DHLNL and HLNL (P<0.05; see 
Figure 5.13) and the mature cross-links PYD and DPD (P<0.01; Figure 5.14) compared to C57 mice. 
No significant effect of high fat diet was observed on the formation of the mature cross-link HHL, 
although there was a tendency for this to be increased in all ApoE
-/-
 mice. Moreover, the total content 
of elastin cross-links DES and IDE (P<0.01; see Figure 5.14) was significantly reduced in the control 
ApoE
-/-
 group.  No statistically significant effects were observed on any cross-links in ApoE
-/-
 mice 
given EPA or fibrate supplementation, compared to control ApoE
-/-
 mice. 
 
The ratio of mature to immature cross-linking was calculated and is presented in Figure 5.15. This 
ratio serves as an indicator of the rate of cross-link turnover from immature to mature conformations. 
C57 mice exhibited the highest ratio (2.0±0.5). Lower ratios were observed in all three ApoE
-/-
 groups, 
however this only reached statistical significance in the EPA supplemented mice (1.0±0.7). 
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Figure 5.9 Plasma lipid profiles – HDL cholesterol: The blood plasma concentration of HDL 
cholesterol was measured and analysed as described previously. n=7-10 per group. **P<0.01, 
***P<0.001 vs C57 mice (one-way ANOVA, Dunnett’s multiple comparison post-hoc test). Values 
represent mean±SEM.  
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Figure 5.10 Plasma lipid profiles - total cholesterol/HDL cholesterol ratio: The ratio of total 
cholesterol to HDL cholesterol in the plasma of C57 and ApoE
-/- 
mice was calculated (calculated 
as total cholesterol value divided by HDL cholesterol value). n=7-10 per group. **P<0.01 vs C57 
mice; 
#
P<0.05 vs control ApoE
-/- 
mice (one-way ANOVA, Dunnett’s multiple comparison post-hoc 
test). Values represent mean±SEM. 
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Figure 5.11 Plasma lipid profiles - triglycerides: The concentration of triglycerides present in the 
blood plasma of C57 and ApoE
-/- 
mice was measured as described previously. n=7-10 per group. 
***P<0.001 vs C57 mice; 
###
P<0.001 vs control ApoE
-/- 
mice (one-way ANOVA, Dunnett’s multiple 
comparison post-hoc test). Values represent mean±SEM. 
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Figure 5.12 The total collagen content of C57 and ApoE
-/- 
mouse heart tissue: The collagen content of 
cardiac tissue from C57 and ApoE
-‘-
 mice was measured. Post intervention, hearts were removed, the atria 
discarded and the ventricles snap frozen for analysis. Collagen content was determined from the total 
hydroxyproline content of the sample which was measured using LC-MS/MS. Data is expressed as a 
percentage of the original dry weight of sample – to which it is normalised. n=5-7 per group.  Values 
represent mean±SEM. 
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Figure 5.13 The DHLNL, HLNL and HHL content of C57 and ApoE
-/-
 mouse 
heart tissue: The presence and concentration of DHLNL, HLNL and HHL cross 
links in the heart samples collected and analysed as described previously were 
measured. n=5-7 per group. *P<0.05; **P<0.01 vs C57 mice (one-way ANOVA, 
Dunnett’s multiple comparison post-hoc test). Values represent mean±SEM.  
C57 High Fat EPA Fibrate
0.00
0.05
0.10
0.15
0.20
ApoE
-/-
** **
*
H
L
N
L
: 
re
s
/m
o
l 
c
o
ll
a
g
e
n
C57 High Fat EPA Fibrate
0.00
0.02
0.04
0.06
ApoE
-/-
H
H
L
: 
re
s
/m
o
l 
c
o
ll
a
g
e
n
C57 High Fat EPA Fibrate
0.0
0.1
0.2
0.3
0.4
ApoE
-/-
**
**
**
D
H
L
N
L
: 
re
s
/m
o
l 
c
o
ll
a
g
e
n
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 The PYD, DPD and total DES/IDE content of C57 and ApoE
-/-
 
mouse heart tissue: The presence and concentration of PYD, DPD and the total 
DES/IDE cross links in heart samples collected and analysed as described previously 
were measured. n=5-7 per group. *P<0.05; **P<0.01 vs C57 mice (one-way 
ANOVA, Dunnett’s multiple comparison post-hoc test). Values represent 
mean±SEM.  
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Figure 5.15 Mature:immature cross-link ratio in cardiac tissue: The ratio of mature to immature 
cross-links was calculated by dividing the total mature cross-link content (PYD, DPD and HHL) by 
the total immature cross-link content (DHLNL and HLNL). n=5-7 per group. *P<0.05 (one-way 
ANOVA, Dunnett’s multiple comparison post-hoc test). Values represent mean±SEM. 
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5.3.4.2 Vascular Tissue 
The total collagen content and collagen cross-link content of vascular tissue from ApoE
-/-
 mice is 
displayed in Table 5.3 and Table 5.4. No variations in total collagen content were observed between 
the ApoE
-/-
 mice interventions. Similarly, the cross-link content of vascular tissue did not vary 
significantly between ApoE
-/-
 mice intervention groups. Due to technical error, there was insufficient 
tissue retrieved from the C57 group to undertake collagen and cross-link analysis. 
5.3.5 Tissue endocannabinoid levels 
5.3.5.1 Thoracic aorta endocannabinoid levels 
The concentration of 2-AG and AEA in vascular tissue is presented in Figure 5.16. High fat fed 
ApoE
-/-
 mice exhibited significantly elevated levels of both 2-AG (p<0.05) and AEA (P<0.01) 
compared to C57 mice fed standard laboratory chow. Compared to control ApoE
-/-
 mice, EPA 
supplementation significantly attenuated elevated 2-AG levels (3777±316 pmol/g; P<0.05) and 
reduced AEA levels, although this effect was not statistically significant. Conversely, fibrate 
supplementation significantly attenuated elevated AEA levels (6.8±1.5 pmol/g; P<0.05) but had no 
effect on 2-AG.  
5.3.5.2 Brain endocannabinoid levels 
The content of 2-AG and AEA present in brain tissue from C57 and ApoE
-/-
 mice is illustrated in 
Figure 5.17. High fat feeding of ApoE
-/-
 mice significantly elevated the concentration of 2-AG in 
brain tissue (34750±4521 pmol/g; P<0.05) compared to C57 mice (23074±1776 pmol/g) fed standard 
laboratory chow. Inclusion of EPA (36016±2843 pmol/g) or fibrate (43260±3424 pmol/g) in the diet 
had no effect on these elevated levels.  
High fat feeding of ApoE
-/-
 mice also significantly elevated brain AEA levels (70.4±12.7 pmol/g; 
P<0.01) compared to C57 mice (35.0±3.2 pmol/g) fed standard laboratory chow. In contrast to 2-AG, 
EPA supplementation significantly attenuated (32.3±5.2 pmol/g; P<0.01) the enhanced AEA levels 
induced by high fat feeding. Fibrate supplementation also tended to reduce AEA levels compared to 
control ApoE
-/-
 mice, but this did not achieve statistical significance. 
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Group 
 
Total Collagen: % Dry Weight 
 
ApoE
-/-
 High Fat 
 
30.56±1.6 
 
ApoE
-/-
 EPA 
 
32.33±1.8 
 
ApoE
-/-
 Fibrate 
 
33.32±0.9 
Table 5.3 Collagen content of ApoE
-/-
 mouse thoracic aorta tissue: Data is 
expressed as a percentage of the original sample dry weight. n=4-6 per group. 
Values represent mean±SEM.  
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Table 5.4 Collagen and elastin cross-link content of ApoE
-/-
 mouse tissue: Collagen and elastin cross-link 
concentrations were determined using LC-MS/MS as described previously. n=4-6 per group. 
  
 
Group 
 
DHLNL 
(res/mol) 
 
HLNL 
(res/mol) 
 
HHL 
(res/mol) 
 
PYD 
(res/mol) 
 
DPD 
(res/mol) 
 
Total 
DES/IDE 
(nmol/mg 
dry tissue) 
 
Mature: 
immature 
cross-link 
ratio 
 
ApoE
-/-
 
High Fat 
 
0.33±0.02 
 
 
0.26±0.03 
 
0.04±0.03 
 
0.30±0.02 
 
0.02±0.0 
 
1.02±0.1 
 
0.61±0.04 
 
ApoE
-/-
 
EPA 
 
0.36±0.28 
 
0.24±0.01 
 
0.03±0.00 
 
0.29±0.02 
 
0.02±0.0 
 
0.99±0.1 
 
0.57±0.02 
 
ApoE
-/-
 
Fibrate 
 
 
0.24±0.18 
 
0.22±0.03 
 
0.04±0.03 
 
0.26±0.01 
 
0.02±0.0 
 
0.98±0.1 
 
0.73±0.07 
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Figure 5.16 Endocannabinoid content of C57 and ApoE
-/-
 mouse vascular 
tissue: The 2-AG and AEA content of thoracic aorta tissue from C57 and 
ApoE
-/-
 mice was determined and analysed as described previously. n=9-10 
per group. *P<0.05; **P<0.01 vs C57 mice; #P<0.05 vs control ApoE-/- mice (one-
way ANOVA, Dunnett’s multiple comparison post-hoc test). Values represent 
mean±SEM.  
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Figure 5.17 Endocannabinoid content of C57 and ApoE
-/-
 mouse brain tissue: 
The concentration of 2-AG and AEA present in brain tissue from C57 and ApoE
-/-
 
mice was quantified. Brains were removed, rinsed in PBS and snap frozen. Tissue 
was analysed using LC-MS/MS. Data was normalised to the original tissue weight 
and expressed as pico mole per gram of tissue. n=9-10 per group. *P<0.05; 
**P<0.01 vs C57 mice; 
##
P<0.01 vs control ApoE
-/-
 mice (one-way ANOVA, 
Dunnett’s multiple comparison post-hoc test). Values represent mean±SEM.  
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5.3.5.3 Heart endocannabinoid levels 
Cardiac tissue from C57 mice fed standard laboratory chow contained 11163±1168 pmol/g 2-AG 
(Figure 5.18). High fat feeding of ApoE
-/-
 mice, either alone or in combination with either EPA or 
fibrate, did not significantly affect 2-AG levels.  In contrast, cardiac AEA was significantly elevated 
in high fat fed ApoE
-/-
 mice (22.1±2.6 pmol/g; P<0.01) compared to C57 mice (11.6±2.1 pmol/g) fed 
standard laboratory chow. EPA supplemented ApoE
-/-
 mice exhibited cardiac AEA levels that were 
significantly lower (2.8±0.8 pmol/g; P<0.01) than in both C57 mice and control ApoE
-/-
 mice. Fibrate 
supplementation also significantly reduced AEA levels (14.5±1.6 pmol/g; P<0.01), but only in 
comparison with control ApoE
-/-
 mice.    
5.3.6 Haemodynamic responses to bradykinin 
Baseline haemodynamics in all groups is summarised in Table 5.5. Resting blood pressure and heart 
rate did not vary significantly between any of the experimental groups. Original traces showing 
examples of the saline response, depressor response to BK and depressor response to SNP are illustrated in 
Figures 5.19, 5.20 and 5.21 respectively. Figures 5.22 and 5.23 show the averaged time-dependent 
depressor responses to both saline (vehicle) and BK (3 - 300µg kg
-1
), where data is expressed as a 
percentage change in mean arterial blood pressure (MABP) from resting blood pressure (measured in 
millimetres of mercury; mmHg). Bradykinin was observed to induce a dose dependent reduction in 
MABP. Moreover, with increasing dose, the duration and magnitude of the response was augmented. 
To account for the injection artefact, as observed with the response to saline, area under the curve 
(AUTC) analysis was conducted to quantify the blood pressure responses to BK in each study group 
(see Figure 5.24). In all study groups, BK induced a dose dependent increase in the AUTC. High fat 
feeding of ApoE
-/-
 mice significantly reduced the AUTC (4530±945 AU; P<0.05) response to 300µg 
kg
-1
 BK compared to C57 mice (7903±1202 AU). Fibrate supplementation restored this response 
(7470±394 AU; P<0.05), whereas EPA supplementation did not.  
The effect of BK on heart rate is illustrated in Figure 5.25. Compared to saline, BK had no significant 
effect on heart rate at any dose, in any of the study groups.  
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Figure 5.18 Endocannabinoid content of C57 and ApoE
-/-
 mouse cardiac tissue: 2-
AG and AEA levels in cardiac tissue from C57 and ApoE
-/-
 mice were quantified and 
analysed as described previously. n=9-10 per group. **P<0.01 vs C57 mice; 
##
P<0.01 vs 
control ApoE
-/-
 mice (one-way ANOVA, Dunnett’s multiple comparison post-hoc test). 
Values represent mean±SEM.  
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Group 
 
 
Resting Blood 
Pressure (mmHg) 
 
 
Resting Heart rate 
(BPM) 
 
C57 
 
90.7±4.7 
 
360.2±18.28 
 
ApoE
-/-
: High Fat 
 
92.4±7.7 
 
364.1±18.51 
 
ApoE
-/-
: EPA 
 
91.8±7.3 
 
360.6±20.89 
 
ApoE
-/-
: Fibrate 
 
88.6±4.5 
 
340.9±13.44 
Table 5.5 Resting blood pressure and heart rate: Blood pressure (mmHg) and heart 
rate (BPM) was recorded at baseline (prior to drug administration). n=4-8 per group. 
Values represent mean±SEM.  
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Figure 5.19 Original trace showing the haemodynamic response to heparinised saline: Heart rate (HR) was 
calculated by the software from the Lead I ECG (µV) recorded from subcutaneous limb leads. One hundred and 
fifty microlitres of saline (flush volume of drug) was administered I.V. 
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Figure 5.20 Original trace showing the depressor response to 3µg kg
-1
 bradykinin: Heart rate (HR) was 
calculated as described previously.  
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Figure 5.21 Original trace showing the depressor response to 3µg kg
-1
 sodium nitroprusside: HR was 
calculated as described previously.  
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Figure 5.22 Blood pressure responses to bradykinin (3µg kg
-1
): Depressor 
responses to endothelium dependent vasodilator bradykinin (BK) were recorded 
via a carotid artery cannula and presented as changes in mean arterial blood 
pressure (MABP; mmHg). Responses to saline and 3µg kg
-1
 BK are illustrated 
above. Data is expressed as a percentage fall in MABP respective to the resting 
blood pressure (denoted ‘100%’). n=4-8 per group. Values represent 
mean±SEM.  
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Figure 5.23 Blood pressure responses to bradykinin (30 and 300µg kg
-1
): 
Depressor responses to 30 and 300µg
 
kg
-1
 BK were recorded via carotid artery 
cannula as described previously. Data is expressed as a percentage fall in 
MABP respective to resting blood pressure. n=4-8 per group. Values represent 
mean±SEM. 
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Figure 5.24 Area under the curve analysis of blood pressure responses to bradykinin: The 
depressor response to bradykinin was quantitatively measured through conducting area under 
the curve analysis. MABP data (expressed as % change) was inverted, where resting BP 
(denoted 100%) was denoted as ‘0’. n=4-8 per group. *P<0.05 vs C57 mice; #P<0.05 vs control 
ApoE
-/-
 mice (two-way ANOVA, Bonferroni post-hoc test). Values represent mean±SEM. 
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5.3.7 Haemodynamic responses to sodium nitroprusside 
Figures 5.26 and 5.27 illustrate the time-dependent depressor responses to sodium nitroprusside 
(SNP; 3 - 300µg kg
-1
). A dose dependent response to SNP was not observed in any of the study 
groups, with a maximum reduction in MABP (40%) observed with 3µg kg
-1
 SNP. Subsequent AUTC 
analysis of the responses confirmed that there was no dose dependent response observed to SNP 
(Figure 5.28). Moreover, there was no effect of either high fat feeding, or EPA or fibrate 
supplementation, in any of the groups. 
The effect of SNP on heart rate is shown in Figure 5.29. Compared to saline responses, heart rate was 
unaffected by increasing sodium nitroprusside administration. Moreover, there was no statistically 
significant variation in heart rate between any of the treatment groups. 
5.4 Discussion  
In light of the findings from Chapter 4 that indicated the existence of interaction between ω-3 PUFAs 
and endocannabinoids at the cellular level, the principle aim of this part of the thesis was to determine 
whether dietary supplementation with EPA (using fenofibrate as a lipid lowering control) has any 
effect on the endocannabinoid system in vivo.  In order to assess this, it was necessary to first 
determine the impact of a high fat diet intervention alone on tissue endocannabinoid levels alongside 
the development of hyperlipidaemia, vascular dysfunction and tissue remodelling, and to compare 
these changes in high fat fed mice supplemented with EPA and fenofibrate. 
The ApoE
-/- 
mouse was utilised as an in vivo model of hyperlipidaemia and its development, a process 
which was hastened by maintenance on an atherogenic diet. The composition of the atherogenic diet 
used in the current study was based on the widely used semi-synthetic ‘Paigen’ diet. First formulated 
in the laboratory of Paigen and colleagues in 1990 (Nishina et al., 1990), the original Paigen diet 
contained 15% fat (cocoa or butter fat), 1.25% cholesterol, 1% corn oil and 0.5% sodium cholate. For 
the present study, the diet was modified to contain a marginally higher quantity of fat (16%, sourced 
from cocoa butter), a reduced quantity of cholesterol (0.25%) and without cholate due to its 
confounding influence on the genetic regulation of inflammation, cholesterol processing and 
lipoprotein metabolism (Vergnes et al., 2003; Lambert et al., 2003). Corn oil was substituted with 3% 
high oleic sunflower (HOSF) oil, the purpose of which was to prevent polyunsaturated fatty acid 
deficiency (the predominant fat present in the diet was derived from saturated fatty acids) and to equal 
the content of polyunsaturated fatty acids present in the EPA oil supplemented diet.   
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Figure 5.25 Heart rate responses to bradykinin: The effect of BK (3-300µg kg
-1
) on HR 
was measured. Data was recorded as beats per minute (BPM) through Lead I ECG limb 
leads. Data was expressed as a percentage change in HR compared to baseline HR. n=4-8 per 
group. Values represent mean±SEM. 
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Figure 5.26 Blood pressure responses to sodium nitroprusside (3µg kg
-1
): 
Depressor responses to endothelium independent vasodilator SNP were 
recorded across a 300 second sampling period as described previously. 
Responses to saline and 3µg kg
-1
 are shown above, expressed as a percentage 
fall in MABP respective to resting blood pressure. n=4-8 per group. Values 
represent mean±SEM. 
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Figure 5.27 Blood pressure responses to sodium nitroprusside (30 and 
300µg kg
-1
): Depressor responses to 30 and 300µg kg
-1
 SNP were recorded and 
analysed as described previously. n=4-8 per group. Values represent 
mean±SEM. 
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Figure 5.28 Area under the curve analysis of blood pressure responses to sodium 
nitroprusside: Depressor responses to SNP were measured quantitatively using area under the 
curve analysis as described previously. n=4-8 per group. Values represent mean±SEM. 
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Figure 5.29 Heart rate responses to sodium nitroprusside: The effect of SNP (3-300µg 
kg
-1
) on HR was measured and analysed as described previously. n=4-8 per group Values 
represent mean±SEM. 
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As outlined in the methods section, one ApoE
-/- 
cohort received 3% EPA oil in addition to the 
atherogenic diet. Investigations of the effects of dietary EPA oil have been conducted in numerous 
animal studies in which intervention doses have been within the range of 1% to 5% (w/w) of total 
food intake (Xu et al., 2007; Matsumoto et al., 2008; Mavrommatis et al., 2010; Burri et al., 2011). 
Therefore based on the literature, a dose of 3% EPA oil was chosen for the current study. A final 
ApoE
-/-
 cohort received the atherogenic diet supplemented with 0.04% fenofibrate: an established 
lipid lowering drug from the fibrate class of amphipathic carboxylic acids (refer to chapter 1 for 
details). The dose of fenofibrate employed in the present study was based on a previously used dose 
(de Roos et al., 2005).  
5.4.1 The impact of dietary intervention on baseline physiology in the ApoE-/- mouse 
Although it might be expected that maintenance on a high fat diet would increase mean body weight, 
when compared with age-matched wild-type mice fed regular chow, high fat feeding of ApoE
-/-
 mice 
did not influence mean body weight. However, as ApoE
-/-
 mice primarily represent a model of 
hyperlipidaemia and not obesity, the current result is not entirely unexpected and is consistent with 
previous dietary studies that have indicated no significant effect of high fat feeding on ApoE
-/-
 body 
weight (Davis et al., 2001; Harrington et al., 2007; Nakagami et al., 2009), suggesting that these mice 
follow a normal body weight pattern irrespective of diet. Of the other baseline characteristics 
measured, there was negligible variation in mean heart weights between wild-type mice and ApoE
-/-
 
mice. Additionally, there was no variation in heart/body weight ratios. Together this evidence 
demonstrates that there is no impact of high fat feeding on cardiac mass. This finding is in contrast to 
those of a study conducted by Hartley et al. (2000), which reported significant cardiac hypertrophy in 
chow fed ApoE
-/-
 mice compared to wild-type mice. Interestingly, mice used in the Hartley study 
were 13 months of age, which is considerably older than those used in the current study (6 months), 
suggesting that development of cardiac hypertrophy in the ApoE
-/-
 mouse is influenced by age rather 
than diet.  
EPA supplementation had no effect on mean body weight, a finding which is reported inconsistently 
in the literature. Studies in ApoE
-/-
 mice have reported no effect of fish oil supplementation on mean 
body weight (Xu et al., 2007). In wild-type mice however, inclusion of EPA in the diet was reported 
to significantly increase body weight (Halade et al., 2010), suggesting the discrepancy could be strain 
specific. EPA supplementation did not alter either mean heart weight or heart/body weight ratios, 
while fenofibrate supplementation modestly, but significantly, lowered mean body weight compared 
with both wild-type mice and high fat fed ApoE
-/-
 mice.  This latter observation is supported by 
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findings from multiple studies in wild-type and genetic knockout murine strains and is thought to 
arise from PPAR-α mediated induction of hepatic fatty acid metabolism (Mancini et al., 2001; Jeong 
et al., 2004; Motawi et al., 2009). Fenofibrate supplementation had no impact on mean heart weights 
or mean heart/body weight ratios. 
5.4.2 The impact of an atherogenic diet on lipid metabolism in the ApoE-/- mouse 
In terms of hepatic lipid physiology, the observation that the atherogenic diet significantly elevated 
the hepatic crude lipid levels of ApoE
-/-
 mice compared to chow fed wild-type mice, is consistent with 
the notion that a high fat diet is conducive to altered hepatic lipid metabolism and accumulation in 
this model. These findings are in agreement with similar studies in C57BL/6J mice and Wistar rats 
(Kim et al., 2004; Vijaimohan et al., 2006).  However, hepatic triglyceride levels were unaltered by 
the atherogenic diet, suggesting that the observed changes in hepatic lipid levels were independent of 
triglyceride synthesis. This finding is in contrast to previous reports of a positive association between 
high fat feeding and hepatic triglyceride synthesis, where 6 weeks of high fat feeding in 3 month old 
C57BL/6J mice was shown to significantly elevate hepatic triglyceride levels (Oosterveer et al., 
2009), although this difference could be accounted for by different mouse strains. Genetic ablation of 
the apoE impairs hepatic clearance of both chylomicron remnants and LDL, generating a 
hyperlipidaemic profile. It is possible that such elevated levels of circulating chylomicrons, combined 
with an increased pool of exogenously derived triglycerides, could induce negative feedback 
inhibition whereby de novo hepatic triglyceride synthesis is down-regulated. Analysis of hepatic fatty 
acid composition of the ApoE-/- mice in this study revealed that the high fat diet markedly increased 
the quantity of MUFAs, a finding which has been previously reported in C57BL/6J mice (Oosterveer 
et al., 2009). In contrast, the overall proportion of PUFAs was decreased and there was a shift in 
PUFA composition towards profound ω-6 predominance, an effect that has been linked to 
atherosclerotic lesion progression (Wang et al., 2008; Wan et al., 2010) and suggests an increased 
abundance of the metabolic products of ω-6 PUFAs (arachidonic acid (AA) derived prostaglandins, 
thromboxanes, leukotrienes, lipoxins).  
In relation to plasma lipid profiles, maintenance on the atherogenic diet significantly elevated total 
cholesterol and LDL-cholesterol, an effect which is consistent with reports in high fat fed ApoE
-/-
 
mice (Moghadasian et al., 2001; Guo et al., 2005) and represents a widely recognised risk factor for 
coronary artery disease. Absolute HDL-cholesterol levels were also significantly increased - an effect 
which could suggest a beneficial action of the diet. However, in light of the elevated total cholesterol: 
HDL ratio, it is likely that the increase was secondary to the overall elevation of total cholesterol and 
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that the majority of circulating cholesterol was confined to the lower density, pro-atherogenic 
particles. Indeed, elevated LDL-cholesterol measured in the present study, together with previous 
reports of elevated VLDL-cholesterol in high fat fed ApoE
-/- 
mice support this notion (Guo et al., 
2005). The observation that the atherogenic diet induced a slight, although not significant, increase in 
plasma triglycerides was not unexpected considering the negligible effect of the diet on hepatic 
triglyceride synthesis. 
5.4.2.1 EPA supplementation and lipid metabolism in the ApoE-/- mouse 
The present finding that supplementation with EPA significantly reduced hepatic lipid levels is 
consistent with previously reported studies in mice and rats (De Roos et al., 2005; Vijaimohan et al., 
2006). The current study found that EPA supplementation had a negligible impact on hepatic 
triglyceride levels, while causing a significant rise in serum triglycerides. This is in contrast to the 
well accepted hypotriglyceridaemic effects of EPA (Chapter 1, Section 1.3.4), which are thought to be 
the result of reduced hepatic VLDL assembly and secretion and, increased chylomicron and VLDL 
clearance (Harris et al., 1997; Yongsoon and Harris, 2003). Thus a potential explanation for the 
failure of EPA to influence hepatic triglyceride levels in ApoE
-/-
 mice could be due to impaired 
hepatic clearance of chylomicrons due to the apoE deficiency characteristic of this strain. Consistent 
with previous findings (De Roos et al., 2005), EPA supplementation raised hepatic PUFA 
composition considerably, an effect which was accompanied by a favourable increase in the ω-3/ω-6 
PUFA ratio. Moreover, hepatic EPA and DHA levels were significantly elevated in the EPA 
supplemented group, which strongly suggests that the supplementation was sufficient to effect 
alterations in tissue fatty acid composition.   
In terms of plasma profiles, EPA supplementation moderately improved the lipid profile. Compared 
to high fat fed ApoE
-/-
 mice, total cholesterol and LDL-cholesterol levels were significantly reduced. 
While the cholesterol lowering effects of ω-3 PUFAs have been reported previously (Illingworth et 
al., 1984; De Roos et al., 2005), data concerning the impact of ω-3 PUFA supplementation on LDL-
cholesterol levels remains inconsistent. Indeed high, often supraphysiological, doses (Illingworth et 
al., 1984) have been reported to significantly lower LDL-cholesterol while low to moderate doses 
paradoxically often induce an increase in LDL-cholesterol levels (Radack et al., 1990; Suzukawa et 
al., 1995). Negligible variation in absolute HDL-cholesterol levels, in combination with a moderately 
reduced total cholesterol: HDL cholesterol ratio (insignificant), suggested minimal impact of EPA 
supplementation on the plasma HDL fraction in this model. In contradiction, EPA supplementation 
significantly enhanced plasma triglyceride levels. This finding is in stark contrast to an abundance of 
previous studies describing the hypotriglyceridemic actions of ω-3 PUFAs, which have been largely 
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attributed to decreased hepatic assembly and secretion of triglyceride rich VLDL particles secondary 
to decreased triglyceride synthesis. However, given that EPA supplementation had no impact on 
hepatic triglyceride synthesis, the observed increase is yet more puzzling. It is possible that this 
finding is strain specific, a notion supported by a dietary study in high fat fed ApoE
-/-
 mice which 
reported a significant elevation of plasma triglyceride levels following fish oil supplementation (Xu et 
al., 2007). Moreover, in light of the observation that fish oil supplementation significantly reduced 
hepatocyte LDL receptor mRNA and protein expression (Lindsey et al., 1992), fish oil 
supplementation of ApoE
-/-
 mice may serve to augment impaired chylomicron and IDL clearance 
through a lack of functional apoE combined with reduced LDL-receptor availability.  
5.4.2.2 Fenofibrate supplementation and lipid metabolism in the ApoE-/- mouse 
Fenofibrate supplementation significantly lowered total hepatic lipids compared to high fat fed mice, 
although hepatic triglyceride levels were significantly elevated compared to wild-type and high fat fed 
ApoE
-/-
 mice.  This latter observation is a curious finding considering the established capacity of 
fibrates to lower serum triglycerides, a process that has been linked to increased hepatic uptake and β-
oxidation of free fatty acids (Schoonjans et al., 1995; Martin et al., 1997) resulting in reduced 
bioavailability of fatty acids for hepatic triglyceride synthesis. However, a similar effect has been 
observed in chow fed Wistar rats where hepatic triglyceride levels were significantly augmented by 
fenofibrate (0.5%) supplementation (Waterman and Zammit, 2002). One explanation for this could be 
a consequence of PPAR-α mediated overexpression of adipose differentiation-related protein 
(ADRP), a perilipin surface protein expressed on lipid droplets (Listenberger et al., 2007). In support 
of this, in the present study, hepatic ADRP protein expression was found to be significantly elevated 
in the fenofibrate supplemented group (but not EPA), implying this was an effect specific to 
fenofibrate and not due to non-specific effects of lipid lowering. While PPAR-α stimulation has 
previously been shown to modulate hepatic ADRP mRNA and protein expression in humans (Liu et 
al., 2003; Schadinger et al., 2005; Inoue et al., 2005) and C57BL/6J mice (Edvardsson et al., 2005), 
the current findings are the first to suggest that the same effect may occur in the ApoE
-/-
 mouse and 
warrants further investigation.  
Fenofibrate supplementation had negligible effects on hepatic fatty acid composition, a finding that is 
in disagreement with a study conducted in chow fed C57BL/6J mice where 0.2% fenofibrate 
supplementation significantly enhanced hepatic MUFA composition (Oosterveer et al., 2009). One 
possible explanation for this discrepancy is that the capacity of fenofibrate to elevate hepatic MUFAs 
may have been shrouded by the parallel actions of the high fat diet alone, or that the dose used in the 
158 
 
present study may have been too low to achieve such an effect, but this clearly warrants further 
investigation before any firm conclusion can be reached.  
In terms of plasma profiles, fenofibrate supplementation significantly attenuated diet induced 
hypercholesterolemia in the present model. Total cholesterol and LDL-cholesterol were significantly 
reduced compared to the high fat fed group – an effect consistent with previous studies (Caslake et 
al., 1993 Guerin et al., 2003). Such actions are thought to be mediated, at least in part, through PPAR-
α mediated stimulation of lipoprotein lipase activity and repression of hepatic ApoC-III expression, 
which together, enhance VLDL (and ultimately LDL) hydrolysis (Staels et al., 1995; Schoonjans et 
al., 1996). Therefore the present findings are most likely the result of transcriptional modulation of 
VLDL metabolism. Interestingly, fenofibrate supplementation mediated a modest, although not 
significant, reduction in plasma triglyceride levels compared to wild-type and high fat fed ApoE
-/-
 
mice. In light of the observation that fenofibrate supplementation significantly elevated hepatic 
triglyceride levels, sequestration of triglycerides from VLDL assembly through their cytosolic storage 
could in effect reduce hepatic VLDL secretion, representing a possible mechanism for the 
hypolipidemic action of fenofibrate in this model.   
5.4.3 The impact of an atherogenic diet on cardiac and vascular remodelling 
As described in Chapter 1 (Section 1.1.3), cardiac fibrosis is due to the progressive accumulation of 
fibrous collagen in the heart and is associated with increased myocardial stiffness (Conrad et al., 
1995; Norton et al., 1997) and cardiac dysfunction (Kuwahara et al., 2002). Therefore, cardiac 
collagen content was measured in the present study to ascertain whether high fat feeding induced 
cardiac fibrosis. Although hypercholesterolemia was recently demonstrated to induce collagen 
deposition in the hearts of LDLr
-/-
 mice (Kang et al., 2009), few studies have examined the 
association between high fat feeding and cardiac remodelling in the ApoE
-/-
 model. In the present 
study, maintenance of ApoE
-/-
 mice on a high fat/high cholesterol diet had no impact on cardiac 
collagen deposition compared to chow fed wild-type mice. This finding is in disagreement with a very 
recent study conducted in ApoE
-/-
 mice fed a Western style diet (21% fat, 0.15% cholesterol) which 
reported an age-dependent increase in heart/body weight ratio and left ventricular (LV) collagen 
volume fraction after 32 weeks feeding and a significant increase in LV wall thickness after 40 weeks 
feeding, when compared to baseline measurements at 24 weeks (Qin et al. 2010). Thus since the 
present study was terminated at 24 weeks, it is likely that this was too early to detect the development 
of significant cardiac remodelling and the lack of effect of high fat feeding on heart/body weight 
ratios in the present study is supportive of this notion.  
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However, although total collagen levels were not affected by high fat feeding, the quantity of both 
mature (DPD, PYD, HHL) and immature (DHLNL, HLNL) collagen cross-links were significantly 
elevated in cardiac tissue compared to matched measurements in wild-type mice.  This is an 
interesting finding considering the mounting evidence that suggests myocardial stiffness arises from 
increased collagen cross-link formation and not absolute collagen levels per se (Norton et al., 1997; 
Woodiwiss et al., 2001). Indeed, the observed elevation in mature cross-links (DPD, PYD, HHL), 
together with the significant reduction in elastin cross-links, might imply increased ventricular 
stiffness and, in effect, reduced cardiac contractility. However, this notion is undermined by the 
observation that the atherogenic diet also elevated immature cross-link formation and resulted in a 
lower mature: immature cross-link ratio – findings which could imply impaired maturation of 
collagen and ultimately, greater ventricular compliance. The dichotomous effect of the atherogenic 
diet on cross-link maturation may be explained by abnormal structural rearrangements of cross-links. 
The process of cross-link maturation, detailed in Chapter 1 (Section 1.1.3.2), imparts tensile strength 
to collagen by forming covalent intermolecular bonds between protein sub-units. Immature cross-
links stabilise collagen microfibrils, quasi-hexagonal units containing five tropocollagen monomers 
(Orgel et al., 2001), by forming intermolecular bonds between the tropocollagen monomers of the 
microfibril structure (Kang, 1972; Nicholls and Bailey, 1980; see Figure 5.30A). Individual 
microfibrils are then further stabilised by mature cross-links, which constitute intermolecular bonds 
between microfibril units (Figure 5.30B) that together comprise the mature collagen fibril (Light and 
Bailey, 1985). Conversion of the difunctional, immature cross-links to trifunctional, mature cross-
links normally allows the formation of a complete inter-microfibrillar network of cross-links (Fig 
5.29B). In the present study, it is postulated that, perhaps because of structural changes within the 
tissue, formation of mature cross-links occurs within, as opposed to between, individual microfibrils, 
thus providing an explanation as to the anomaly in cross-link measurements (Figure 5.30C). 
While it is clear that cross-link formation, but not total collagen, is altered by an atherogenic diet in 
the ApoE
-/-
 model, the present study was not designed to assess the implication of these changes in 
terms of cardiac function. However, other studies from this laboratory have shown that 24 weeks of 
high fat feeding in ApoE
-/-
 mice results in changes in various load-dependent measures of cardiac 
function including a significant reduction in end diastolic volume (EDV) combined with a significant 
elevation of end diastolic pressure (EDP), implying increased ventricular stiffness (Walsh and 
Wainwright, unpublished). Furthermore, an increase in the slope (leftward shift) of the end diastolic 
pressure volume relationship (EDPVR) indicates reduced LV compliance, possibly as a consequence 
of adverse ventricular remodelling. These findings are not in isolation, as similar alterations to cardiac 
function have been measured in high fat fed, ageing C57BL/6J mice; effects which were also  
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Figure 5.30 Schematic representation of cardiac collagen cross-link formation Diagram details 
structural placement of A) immature cross-links within individual microfibrils; B) mature cross-links 
between microfibrils; C) Postulated re-arrangement of intra-fibrillar cross-links in ApoE
-/-
 model of 
hyperlipidaemia. 
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accompanied by an increase in collagen cross-linking (Zibadi et al., 2009). Moreover, the proposed 
link between cardiac fibrosis and altered cardiac function has also been described previously in pig 
and human models (Martos et al., 2007; Zhu et al., 2007). Together this data suggests that in the 
ApoE
-/-
 model, hyperlipidaemia induced alterations to the underlying structure and quality of cardiac 
collagen may alter normal cardiac function. From the present study, there is a clear requirement for 
full characterisation of the functional implication of abnormal cross-linking.  
Considering the mounting evidence of a direct association between hyperlipidaemia and plaque 
instability, it was considered likely that high fat feeding would lower total aortic collagen levels. 
Indeed, it has been confirmed in both murine and rabbit models, that hyperlipidaemia reduces the 
collagen content of plaques and likewise its reversal results in increased collagen content of plaques 
(Aikawa et al., 1998; Rekhter et al., 2000; Feig et al., 2011) since lipid lowering has been observed to 
reduce lesional macrophage numbers and thus the activation and secretion of collagen degrading 
MMP’s (Aikawa et al., 1998). In terms of cross-link formation, a recent study demonstrated that 
cross-link maturation was reduced in advanced plaques from human carotid arteries (Hector et al., 
2010), a finding which would imply reduced tensile strength and an increased likelihood of rupture in 
these plaques. In contrast, Rekhter et al. (2000) reported no change in cross-link levels (albeit 
measured as the ratio of hydroxyproline/pyridinoline) between cholesterol fed and chow fed rabbits, 
despite a time-dependent reduction in the total collagen content of aortic plaques from cholesterol fed 
animals. However, due to a technical error, no aortic collagen data was collected from the wild-type 
group which presents a major limitation of the present study. The nature of this limitation prevented 
comparison of the high fat diet and its effects on baseline vascular collagen levels.  
5.4.3.1 EPA supplementation and cardiac and vascular remodelling 
EPA supplementation had no impact on either cardiac collagen or cross-link levels in the present 
study – a finding which is not entirely unexpected given that the atherogenic diet alone had no impact 
on total cardiac collagen. This data implies no effect of EPA supplementation on remodelling in the 
ApoE
-/-
 heart, an effect which may be species specific given the recent report that fish oil 
supplementation (5% EPA + DHA) significantly attenuated LV collagen deposition induced by corn 
oil feeding in ageing C57BL/6 mice (Halade et al., 2011). However, while the murine model could 
account for the inconsistency between the studies, the substantially higher dose of ω-3 PUFAs and 
different method of collagen quantification used in the Halade study cannot be overlooked. 
Furthermore, in studies of pressure-overload induced cardiac dysfunction, fish oil supplementation 
has been shown to attenuate cardiac fibrosis and improve contractile function in both rat and mouse 
162 
 
models (Duda et al., 2009; Chen et al., 2011).  Both of these studies support the theory that the lack of 
impact of EPA on cardiac collagen in the present study could be specific to the ApoE
-/-
 model. 
In terms of vascular remodelling, EPA supplementation had a negligible effect on total collagen and 
cross-link levels in the aorta compared to high fat fed mice. This finding is somewhat surprising in 
view of the propounded plaque stabilising properties of fish oil which have been attributed to 
modulation of macrophage numbers and activity, attenuation of MMP expression, and reduced 
adhesion molecule expression (Thies et al., 2003; Matsumoto et al., 2008). In support of this, 
Matsumoto et al. (2008) reported increased collagen content of aortic root plaques in high fat fed 
ApoE
-/- 
mice supplemented with 5% EPA respective to high fat fed controls. However, in that study 
collagen levels were assessed qualitatively, using Sirius red polarisation microscopy of stained aortic 
sections, whereas the present study employed a more robust, quantitative measurement of total 
collagen; hence contrast in methodological approaches may explain the equivocal results. The high 
dose of EPA used in the Matsumoto study also suggests a greater dose than that used in the present 
study may be required to elicit alterations to aortic plaque morphology. However, it is the 
brachiocephalic artery, and not the aorta, that represents the major location of plaque rupture 
predilection in the ApoE
-/-
 mouse (Johnson and Jackson, 2001). Therefore it is possible that any 
effects of EPA on hyperlipidaemia induced vascular remodelling would be more likely to be detected 
in these vessels, although considering the small size of this vessel, biochemical quantification of 
collagen and associated cross-links was not possible.  
5.4.3.2 Fenofibrate supplementation and cardiac and vascular remodelling 
Parallel to the findings with EPA, fenofibrate supplementation had no impact on the total collagen 
and cross-link content of either cardiac or aortic tissue in the present study, which together implies a 
lack of effect of fenofibrate on cardiac and vascular remodelling in the ApoE
-/-
 model. Reports of the 
effect of fenofibrate on cardiac function are sparse and, of the studies which have examined these 
variables, the results are equivocal. In keeping with the present findings, fenofibrate supplementation 
(160mg/d) failed to improve LV diastolic dysfunction in type 2 diabetes patients (Chew et al., 2008). 
In contrast, fenofibrate supplementation (80mg/kg/day) significantly attenuated myocardial fibrosis 
and endothelial dysfunction in hypertensive rats; an effect that was attributed, in part, to modulation 
of the NF-кB pathway (Ogata et al., 2004). Interestingly, fenofibrate supplementation was observed 
to significantly exacerbate LV fibrosis in pressure overloaded PPAR-α deficient rats (Duhaney et al., 
2007). From these studies, it is apparent that the pleitropic actions of fenofibrate in the heart are 
further complicated by differences in technical approach and drug doses employed in these studies.  
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In relation to vascular remodelling, Corti and colleagues (2007) reported a significant increase in the 
collagen content of aortic plaque sections in ageing New Zealand white rabbits maintained on a high 
cholesterol diet supplemented with fenofibrate, an effect that was not observed in the present study. 
The considerably different study designs, together with species variation, may explain this 
inconsistency between the Corti study and findings from the present study. Indeed, as mentioned 
above, if it had been possible to measure collagen and cross-links in the plaque rupture-prone 
brachiocephalic artery, some effect may have been observed. 
5.4.4 The impact of an atherogenic diet on tissue endocannabinoid levels 
Given that the major endocannabinoids, AEA and 2-AG, are synthesised from AA and that tissue 
fatty acid content is influenced by diet, the impact of the atherogenic diet on tissue endocannabinoid 
levels was assessed. Interestingly, maintenance of ApoE
-/-
 mice on the atherogenic diet significantly 
elevated endocannabinoid levels in the brain, heart and thoracic aorta compared to chow fed wild type 
mice. These findings correlate with previous studies, which have highlighted an association between 
high fat/high cholesterol feeding and modulation of endocannabinoid levels in peripheral tissues, the 
majority of which report elevated endocannabinoids in heart, thoracic aorta, kidney, skeletal muscle 
and brown adipose tissue and reduced endocannabinoid levels in thyroid and subcutaneous white 
adipose tissue (Matias et al., 2008; Starowicz et al., 2008; Montecucco et al., 2009; Bartelt et al., 
2011). However, to our knowledge, this is the first study to demonstrate a rise in brain 
endocannabinoid levels (both AEA and 2-AG) in response to a high fat diet. 
In terms of brain endocannabinoid levels, the diet induced elevation of both 2-AG and AEA observed 
in the present study was supported, in part, by the findings of a dietary study in rats where 
maintenance on a high fat diet enriched with oleic acid increased the levels of 2-AG, but not AEA in 
the brain (Artmann et al., 2008). In the latter study however, the dietary intervention period was 
substantially shorter than that of the present study (1 week), which may offer a possible explanation 
for the lack of impact of the diet on AEA levels. Conversely, ketogenic and/or food restriction diets 
have been reported to lower brain endocannabinoids (Hanus et al., 2003; Hansen et al., 2009). 
Together these findings present further confirmation of the modulation of central endocannabinoid 
levels by diet. The functional implications of elevated brain endocannabinoids, although not 
examined in the present study, would most likely reflect the action of endocannabinoids on food 
intake, appetite regulation and mood. The observation that CB1 receptors are expressed in regions of 
the brain that control food intake (hypothalamus, nucleus accumbens shell and vagus nerve), 
combined with reports that hypothalamic endocannabinoid levels (both AEA and 2-AG) are increased  
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during fasting suggests a regulatory role of endocannabinoids  in food intake (Kirkham et al., 2002; 
Robbe et al., 2002; Burdyga et al., 2004). Indeed, the observation that injection of a CB1 receptor 
agonist (anandamide) directly into the hypothalamus induced hyperphagia in satiated rats, while a 
CB1 receptor antagonist (rimonabant) reduced appetite, combined with the observation that systemic 
administration of rimonabant reduced food intake in fasted rats, support this notion (Jamshidi and 
Taylor, 2001; Gomez et al., 2002). Excessive brain endocannabinoid production, as observed in 
response to hyperlipidaemia in the present study, could generate dysregulation of food intake and 
energy expenditure by over stimulation of the CB1 receptor and its associated pathways. In terms of 
mood responses, altered endocannabinoid signalling has been reported in schizophrenia, anxiety and 
depression (Guiffrida et al., 2004; Gobbi et al., 2005), conditions which could thus be affected by 
overproduction of endocannabinoids in the brain. 
In the present study, the observed elevation of AEA in the heart following high fat/high cholesterol 
feeding is in agreement with the findings of a previous dietary study in C57BL/6J mice (Matias et al., 
2008). The endocannabinoid system is known to be activated in the heart under pathological 
conditions, including experimental models of endotoxic, hemorrhagic and septic shock and heart 
failure, where the activity of endocannabinoids (whether beneficial or detrimental) remains a point of 
contention. Several studies have implicated CB1 receptor activation in the exacerbation of certain 
cardiac pathologies. In a murine model of doxorubicin (DOX) induced ventricular dysfunction, CB1 
receptor blockade with either rimonabant or AM251, alleviated cardiac dysfunction (Mukhopadhyay 
et al., 2007), while abolition of fatty acid amide hydrolase, the enzyme responsible for AEA 
metabolism, potentiated myocardial injury in DOX treated mice (Mukhopadhyay et al., 2011). 
Furthermore, chronic treatment with rimonabant (CB1 selective antagonist) reduced infarct size in a 
murine model of myocardial infarction (Lim et al., 2009). In contrast, the presence and activation of 
CB2 receptors is generally thought to be cardioprotective. Indeed in the setting of experimental 
myocardial ischaemia, CB2 receptors have been implicated in the preconditioning response where 
CB2 receptor agonism has been observed to reduce infarct size, oxidative stress and neutrophil 
infiltration in the infarcted myocardium, effects which were abolished by CB2, but not CB1, receptor 
blockade (Montecucco et al., 2009). In relation to studies in heart failure, genetic abolition of the CB2 
receptor has been demonstrated to induce significant cardiac remodelling in mice (Defer et al., 2009). 
Elevated endocannabinoids and upregulated CB2 receptor expression have also been measured in 
patients with chronic heart failure, an effect which was proposed as detrimental in this model whereby 
receptor activation, through inhibitory G protein signalling and reduced cAMP levels, could 
propagate negative inotropic conditions that would further weaken the failing ventricles (Weis et al., 
2010). Overproduction of endocannabinoids in response to an atherogenic diet, as observed in the 
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present study, implies increased activation of the endocannabinoid system. While activation of CB2 
receptors may confer protection in some cardiac pathologies, the deleterious effects of CB1 receptor 
activation cannot be ignored and, as AEA has a greater affinity for CB1 receptors, it is not 
unreasonable to suggest that the observed elevation of cardiac AEA seen in response to a high 
fat/high cholesterol diet in the present study may suggest high fat intake predisposes the heart to 
additional pathological stress beyond the development of atheroma. 
The significant elevation in aortic content of AEA and 2-AG measured in response to the atherogenic 
diet supports the findings of a similar study conducted in ApoE
-/-
 mice, where maintenance on a high 
cholesterol diet elevated the aortic content of 2-AG, although AEA levels were out-with detection 
limits (Montecucco et al., 2009). In the latter study, a lack of impact of the cholesterol enriched diet 
on endocannabinoid levels in wild-type mice led the authors to assume that the elevation in 
endocannabinoids was independent of the effects of the diet. However, since high fat feeding in wild 
type mice does not induce the same degree of hyperlipidaemia as that seen in the ApoE
-/-
 mouse, it is 
possible that a critical cholesterol/LDL level must be reached to activate increased endocannabinoid 
synthesis. Moreover, as the endocannabinoid system is known to be activated in pathological 
conditions, the lack of atherosclerosis pathology in the wild-type strain could also account for the 
negligible increase in endocannabinoids. The physiological impact of activation of the 
endocannabinoid system in the aorta has been linked to atherogenesis. In patients with coronary artery 
disease, CB1 receptor expression was significantly increased in coronary plaques, while circulating 
endocannabinoid levels were also significantly elevated, providing evidence of activation of the 
endocannabinoid system in atherosclerosis pathology (Sugamura et al., 2009). Subsequently, it has 
been demonstrated that CB1 receptor agonism most likely propagates atherogenesis since, in LDLr
-/-
 
mice fed a Western style diet, CB1 receptor blockade with rimonabant dose dependently reduced 
atherosclerotic lesion progression in the aorta and aortic sinus, an effect that  implicates CB1 receptor 
agonism in the progression of the condition (Dol-Gleizes et al., 2009). In line with this notion, in vitro 
studies revealed that blockade of the CB1 receptor inhibited PDGF-induced proliferation and 
migration of human coronary artery smooth muscle cells (Rajesh et al., 2008), key events in plaque 
progression and vessel restenosis. Furthermore AEA, at micromolar concentrations, has been 
observed to promote reactive oxygen species (ROS) generation and apoptotic cell death in human 
coronary artery endothelial cells; an effect which was significantly attenuated by CB1 receptor 
antagonism (Rajesh et al., 2010). While key observations in studies using synthetic cannabinoids have 
provided evidence of an anti-atherosclerotic and anti-inflammatory role of CB2 receptor activation 
where lesion development and pro-inflammatory cytokine activity is downregulated by receptor 
signalling (Steffens et al., 2005; Rajesh et al., 2007), other studies have demonstrated that 
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endogenous activation of these receptors can induce both pro- and anti-inflammatory actions 
depending on the concentration and biosynthetic origin of the endocannabinoid (Gallily et al., 2000; 
Gokoh et al., 2005). 
5.4.4.1 EPA supplementation and tissue endocannabinoid levels 
In the present study, supplementation of the atherogenic diet with EPA significantly attenuated the 
diet induced elevation of endocannabinoids in all tissues examined. Concomitant with its 
hypolipidaemic effects, EPA supplementation significantly lowered elevated AEA levels in the brain 
and heart, and lowered 2-AG levels in the vasculature. The ability of EPA to modulate tissue 
endocannabinoid levels is not unexpected given that incorporation of ω-3 PUFAs into membrane 
phospholipids alters the ω-3/ω-6 PUFA ratio and thus the availability of arachidonic acid for 
endocannabinoid biosynthesis (both AEA and 2-AG), an effect which has been previously reported in 
brain tissue of mice fed a DHA-enriched diet (Wood et al., 2010). In contrast, a dietary study in 
Sprague-Dawley rats observed no change in brain endocannabinoids in response to a fish oil enriched 
diet (Artmann et al., 2008). However as the intervention period lasted only 7 days, these findings 
would suggest a substantially longer time period is required for the alteration of tissue phospholipid 
content and ultimately, endocannabinoid content. Moreover, these studies were undertaken in 
normocholesterolaemic animals. 
Normalisation of the hyperlipidaemia-activated endocannabinoid system in the heart may represent 
one of the underlying mechanisms in which the propounded cardioprotective effects of EPA 
supplementation are conferred. Indeed, several studies have reported a beneficial effect of ω-3 PUFAs 
in experimental myocardial infarction, where ω-3 PUFA supplementation or an increase in the ω-3/ω-
6 PUFA ratio has been shown to reduce infarct size and systemic inflammatory marker circulation, an 
effect which was linked to activation of the reperfusion injury salvage kinase (RISK) pathway 
(Abdukeyum, Owen and McLennan, 2008; Rondeau et al., 2011). Furthermore, studies have reported 
beneficial effects of EPA supplementation on both atrial and ventricular arrhythmias in several animal 
models (Yang et al., 1993; Tsuburaya et al., 2011). As previously discussed, CB1 receptor activation 
has been linked to exacerbation of myocardial injury and heart failure. In light of the observation that 
EPA supplementation significantly attenuated the hyperlipidaemia induced elevation of cardiac AEA 
levels in the present study, this finding suggests that a potential cardioprotective mechanism of EPA 
could be to reduce endocannabinoid mediated CB1 receptor activation.  
The anti-atherosclerotic effects of ω-3 PUFAs at the level of the blood vessel have been attributed to 
plaque stabilisation and modulation of the atherosclerotic inflammatory response, including decreased 
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pro-inflammatory cytokine production (TNF-α, IL-8), decreased monocyte infiltration (reduced MCP-
1, VCAM-1, ICAM-1 expression) and decreased platelet activation (Yaqoob and Calder, 1995; Zhao 
et al., 2004; Yamada et al., 2008). Indeed a correlation between low serum ω3/ω6 PUFA ratios and 
vulnerable plaques has been identified in patients exhibiting CAD (Kashiyama et al., 2011). Although 
CB2 receptor activation has been shown to mediate anti-atherosclerotic actions in some studies, the 
observation from the present studies (Chapter 4) that activation of CB2 receptors with JWH133 causes 
an increased release of MCP-1 from activated macrophages, coupled with the observed reduction in 
vascular 2-AG and AEA levels by EPA in vivo, is suggestive of an interaction between EPA and the 
endocannabinoids playing a part in the anti-atherosclerotic effects of ω-3 PUFAs. This notion is 
further supported by the observation from the present studies that DHA directly inhibited 
endocannabinoid production by activated macrophages in vitro (Chapter 4). It is possible therefore 
that the macrophage is one of the sources of the vascular endocannabinoids. 
5.4.4.2 Fenofibrate supplementation and tissue endocannabinoid levels 
The present study provided the novel finding that fenofibrate supplementation significantly alters the 
concentrations of endocannabinoids in tissues from hyperlipidaemic ApoE
-/-
 mice. While several 
endogenous and synthetic endocannabinoid ligands have been demonstrated to activate PPARs (Sun 
et al., 2007), the current findings represent the first in vivo evidence of PPAR associated modulation 
of tissue endocannabinoids. Compared to ApoE
-/-
 mice fed the atherogenic diet alone, fenofibrate 
supplementation significantly attenuated elevated AEA concentrations in brain and aortic tissue and 
substantially, albeit not significantly, in cardiac tissue. The effect of fenofibrate on 2-AG tissue 
concentrations however, was minimal. From the present study, it is not clear whether fenofibrate is 
influencing endocannabinoid synthesis directly, through PPARα agonism, or indirectly via non-
specific lipid lowering. It was previously reported that both fenofibrate and EPA treatment attenuated 
hyperlipidaemia to a similar degree. While both fenofibrate and EPA lowered tissue endocannabinoid 
concentrations, they exerted different effects in terms of the endocannabinoid being reduced (either 
AEA or 2-AG, or both) which was dependent upon the tissue type being examined. If the effects of 
fenofibrate were due solely to non-specific lipid lowering, it could be assumed that both fenofibrate 
and EPA would exert similar effects on tissue endocannabinoids; therefore it is possible that 
fenofibrate may be mediating its effects, at least in part, via PPARα agonism. Indeed, evidence that 
PPARs are expressed in the heart (Braissant et al., 1996) and in blood vessels (coronary artery and 
aortic endothelial cells and vascular smooth muscle cells) supports this notion (Inoue et al., 1998; 
Marx et al., 1998). 
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Tabernero et al. (2002) observed reduced myocardial infarct size and improved contractile function 
following ischemia/reperfusion induced injury in fenofibrate supplemented C57BL/6J mice, 
compared to sham controls. Moreover, upregulation of PPARα mRNA and protein expression was 
linked to a reduced occurrence of severe ventricular arrhythmias following ischemia/reperfusion 
induced injury in normocholesterolaemic rats (Ravingerová et al., 2009); a finding which would 
suggest agonism of this receptor could have a similar effect. Fenofibrate was also demonstrated to 
attenuate the development of heart failure in Dahl salt sensitive rats fed a high salt diet (Ichihara et 
al., 2006). In the setting of atherosclerosis, fenofibrate treatment has been demonstrated to enhance 
plaque stability. In a rabbit model of experimental atherosclerosis, fenofibrate supplementation 
induced significant regression of established plaques; an effect associated with reduced macrophage 
infiltration and increased smooth muscle cell and collagen content of plaques (Corti et al., 2007). 
Furthermore it was demonstrated in a rabbit model of plaque rupture, that fenofibrate supplementation 
improved re-endothelialisation and attenuated arterial tissue factor expression, findings which 
together suggest increased plaque stability and reduced thrombogenicity (Jeanpierre et al., 2009).  
The mechanism(s) underlying the described cardioprotective and anti-atherosclerotic actions of 
fenofibrate remain under scrutiny. In the present study, hyperlipidaemia was demonstrated to induce 
overactivation of the endocannabinoid system which, as described previously, may be conducive to 
cardiac and vasculature disease pathology. It is possible that fenofibrate mediated normalisation of 
elevated tissue endocannabinoid concentrations, either through the non-specific effects of lipid 
lowering or through direct PPARα agonism, could represent a possible mechanism in which 
fenofibrate mediates its beneficial effects. 
5.4.5 The impact of an atherogenic diet on endothelial function 
Endothelial dysfunction, characterised by abnormal vascular vasoreactivity, has been reported in the 
coronary and peripheral circulation of patients with established coronary artery disease. Moreover, 
vasodilatory dysfunction has been deemed a predictor of increased cardiovascular risk (Suwaidi et al., 
2000; Heitzer et al., 2001). Compared to baseline measurements obtained in chow fed wild-type mice, 
high fat feeding of ApoE
-/-
 mice significantly blunted depressor responses to the endothelium 
dependent vasodilator bradykinin – an indication of impaired vasorelaxation and endothelial 
dysfunction in these animals. This finding represents the first in vivo demonstration of an association 
between hypercholesterolemia and endothelial dysfunction in the ApoE
-/-
 model; an association which 
has previously only been described in ApoE
-/-
 mice ex vivo using aortic ring preparations. However, 
this finding is in complement to a wealth of in vivo studies using both human and animal (porcine, 
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non-human primate, rabbit and murine) models (Cohen et al., 1988; Creager et al., 1990; Sellke et al., 
1990; Laight et al., 1996; D’Uscio, Smith and Katusic, 2001).  
Administration of the NO-donor, sodium nitroprusside, induced a vasodepressor response in both 
control and hypercholesterolaemic mice, an effect which has been previously reported in ex vivo 
studies using  vessels from high fat fed ApoE
-/-
 mice (Deckert et al., 1999; Kaul et al., 2004). This 
finding suggests that, in the ApoE
-/-
 group, the underlying vascular smooth muscle cells remained 
responsive to NO, and that the impaired vasodilatation observed in response to bradykinin 
administration was specific to endothelial activity. Heart rate was not found to vary significantly 
between experimental groups during endothelial function studies, which would suggest that the 
depressor responses induced by both bradykinin and sodium nitroprusside were likely mediated via an 
effect on the vasculature and not in response to a fall in heart rate. Furthermore, there was no 
significant compensatory increase in heart rate associated with the depressor responses.  
Although it was not explored in the present study, the mechanism(s) underlying the impaired 
endothelium dependent vasodilation associated with hyperlipidaemia could be attributed to the 
modulation of several pathways, including (a) a change in bradykinin receptor (BR) expression; (b) 
nitric oxide production (endothelial nitric oxide synthase (eNOS) activity); (c) ROS generation; (d) 
anti-oxidant enzymatic activity and (e) oxidation of plasma lipoproteins. Reduced NO production, due 
to reduced eNOS activity and/or increased sequestration of NO by ROS may lead to reduced NO 
availability and hence reduced NO mediated vasodilation. Indeed in the ApoE
-/-
 model, studies have 
suggested a decreased availability of NO as a key mechanism underlying hypercholesterolemia 
mediated endothelial dysfunction. Maintenance of ApoE
-/-
 mice on a Western style diet was observed 
to upregulate the expression of NADPH oxidase 2 (Nox2), a ROS generating membrane bound 
enzyme expressed on endothelial cells, and concomitantly, to decrease NO bioavailability (Judkins et 
al., 2010). Furthermore, the progression of atherosclerosis was impaired in high fat fed ApoE
-/-
 mice 
deficient in NADPH oxidase (Barry-Lane et al., 2001). Thus it is likely that upregulated ROS 
production plays a role in endothelial dysfunction in the ApoE
-/-
 mouse. 
5.4.5.1 EPA/ fenofibrate supplementation and endothelial function 
As previously discussed, both EPA and fenofibrate supplementation of high fat fed ApoE
-/-
 mice 
induced significant lipid-lowering effects leading to a marked improvement of the hyperlipidaemia 
induced by the atherogenic diet. In particular, EPA and fenofibrate were observed to lower plasma 
total cholesterol and LDL-cholesterol levels to a similar degree. Given the reported inverse 
association between plasma cholesterol levels and endothelial dependent vasodilation (Steinberg et 
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al., 1997), and the observation that hyperlipidaemia in the present study was associated with 
endothelial dysfunction, it may seem likely that both agents would improve endothelial vasoreactivity 
as a consequence of their effects on lipid profiles.  
However, EPA supplementation had no significant effect on hypercholesterolaemia induced 
endothelial dysfunction. This finding is in agreement with evidence from human studies that indicate 
negligible benefit of ω-3 PUFA supplementation (doses ranging from 0.45g/d – 3.4g/d EPA + DHA) 
on endothelial function (Anderson et al., 2010; Sanders et al., 2011; Skulas-ray et al., 2011). In 
contrast, fenofibrate supplementation significantly attenuated the diet induced endothelial dysfunction 
observed in control ApoE
-/-
 mice. This finding complements a study conducted by Olukman et al. 
(2010) who reported that fenofibrate supplementation improved endothelial function in diabetic rats; 
an effect associated with increased aortic NO production and gene expression of anti-oxidant enzymes 
(superoxide dismutase and catalase). Given that both EPA and fenofibrate improved 
hypercholesterolaemia, but only fenofibrate improved endothelial function, this may suggest that the 
vasculoprotective effects of the latter are independent of its effects on lipid-lowering.  
The clear disparity between the ability of EPA and fenofibrate to preserve endothelial function may 
be linked to their opposing effects on vascular endocannabinoid concentrations: EPA supplementation 
significantly attenuated 2-AG levels whereas fenofibrate supplementation significantly attenuated 
AEA levels. Together these findings suggest that, in the present study, the reduction of vascular AEA 
levels may explain the improved endothelial function associated with fenofibrate supplementation. 
Activation of CB1 receptors is known to promote oxidative stress and apoptosis in cells of the vascular 
wall. Studies have demonstrated an increase in inflammatory marker production (TNF-α, MCP-1, IL-
1β, IL-6 and IL-8), ROS generation and the activation of p38/Jun N-terminal kinase (JNK) mitogen-
activated protein kinases (MAPKs), kinases involved in cell death pathways, in response to CB1 
receptor activation in macrophages and endothelial cells (Han et al., 2009; Sagamura et al., 2009; 
Rajesh et al., 2010). Given that AEA preferentially binds CB1 receptors, and increases ROS 
generation dose dependently (Rajesh et al., 2010), it is possible that excessive production of AEA in 
the vasculature in response to hypercholesterolaemia may contribute to endothelial dysfunction 
through the promotion of oxidative stress and inflammation. However, as the differential effects of 
EPA and fenofibrate supplementation on vascular AEA concentrations are very subtle (EPA also 
reduces the concentration of vascular AEA, although not significantly), the discrepancy between their 
effects on endothelial function are unlikely to be explained solely by modulation of vascular AEA 
concentrations. Further investigation is therefore essential to determine the mechanism underlying the 
differential effects of EPA and fibrate on endothelial function.  
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5.4.6 Conclusion 
In summary, maintenance of ApoE
-/-
 mice on an atherogenic diet induced marked hyperlipidaemia, 
altered cardiac collagen cross-linking, induced significant endothelial dysfunction and elevated tissue 
reservoirs of endocannabinoids. Intriguingly, endothelial dysfunction was associated with 
significantly elevated AEA and 2-AG levels in the vasculature, which could be interpreted as 
suggestive of a detrimental role of these mediators on endothelial function. Moreover, while 
supplementation of the atherogenic diet with EPA had a moderate lowering effect on hyperlipidaemia, 
it had no effect on endothelial dysfunction or on 2-AG or AEA levels in the vasculature. In contrast, 
fenofibrate supplementation significantly improved the hyperlipidaemic profile and endothelial 
dysfunction, an effect which was in association with significantly attenuated AEA levels in the 
vasculature. Therefore it is postulated that ligands of the endocannabinoid system may play a role in 
hyperlipidaemia induced endothelial dysfunction. Furthermore, the hyperlipidaemia induced elevation 
of cardiac endocannabinoid concentrations was normalised through dietary intervention with both 
EPA and fibrate. As these agents have been reported as beneficial in the setting of myocardial 
ischaemia and the associated adverse electrophysiological events (i.e. ventricular arrhythmias), it is 
possible that such cardioprotective effects are related to attenuation of the overactive 
endocannabinoid system. 
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Chapter 6: General Discussion 
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6.1 Key Findings 
The benefits of PUFA consumption were first highlighted by Dyerberg and colleagues, who 
demonstrated that Greenland Inuit populations exhibit low mortality rates from coronary heart disease 
despite consuming a diet rich in fat; a finding which was attributed to the predominance of PUFAs as 
opposed to SFAs in the diet (Dyerberg, Bang and Hjorne, 1975). Anti-atherosclerotic actions of ω-3 
PUFAs have subsequently been demonstrated (Thies et al., 2003; Matsumoto et al., 2008), although 
the mechanisms are not yet fully understood. In light of reports that increased dietary intake of ω-3 
PUFAs influences endocannabinoid levels (Wood et al., 2010), and that synthetic cannabinoids exert 
anti-atherosclerotic actions (Steffens et al., 2005), the present study was designed to examine the anti-
atherosclerotic effects of ω-3 PUFAs in 1) an in vitro model of macrophage activity and 2) a murine 
model of atherosclerosis and to determine whether or not these effects involve a functional role of the 
endocannabinoid system. The present study has demonstrated, at the cellular level, that activation of 
the endocannabinoid system altered intracellular uptake of the ω-3 PUFA, DHA, in activated 
macrophages, signifying a functional role of the endocannabinoid system in the activity of these cells. 
Moreover, DHA was found to inhibit macrophage synthesis of 2-AG, evidence of a direct association 
between the endocannabinoid system and the ω-3 PUFAs, an effect which was mimicked by the 
PPARα agonist, fenofibrate. In an in vivo model of atherosclerosis, maintenance on an atherogenic 
diet induced significant hyperlipidaemia, an effect which was associated with endothelial dysfunction, 
cardiac remodelling, and elevated tissue endocannabinoid levels. Supplementation of the atherogenic 
diet with the ω-3 PUFA, EPA, while having minimal impact on endothelial dysfunction or cardiac 
remodelling, moderately improved the hyperlipidaemic profile and significantly attenuated elevated 
tissue endocannabinoid levels. Finally, supplementation of the atherogenic diet with fenofibrate 
significantly attenuated hyperlipidaemia, endothelial dysfunction and elevated endocannabinoids 
although no effect on cardiac remodelling was observed. 
6.1.1 Activated endocannabinoid system in stimulated THP-1 macrophages 
Functional activity of the endocannabinoid system was detected in activated THP-1 macrophages. 
The concentration of the endocannabinoid 2-AG was significantly elevated in PMA stimulated cells, 
compared to unstimulated cells. This finding is in agreement with a number of studies that have 
reported basal 2-AG production in both macrophages (RAW264.7, J774, microglial and rat 
peritoneal) and endothelial cells which is upregulated in response to a number of stimulants including 
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ionomycin, lipopolysaccharide (LPS) and thrombin (Suguira et al., 1998; Di Marzo et al., 1999; 
Carrier et al., 2004; Jiang et al., 2009). Neither basal nor altered synthesis of AEA was detected in the 
present study. This finding is in disagreement with other studies that have demonstrated the 
production of AEA in macrophages stimulated with LPS or oxLDL (Liu et al., 2003; Carrier et al., 
2004; Jiang et al., 2009). However, the lack of inclusion of an inflammatory stimulus in the present 
study is a likely source of this discrepancy. 
6.1.2 Regulation of endocannabinoid synthesis 
Evidence of a direct regulation of endocannabinoid activation by ω-3 PUFAs was discovered. DHA 
was found to exert a significant inhibitory effect on 2-AG synthesis in stimulated macrophages which 
reduced production to basal levels measured in unstimulated cells. To our knowledge, this finding 
presents the first demonstration of such an effect in macrophages although DHA has been shown to 
reduce 2-AG synthesis in adipocytes (Matias et al., 2008). Of the other FAs examined in the present 
study, neither OA nor EPA had any significant impact on 2-AG synthesis, a finding which was also 
described in the Matias study. A possible mechanism through which DHA reduced 2-AG synthesis 
could be to alter the bioavailability of the phospholipid precursors essential for 2-AG production. 
Fenofibrate, at equimolar concentrations to DHA, significantly attenuated 2-AG synthesis in 
stimulated macrophages. This finding constitutes the first reported link of PPARα agonism and 
endocannabinoid synthesis in the macrophage. The present study did not investigate the mechanism 
underpinning this effect however it is possible that fenofibrate is influencing the enzymatic regulation 
of 2-AG synthesis and/or the pre-cursor pool. As ω-3 PUFAs are also known agonists of PPAR 
receptors (Xu et al., 1999), DHA and fenofibrate may be influencing endocannabinoid synthesis 
through the modulation of common cell signalling pathways. 
6.1.3 Activated endocannabinoid system and dysregulated FA uptake 
Activation of cannabinoid (CB) receptors using a range of endogenous and synthetic CB ligands was 
demonstrated to influence the process of FA uptake in activated THP-1 macrophages. Selective 
activation of the CB1 receptor had no impact on FA uptake, despite a previous report of increased 
cholesterol uptake in macrophages treated with the CB1 selective agonist WIN,212-2 (Jiang et al., 
2009). Selective activation of the CB2 receptor significantly attenuated FA uptake. The non-selective 
CB agonist AEA, which is reported to act at receptors independent of the CB family including 
TRPV1 and GPR55 (Smart et al., 2000; Ryberg et al., 2007), also induced a significant reduction in 
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FA uptake. Modulation of FA uptake in activated THP-1 macrophages was thus concluded to be 
mediated in part, through CB2 receptor signalling, although other target receptors may also play a role 
in this effect. 
In addition to these findings, it was also discovered that modulation of FA uptake was dependent 
upon the FA being internalised, as the aforementioned effects were only observed in macrophages 
exposed to DHA, and not OA or EPA. The mechanism conferring this effect was not investigated in 
the present study however speculation can be drawn from evidence provided in the literature. Direct 
activation of PPAR receptors by ω-3 PUFAs and CB ligands (both endogenous and synthetic) has 
previously been documented (Xu et al., 1999; Bouaboula et al., 2005; Sun et al., 2007). CB1 receptor 
activation increases CD36 scavenger receptor mRNA expression, one of the downstream targets of 
PPAR signalling, in macrophages and peripheral blood mononuclear cells (Malfitano et al., 2007; 
Jiang et al., 2009). DHA treatment of human colon cancer cells suppresses CD36 scavenger receptor 
mRNA expression (Madonna et al., 2011). Therefore an overlapping role in PPAR signalling and its 
regulation of intracellular cholesterol influx/efflux may underlie the present findings. 
6.1.4 Hypercholesterolaemia in a murine model of atherosclerosis 
The present study demonstrated that maintenance of ApoE
-/-
 mice on an atherogenic diet induced 
marked hyperlipidaemia. Plasma cholesterol and LDL-cholesterol was significantly elevated by the 
consumption of a high fat/high cholesterol diet. These findings are in agreement with several studies 
in ApoE
-/-
 mice fed a high fat diet (Moghadasian et al., 2001; Guo et al., 2005).  
The induction of hyperlipidaemia in ApoE
-/-
 mice was associated with a degree of cardiac 
remodelling. There was no evidence of collagen deposition in the ApoE
-/-
 heart compared to the chow 
fed wild-type controls, despite previous reports that hypercholesterolaemia induces cardiac fibrosis in 
LDLr
-/-
 mice and ageing ApoE
-/-
 mice (Kang et al., 2009; Qin et al. 2010). However, it was 
discovered that collagen cross-link levels were elevated and cross-link maturation reduced. While 
fibrosis has been linked to impaired cardiac function in humans and pigs (Martos et al., 2007; Zhu et 
al., 2007), the functional impact of remodelling in the ApoE
-/-
 model was not assessed. However 
evidence from other studies have provided a basis for speculation. In C57BL6 and ApoE
-/-
 mice, high 
fat feeding was associated with altered cardiac function indicative of increased ventricular stiffness 
and reduced compliance (Zibadi et al., 2009; Walsh and Wainwright, unpublished). 
Hyperlipidaemia in the ApoE
-/-
 mouse was associated with elevated endocannabinoid concentrations 
in both central (brain) and peripheral (heart and aorta) tissue compared to chow fed wild-type mice, a 
176 
 
finding which is in agreement with a large body of evidence that describes increased tissue 
endocannabinoid concentrations in pathological conditions (reviewed by Di Marzo, 2008).  
Endothelial function was found to be significantly impaired in hyperlipidaemic ApoE
-/-
 mice - the first 
in vivo evidence of a direct correlation between hyperlipidaemia and vasodilatory dysfunction in the 
ApoE
-/-
 model. These findings are however in complement to a wealth of in vitro and in vivo 
observations in both human and animal models (Cohen et al., 1988; Creager et al., 1990; Sellke et al., 
1990; Laight et al., 1996; Xu et al., 2007). Although not examined in the present study, evidence from 
the literature suggests endothelial dysfunction in the ApoE
-/-
 mouse is due to ROS production and 
reduced NO bioavailability. Enzymatic activity of NADPH oxidase was upregulated in ApoE
-/-
 mice 
fed a Western style diet, while plaque progression was retarded in ApoE
-/-
 mice genetically deficient 
of NADPH oxidase (Barry-Lane et al., 2001; Judkins et al., 2010). 
6.1.5 EPA supplementation in the hyperlipidaemic ApoE-/- mouse 
Supplementation of the atherogenic diet with EPA had a modest impact on ApoE
-/-
 mouse physiology. 
EPA supplementation moderately attenuated hyperlipidaemia in accordance with previous studies 
which have reported cholesterol lowering properties of ω-3 PUFAs (Illingworth et al., 1984; De Roos 
et al., 2005). Paradoxically, EPA supplementation induced a significant elevation of plasma 
triglycerides. Given the quantity of experimental and clinical evidence supporting a 
hypotriglyceridaemic action of the ω-3 PUFAs (as reviewed by Roth and Harris, 2010), this finding 
was unexpected. However, fish oil supplementation was previously demonstrated to elevate plasma 
triglycerides in high fat fed ApoE
-/-
 mice (Xu et al., 2007), and as fish oil was demonstrated to reduce 
LDL receptor activity (Lindsey et al., 1992), it is possible that ω-3 PUFAs augment impaired 
chylomicron clearance in the ApoE
-/-
 mouse - an anomaly of the model.  
EPA supplementation had no impact on hyperlipidaemia associated cardiac remodelling in the ApoE
-/-
 
mouse. There are no reports of the effects of ω-3 PUFA supplementation on cardiac remodelling in 
the ApoE
-/-
 model in which to compare this finding. However, EPA supplementation has been 
demonstrated to attenuate cardiac fibrosis in ageing, hyperlipidaemic C57BL/6J mice (Halade et al., 
2011) and in murine models of pressure overload induced cardiac dysfunction (Duda et al., 2009; 
Chen et al., 2011).  
EPA supplementation significantly attenuated elevated endocannabinoid concentrations in brain, 
cardiac and aortic tissue. While there are no reports of the effects of EPA on tissue endocannabinoid 
concentrations in the setting of experimental hyperlipidaemia, the cardioprotective and anti-
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atherosclerotic actions of ω-3 PUFAs are well documented. Evidence from animal models indicates 
that ω-3 PUFA supplementation reduces infarct size in experimental myocardial infarction, reduces 
systemic inflammatory marker circulation and is beneficial in arrhythmia prevention (Abdukeyum et 
al., 2008; Mayyas et al., 2011; Rondeau et al., 2011; Tsuburaya et al., 2011). In atherosclerosis 
pathology, a low serum ω-3/ω-6 PUFA ratio has been correlated with plaque instability in patients 
with advanced CAD while direct incorporation of EPA into plaques reduces macrophage infiltration 
and inflammatory marker production (Thies et al., 2003; Wang et al., 2009; Kashiyama et al., 2011). 
Lowering the excessive production of endogenous cannabinoids as observed in the hyperlipidaemic 
ApoE
-/-
 model, could represent one of the underlying mechanisms conferring the protective effects of 
EPA. 
Endothelial dysfunction in the hyperlipidaemic ApoE
-/-
 mouse was unaltered by supplementation with 
EPA. Despite the absence of information in the literature regarding the effect of EPA on endothelial 
function in the ApoE
-/-
 mouse, this finding contributes to a mounting body of evidence from human 
studies that indicate a negligible effect of ω-3 PUFA supplementation (0.45g/d – 3.4g/d EPA + DHA) 
on endothelial function (Anderson et al., 2010; Sander et al., 2011; Skulas-ray et al., 2011).  
6.1.6 Fenofibrate supplementation in the hyperlipidaemic ApoE-/- mouse 
In the hyperlipidaemic ApoE
-/-
 mouse, fenofibrate supplementation of the atherogenic diet was 
demonstrated to markedly attenuate plasma total and LDL-cholesterol and to moderately reduce 
plasma triglycerides - findings which are supportive of the hypolipidaemic action of fenofibrate 
documented in humans (Caslake et al., 1993 Guerin et al., 2003; Davidson et al., 2006).  
The study demonstrated that, while improving the hyperlipidaemic profile, fenofibrate treatment did 
not have any significant impact on hyperlipidaemia induced cardiac remodelling. Reports of the 
effects of fenofibrate on cardiac remodelling are equivocal. In type 2 diabetes patients, fenofibrate 
supplementation had a negligible impact on LV diastolic dysfunction (Chew et al., 2008). However, 
in murine models of hypertension (aldosterone or DOCA-salt induced), fenofibrate attenuated LV 
hypertrophy and myocardial fibrosis (Ogata et al., 2004; LeBrasseur et al., 2007). Take together, the 
effect of fenofibrate on structural and functional remodelling in the heart is not yet clear and the 
disparity between reports may due to variation in species dependent disease pathology.   
The present study provided the novel finding that fenofibrate supplementation influences tissue 
endocannabinoid concentrations. Hypercholesterolaemia associated elevations in the AEA, but not 2-
AG, content of brain and aortic tissue was significantly attenuated by dietary supplementation with 
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fenofibrate. It is unlikely that the aforementioned effects of fenofibrate were due solely to non-
specific lipid lowering since both EPA and fenofibrate attenuated hyperlipidaemia to a similar degree, 
yet exerted differential effects on endocannabinoid concentrations. As fenofibrate represents a 
selective agonist of PPARα receptors, it is possible that activation of PPARs may play a role in 
modulating tissue endocannabinoid concentrations. 
Finally, fenofibrate supplementation significantly attenuated hyperlipidaemia induced endothelial 
dysfunction. Given that the present study provided the first in vivo evidence of an association between 
hyperlipidaemia and endothelial dysfunction in the ApoE
-/-
 mouse, this effect of fenofibrate represents 
a novel observation in the ApoE
-/-
 model. However, the vasorelaxant properties of fenofibrate have 
been previously reported ex vivo, in vessel studies from normotensive and hypertensive rats (Li et al., 
2010; Olukman et al., 2010). The capacity of fenofibrate to preserve endothelial function in the 
hyperlipidaemic ApoE
-/-
 mouse was unlikely to be related to its hypolipidaemic actions, as EPA also 
normalised the hyperlipidaemic profile yet failed to modulate endothelial function. It is possible 
therefore, that the effects of fenofibrate are, in part, due to its influence of vascular AEA levels, which 
in the present study, were not significantly altered by EPA supplementation. AEA is known to 
directly enhance the generation of ROS and activation of apoptosis pathways in macrophages and 
endothelial cells (Rajesh et al., 2010). Moreover, studies have implicated a pro-inflammatory and pro-
oxidative role of CB1 receptor agonism in cells of the vascular wall (Han et al., 2009; Sagamura et al., 
2009). Therefore, one possible mechanism by which fenofibrate preserves endothelial function in the 
ApoE
-/-
 model may involve normalisation of the excessive vascular AEA levels that characterise the 
hyperlipidaemic profile of these mice. 
6.2 Future studies 
6.2.1 Histological examination of atherosclerotic lesion development 
The ApoE
-/-
 mouse represents, primarily, a model of atherosclerosis development. While the present 
study demonstrated the induction of marked hypercholesterolaemia and endothelial dysfunction in 
response to maintenance on an atherogenic diet, the presence and extent of lesion formation in the 
vasculature was not assessed. The lack of histological data prevented further characterisation of the 
high fat diet intervention and importantly, investigation of the effects, if any, of EPA and fenofibrate 
on lesion formation. Furthermore, it would be of interest to examine the composition of lesions, in 
order to assess the effect of the interventions on markers of stability (i.e. presence of a lipid core, 
collagen deposition). The upper section of heart samples (including the attached aorta and 
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braciocephalic artery) collected from the dietary study were retained and, while atherosclerotic lesion 
development in the aortic root and braciocephalic artery (the prominent site of lesion formation and 
rupture) was to be assessed histologically, time did not permit the undertaking of these experiments. 
In the brachiocephalic artery, treatment of serial sections with Masson’s Trichrome stain would 
enable visualisation and comparison of the collagen content (appears blue) and connective tissue (cell 
nuclei, cytoplasm and surrounding tissue) content (appears red) of lesions. Moreover Oil red O 
staining, which dyes neutral lipids red, could be employed to identify the lipid content of innominate 
artery lesions. Quantification of morphological differences in serial sections of vessels would be 
conducted using Leica Q-Win software. 
6.2.2 Cannabinoid receptor antagonist studies 
While the present study has demonstrated an association between tissue endocannabinoid levels and 
endothelial dysfunction, it is not known which cannabinoid receptors are involved in mediating these 
effects. As there is growing evidence to suggest a detrimental role of CB1 receptor signalling in many 
pathologies, including atherosclerosis development, examining the impact of CB1 receptor blockade 
may further understanding of its role in the effects described in the current study. Repeating the 
dietary intervention with the additional inclusion of a CB1 selective antagonist (e.g. rimonabant) 
would allow the involvement of this receptor in mediating endothelial dysfunction to be characterised. 
In addition, the involvement of specific cannabinoid receptors could be further investigated by 
conducting immunostaining of serial sections collected from the brachiocephalic artery and aortic root 
sections as described previously. Labelling of sections with CB1 and CB2 receptor specific antibodies 
would allow visualisation of the localisation and extent of CB receptor expression, data which 
together with the aforementioned antagonist studies would provide an understanding of the specific 
receptors mediating the effects described in the present study. 
6.3 Conclusion 
In conclusion, despite the well documented anti-atherosclerotic and cardioprotective effects of long 
chain ω-3 PUFAs, the exact underlying mechanisms have yet to be fully elucidated. Using both in 
vitro and in vivo approaches, the present study demonstrated an association between the effects of ω-3 
PUFAs and functional modulation of the endocannabinoid system, the latter of which has been 
implicated in numerous disease pathologies (Di Marzo, 2008). The in vitro experiments conducted in 
this study demonstrated the capacity of DHA to significantly attenuate the production of 2-AG in 
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activated THP-1 macrophages. Moreover, exogenous CB receptor signalling interfered with DHA 
uptake in activated macrophages, an effect which was shown to be mediated, in part, via the CB2 
receptor. In the ApoE
-/-
 mouse, a murine model of atherosclerosis development, maintenance on an 
atherogenic diet induced marked hypercholesterolaemia, endothelial dysfunction and elevated tissue 
concentrations of the endocannabinoids AEA and 2-AG. Taken together, these findings suggest a 
detrimental involvement of the endocannabinoid system and its activation in hypercholesterolaemia in 
the ApoE
-/-
 model. Supplementation of the atherogenic diet with EPA significantly attenuated 
hypercholesterolaemia and normalised tissue endocannabinoid levels, specifically AEA in the brain 
and heart, and 2-AG in the vasculature, although there was no alleviation of endothelial dysfunction. 
Given the mounting body of evidence that suggests dysregulation of the endocannabinoid system is 
conducive to the progression of certain disease pathologies, manipulation of its activity through long 
chain ω-3 PUFA administration may have therapeutic potential. 
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